RESTful Lookup — Test-Drive (2007 – 2026)

Query complete (41 ms elapsed)

{
  "NDC": [
    {
      "NDCCode": "54118-7979-2",
      "PackageDescription": "60 mL in 1 BOTTLE, DROPPER (54118-7979-2)",
      "NDC11Code": "54118-7979-02",
      "ProductNDC": "54118-7979",
      "ProductTypeName": "HUMAN OTC DRUG",
      "ProprietaryName": "Bacteria Tox",
      "NonProprietaryName": "Adrenal, Atp, Bac Nosode, Belladonna",
      "DosageFormName": "SOLUTION/ DROPS",
      "RouteName": "ORAL",
      "StartMarketingDate": "20121130",
      "MarketingCategoryName": "UNAPPROVED HOMEOPATHIC",
      "LabelerName": "ABCO Laboratories, Inc.",
      "SubstanceName": "BOS TAURUS ADRENAL GLAND; ADENOSINE TRIPHOSPHATE; MYCOBACTERIUM TUBERCULOSIS; ATROPA BELLADONNA; MYRRH; CROTALUS HORRIDUS HORRIDUS VENOM; GOLDENSEAL; HYPERICUM PERFORATUM; BEEF LIVER; LOMATIUM DISSECTUM ROOT; BORRELIA BURGDORFERI; BOS TAURUS MESENCHYME; NASTURTIUM OFFICINALE; PHOSPHORUS; BOS TAURUS SPLEEN; TABEBUIA IMPETIGINOSA BARK; HUMAN THYMUS",
      "StrengthNumber": "3; 5; 12; 6; 3; 12; 3; 12; 3; 3; 12; 6; 3; 12; 5; 3; 5",
      "StrengthUnit": "[hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL",
      "Status": "Deprecated",
      "LastUpdate": "2019-09-21",
      "ProductNdcExcludeFlag": "E",
      "ListingRecordCertifiedThrough": "20171231",
      "IndicationAndUsage": "30 drops 2X daily in warm water . or as recommended by a health care practitioner. Shake Well before use."
    },
    {
      "NDCCode": "63629-7979-2",
      "PackageDescription": "60 TABLET in 1 BOTTLE (63629-7979-2) ",
      "NDC11Code": "63629-7979-02",
      "ProductNDC": "63629-7979",
      "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
      "ProprietaryName": "Flecainide Acetate",
      "NonProprietaryName": "Flecainide Acetate",
      "DosageFormName": "TABLET",
      "RouteName": "ORAL",
      "StartMarketingDate": "20150708",
      "MarketingCategoryName": "ANDA",
      "ApplicationNumber": "ANDA202821",
      "LabelerName": "Bryant Ranch Prepack",
      "SubstanceName": "FLECAINIDE ACETATE",
      "StrengthNumber": "50",
      "StrengthUnit": "mg/1",
      "Pharm_Classes": "Antiarrhythmic [EPC]",
      "Status": "Active",
      "LastUpdate": "2024-05-03",
      "PackageNdcExcludeFlag": "N",
      "ProductNdcExcludeFlag": "N",
      "ListingRecordCertifiedThrough": "20261231",
      "StartMarketingDatePackage": "20190328",
      "SamplePackage": "N",
      "IndicationAndUsage": "In patients without structural heart disease, flecainide acetate tablets, USP are indicated for the prevention of   —   paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms   —   paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptomsFlecainide acetate tablets, USP are also indicated for the prevention of   —   documented ventricular arrhythmias, such as sustained ventricular tachycardia (sustained VT), that in the judgment of the physician are life-threatening.Use of flecainide acetate tablets, USP for the treatment of sustained VT, like other antiarrhythmics, should be initiated in the hospital. The use of flecainide acetate tablets, USP are not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic.Because of the proarrhythmic effects of flecainide acetate tablets, USP, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks.Flecainide acetate tablets, USP should not be used in patients with recent myocardial infarction. (See BOXED WARNINGS.)Use of flecainide acetate tablets, USP in chronic atrial fibrillation has not been adequately studied and is not recommended. (See BOXED WARNINGS.)As is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of flecainide acetate tablets, USP favorably affects survival or the incidence of sudden death.",
      "Description": "Flecainide acetate is an antiarrhythmic drug available in tablets of 50 mg, 100 mg, or 150 mg for oral administration.Flecainide acetate is benzamide, N-(2-piperidinyl-methyl)-2,5-bis (2,2,2-trifluoroethoxy)-monoacetate. The structural formula is given below. Flecainide acetate USP is a white to slightly off-white, crystalline powder with a pKa of 9.3. It has an aqueous solubility of 48.4 mg/mL at 37°C.Flecainide acetate tablets, USP also contain: croscarmellose sodium, hydrogenated vegetable oil type 1, magnesium stearate, microcrystalline cellulose, and pregelatinized starch."
    },
    {
      "NDCCode": "54118-7011-2",
      "PackageDescription": "60 mL in 1 BOTTLE, DROPPER (54118-7011-2)",
      "NDC11Code": "54118-7011-02",
      "ProductNDC": "54118-7011",
      "ProductTypeName": "HUMAN OTC DRUG",
      "ProprietaryName": "Rena Code",
      "NonProprietaryName": "Rena Code",
      "DosageFormName": "SOLUTION/ DROPS",
      "RouteName": "ORAL",
      "StartMarketingDate": "20150721",
      "MarketingCategoryName": "UNAPPROVED HOMEOPATHIC",
      "LabelerName": "ABCO Labratories, Inc.",
      "SubstanceName": "ADENOSINE TRIPHOSPHATE; BERBERIS VULGARIS WHOLE; BOS TAURUS URINARY BLADDER; BRYONIA ALBA WHOLE; EUPATORIUM PURPUREUM ROOT; HYDRANGEA ARBORESCENS WHOLE; BEEF KIDNEY; MERCURIC CHLORIDE; SODIUM SULFATE; PARSLEY; RUBIA TINCTORUM WHOLE; SOLIDAGO VIRGAUREA WHOLE; ARCTOSTAPHYLOS UVA-URSI WHOLE; CHERRY PLUM; POPULUS TREMULA FLOWERING TOP",
      "StrengthNumber": "5; 3; 6; 12; 12; 12; 6; 12; 6; 3; 6; 3; 3; 30; 30",
      "StrengthUnit": "[hp_X]/60mL; [hp_X]/60mL; [hp_C]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_C]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_C]/60mL; [hp_C]/60mL",
      "Status": "Deprecated",
      "LastUpdate": "2019-09-21",
      "ProductNdcExcludeFlag": "E",
      "ListingRecordCertifiedThrough": "20171231",
      "IndicationAndUsage": "Porvides Homeopathic Sarcode Support of Kidneys."
    },
    {
      "NDCCode": "54118-7017-2",
      "PackageDescription": "60 mL in 1 PACKAGE (54118-7017-2)",
      "NDC11Code": "54118-7017-02",
      "ProductNDC": "54118-7017",
      "ProductTypeName": "HUMAN OTC DRUG",
      "ProprietaryName": "Ultimate Phenolics",
      "NonProprietaryName": "Ultimate Phenolics",
      "DosageFormName": "SOLUTION/ DROPS",
      "RouteName": "ORAL",
      "StartMarketingDate": "20150716",
      "MarketingCategoryName": "UNAPPROVED HOMEOPATHIC",
      "LabelerName": "ABCO Labratories, Inc.",
      "SubstanceName": "ACETYLCHOLINE CHLORIDE; ACETALDEHYDE; PARSLEY; ASCORBIC ACID; BUTYLATED HYDROXYTOLUENE; CAFFEIC ACID; CANDIDA ALBICANS; CHLOROGENIC ACID; CINNAMIC ACID; CONIFERYL ALCOHOL; COUMARIN; DOPAMINE; ESTROGENS, CONJUGATED; .GAMMA.-AMINOBUTYRIC ACID; GALLIC ACID; HISTAMINE; INDOLE; DOPA, DL-; MALVIN; YEAST MANNAN; MELATONIN; MENADIONE; NORADRENALINE, (+/-)-; OCTOPAMINE; PHENYLALANINE; PHENYL ISOTHIOCYANATE; PHLORIZIN; PIPERINE; PROGESTERONE; PYRROLE; QUERCETIN; RUTIN; SALSOLINOL; SEROTONIN; TAURINE; TESTOSTERONE; TRYPTOPHAN; ADENOSINE TRIPHOSPHATE; BOS TAURUS MESENCEPHALON",
      "StrengthNumber": "6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6",
      "StrengthUnit": "[hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL",
      "Status": "Deprecated",
      "LastUpdate": "2019-09-21",
      "ProductNdcExcludeFlag": "E",
      "ListingRecordCertifiedThrough": "20171231",
      "IndicationAndUsage": "Phenolics."
    },
    {
      "NDCCode": "54118-7103-2",
      "PackageDescription": "60 mL in 1 BOTTLE, DROPPER (54118-7103-2)",
      "NDC11Code": "54118-7103-02",
      "ProductNDC": "54118-7103",
      "ProductTypeName": "HUMAN OTC DRUG",
      "ProprietaryName": "Myco-tox",
      "NonProprietaryName": "Myco-tox",
      "DosageFormName": "SOLUTION/ DROPS",
      "RouteName": "ORAL",
      "StartMarketingDate": "20150813",
      "MarketingCategoryName": "UNAPPROVED HOMEOPATHIC",
      "LabelerName": "ABCO Labratories, Inc.",
      "SubstanceName": "BOS TAURUS ADRENAL GLAND; ARSENIC; ADENOSINE TRIPHOSPHATE; SODIUM BORATE; ECHINACEA ANGUSTIFOLIA; GLIOTOXIN; HYDRASTIS CANADENSIS WHOLE; BEEF LIVER; LOMATIUM DISSECTUM WHOLE; BOS TAURUS LYMPH; BOS TAURUS MESENCHYME; PHYTOLACCA AMERICANA WHOLE; BOS TAURUS SPLEEN; STACHYBOTRYS CHARTARUM; TABEBUIA IMPETIGINOSA WHOLE; BOS TAURUS THYMUS; ELYMUS REPENS WHOLE",
      "StrengthNumber": "5; 6; 5; 12; 12; 12; 3; 3; 3; 3; 6; 12; 3; 12; 3; 3; 3",
      "StrengthUnit": "[hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL",
      "Status": "Deprecated",
      "LastUpdate": "2019-09-21",
      "ProductNdcExcludeFlag": "E",
      "ListingRecordCertifiedThrough": "20171231",
      "IndicationAndUsage": "Detoxifier Homaccord Tincture. For Professional Use Only. Gluten Free."
    },
    {
      "NDCCode": "54118-7109-2",
      "PackageDescription": "60 mL in 1 BOTTLE, DROPPER (54118-7109-2)",
      "NDC11Code": "54118-7109-02",
      "ProductNDC": "54118-7109",
      "ProductTypeName": "HUMAN OTC DRUG",
      "ProprietaryName": "Pre And Post Milieu",
      "NonProprietaryName": "Pre And Post Milieu",
      "DosageFormName": "SOLUTION/ DROPS",
      "RouteName": "ORAL",
      "StartMarketingDate": "20150825",
      "MarketingCategoryName": "UNAPPROVED HOMEOPATHIC",
      "LabelerName": "ABCO Labratories, Inc.",
      "SubstanceName": "ARNICA MONTANA; BELLADONNA LEAF; CORTISONE; HYPERICUM PERFORATUM; SYMPHYTUM OFFICINALE WHOLE; VALERIANA OFFICINALIS WHOLE",
      "StrengthNumber": "200; 6; 6; 6; 12; 1",
      "StrengthUnit": "[hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL",
      "Status": "Deprecated",
      "LastUpdate": "2019-09-21",
      "ProductNdcExcludeFlag": "E",
      "ListingRecordCertifiedThrough": "20171231",
      "IndicationAndUsage": "Drainage Tonifier. For Professional Use only. Gluten Free."
    },
    {
      "NDCCode": "54118-7114-2",
      "PackageDescription": "60 mL in 1 BOTTLE, DROPPER (54118-7114-2)",
      "NDC11Code": "54118-7114-02",
      "ProductNDC": "54118-7114",
      "ProductTypeName": "HUMAN OTC DRUG",
      "ProprietaryName": "Throat Milieu",
      "NonProprietaryName": "Throat Milieu",
      "DosageFormName": "SOLUTION/ DROPS",
      "RouteName": "ORAL",
      "StartMarketingDate": "20150824",
      "MarketingCategoryName": "UNAPPROVED HOMEOPATHIC",
      "LabelerName": "ABCO labratories, Inc.",
      "SubstanceName": "APIS MELLIFERA; BAPTISIA TINCTORIA; BELLADONNA LEAF; COMMIPHORA MYRRHA WHOLE; ECHINACEA ANGUSTIFOLIA; FERRIC PHOSPHATE; CALCIUM SULFIDE; HYDRASTIS CANADENSIS WHOLE; LACHESIS MUTA WHOLE; MERCURIUS SOLUBILIS; PHYTOLACCA AMERICANA WHOLE; SALVIA OFFICINALIS WHOLE; CLOVE; THYMUS VULGARIS WHOLE",
      "StrengthNumber": "12; 3; 12; 1; 1; 6; 12; 1; 12; 12; 3; 1; 1; 1",
      "StrengthUnit": "[hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL",
      "Status": "Deprecated",
      "LastUpdate": "2019-09-21",
      "ProductNdcExcludeFlag": "E",
      "ListingRecordCertifiedThrough": "20171231",
      "IndicationAndUsage": "Drainage Tonifier."
    },
    {
      "NDCCode": "54118-7134-2",
      "PackageDescription": "60 mL in 1 BOTTLE, DROPPER (54118-7134-2)",
      "NDC11Code": "54118-7134-02",
      "ProductNDC": "54118-7134",
      "ProductTypeName": "HUMAN OTC DRUG",
      "ProprietaryName": "Biocell Salts",
      "NonProprietaryName": "Biocell Slats",
      "DosageFormName": "SOLUTION/ DROPS",
      "RouteName": "ORAL",
      "StartMarketingDate": "20150714",
      "MarketingCategoryName": "UNAPPROVED HOMEOPATHIC",
      "LabelerName": "ABCO Laboratories, Inc.",
      "SubstanceName": "CALCIUM FLUORIDE; CALCIUM SULFATE; POTASSIUM CHLORIDE; CALCIUM PHOSPHATE; FERRUM PHOSPHORICUM; POTASSIUM SULFATE; SODIUM CHLORIDE; SODIUM SULFATE; MAGNESIUM PHOSPHATE ANHYDROUS; SODIUM PHOSPHATE; SILICON DIOXIDE; ADENOSINE TRIPHOSPHATE; BOS TAURUS PARATHYROID GLAND; BOS TAURUS HYPOTHALAMUS",
      "StrengthNumber": "6; 3; 3; 3; 3; 3; 6; 3; 3; 3; 6; 5; 6; 6",
      "StrengthUnit": "[hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_C]/60mL; [hp_C]/60mL",
      "Status": "Deprecated",
      "LastUpdate": "2019-09-21",
      "ProductNdcExcludeFlag": "E",
      "ListingRecordCertifiedThrough": "20171231",
      "IndicationAndUsage": "Dietary Suppliment."
    },
    {
      "NDCCode": "54118-7136-2",
      "PackageDescription": "60 mL in 1 BOTTLE, DROPPER (54118-7136-2)",
      "NDC11Code": "54118-7136-02",
      "ProductNDC": "54118-7136",
      "ProductTypeName": "HUMAN OTC DRUG",
      "ProprietaryName": "Pineal Code",
      "NonProprietaryName": "Pineal Code",
      "DosageFormName": "SOLUTION/ DROPS",
      "RouteName": "ORAL",
      "StartMarketingDate": "20150717",
      "MarketingCategoryName": "UNAPPROVED HOMEOPATHIC",
      "LabelerName": "ABCO Labratories, Inc.",
      "SubstanceName": "BOS TAURUS PINEAL GLAND; GOLD; BERBERIS VULGARIS FRUIT; CALCIUM FLUORIDE",
      "StrengthNumber": "6; 5; 3; 12",
      "StrengthUnit": "[hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_X]/60mL",
      "Status": "Deprecated",
      "LastUpdate": "2019-09-21",
      "ProductNdcExcludeFlag": "E",
      "ListingRecordCertifiedThrough": "20171231",
      "IndicationAndUsage": "Sarcode Organotherapy."
    },
    {
      "NDCCode": "54118-7141-2",
      "PackageDescription": "60 mL in 1 BOTTLE, DROPPER (54118-7141-2)",
      "NDC11Code": "54118-7141-02",
      "ProductNDC": "54118-7141",
      "ProductTypeName": "HUMAN OTC DRUG",
      "ProprietaryName": "Glycopan Tox",
      "NonProprietaryName": "Argentium Nitricum, Kali Carbonicum, Glycirrhiza Glabra",
      "DosageFormName": "SOLUTION/ DROPS",
      "RouteName": "ORAL",
      "StartMarketingDate": "20130201",
      "MarketingCategoryName": "UNAPPROVED HOMEOPATHIC",
      "LabelerName": "ABCO Laboratories, Inc.",
      "SubstanceName": "SILVER NITRATE; POTASSIUM CARBONATE; GLYCYRRHIZA GLABRA; MAMMAL LIVER; BOS TAURUS ADRENAL GLAND; SKIM MILK; SUS SCROFA PANCREAS; LACTIC ACID, DL-; LYCOPODIUM CLAVATUM SPORE; PHOSPHORIC ACID; SUCROSE; URANYL NITRATE HEXAHYDRATE; THYROID, UNSPECIFIED; BOS TAURUS PITUITARY GLAND; CHOLESTEROL; KIDNEY BEAN; GYMNEMA SYLVESTRE LEAF; RHUS AROMATICA ROOT BARK; FENUGREEK SEED; CHROMIUM; SYZYGIUM CUMINI SEED; ZINC; SELENIUM; BOS TAURUS MESENCHYME; ADENOSINE TRIPHOSPHATE",
      "StrengthNumber": "9; 9; 1; 6; 6; 6; 6; 3; 30; 4; 6; 30; 6; 6; 7; 1; 1; 3; 3; 3; 1; 9; 9; 6; 5",
      "StrengthUnit": "[hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_X]/60mL; [hp_C]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL",
      "Status": "Deprecated",
      "LastUpdate": "2019-09-21",
      "ProductNdcExcludeFlag": "E",
      "ListingRecordCertifiedThrough": "20171231",
      "IndicationAndUsage": "30 drops 2X daily . or as recommended by a health care practitioner. Shake well before use."
    },
    {
      "NDCCode": "54118-7188-2",
      "PackageDescription": "60 mL in 1 BOTTLE, DROPPER (54118-7188-2)",
      "NDC11Code": "54118-7188-02",
      "ProductNDC": "54118-7188",
      "ProductTypeName": "HUMAN OTC DRUG",
      "ProprietaryName": "Hcg Plus",
      "NonProprietaryName": "Human Chorionic Gonadotropin (hcg), Garcinia Cambogia, Hypothalamus",
      "DosageFormName": "SOLUTION/ DROPS",
      "RouteName": "ORAL",
      "StartMarketingDate": "20140516",
      "MarketingCategoryName": "UNAPPROVED HOMEOPATHIC",
      "LabelerName": "ABCO Laboratories, Inc.",
      "SubstanceName": "AMERICAN GINSENG; FUCUS VESICULOSUS; CALCIUM ARSENATE; GLUTAMIC ACID; LEUCINE; ARGININE; ACETYLCARNITINE; ORNITHINE; GONADOTROPHIN, CHORIONIC",
      "StrengthNumber": "6; 6; 6; 6; 6; 3; 3; 12; 12",
      "StrengthUnit": "[hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL",
      "Status": "Deprecated",
      "LastUpdate": "2019-09-21",
      "ProductNdcExcludeFlag": "E",
      "ListingRecordCertifiedThrough": "20171231",
      "IndicationAndUsage": "hCG Plus provides homeopathic support for weight management. This product is to be used in conjunction with the specific hCG Nutritional VLCD protocol. . The entire program has shown marvelous results by providing the key nutrients, minerals and essential amino acids that assist with decreasing appetite, restoring hypothalamus function, improving metabolism mechanisms, and detoxifying organs and tissues of the body. ."
    },
    {
      "NDCCode": "54118-7196-2",
      "PackageDescription": "59 mL in 1 BOTTLE, DROPPER (54118-7196-2)",
      "NDC11Code": "54118-7196-02",
      "ProductNDC": "54118-7196",
      "ProductTypeName": "HUMAN OTC DRUG",
      "ProprietaryName": "Oral Hcg Activator",
      "NonProprietaryName": "Hypothalamus, Hepar Suis, Methyl B12, Renal Suis, Gambogia, Graphites",
      "DosageFormName": "SOLUTION/ DROPS",
      "RouteName": "ORAL",
      "StartMarketingDate": "20140305",
      "MarketingCategoryName": "UNAPPROVED HOMEOPATHIC",
      "LabelerName": "ABCO Laboratories, Inc.",
      "SubstanceName": "BOS TAURUS HYPOTHALAMUS; PORK LIVER; METHYLCOBALAMIN; PORK KIDNEY; GAMBOGE; GRAPHITE; STRYCHNOS NUX-VOMICA SEED; PHYTOLACCA AMERICANA ROOT; 7-KETO-DEHYDROEPIANDROSTERONE; ADENOSINE TRIPHOSPHATE; GLUCAGON; INSULIN PORK; LACTIC ACID, L-; ARGININE; LEVOCARNITINE; TRYPTOPHAN; PHENYLALANINE; THYROID, UNSPECIFIED; BOS TAURUS PITUITARY GLAND; GENTIANA LUTEA ROOT; SEMECARPUS ANACARDIUM JUICE",
      "StrengthNumber": "6; 8; 8; 8; 12; 12; 12; 3; 30; 30; 30; 30; 3; 12; 12; 12; 12; 3; 6; 5; 15",
      "StrengthUnit": "[hp_X]/59mL; [hp_X]/59mL; [hp_X]/59mL; [hp_X]/59mL; [hp_X]/59mL; [hp_X]/59mL; [hp_X]/59mL; [hp_X]/59mL; [hp_X]/59mL; [hp_X]/59mL; [hp_X]/59mL; [hp_X]/59mL; [hp_X]/59mL; [hp_C]/59mL; [hp_C]/59mL; [hp_C]/59mL; [hp_C]/59mL; [hp_X]/59mL; [hp_X]/59mL; [hp_C]/59mL; [hp_C]/59mL",
      "Status": "Deprecated",
      "LastUpdate": "2019-09-21",
      "ProductNdcExcludeFlag": "E",
      "ListingRecordCertifiedThrough": "20171231",
      "IndicationAndUsage": "Place 10 drops under the tongue three to six times a day . or as directed by your healthcare professional. Consult a physician for use in children under 12 years of age."
    },
    {
      "NDCCode": "54118-7232-2",
      "PackageDescription": "60 mL in 1 BOTTLE, DROPPER (54118-7232-2)",
      "NDC11Code": "54118-7232-02",
      "ProductNDC": "54118-7232",
      "ProductTypeName": "HUMAN OTC DRUG",
      "ProprietaryName": "Hcg Plus",
      "NonProprietaryName": "Human Chorionic Gonadotropin (hcg), Garcinia Cambogia, Hypothalamus",
      "DosageFormName": "SOLUTION/ DROPS",
      "RouteName": "ORAL",
      "StartMarketingDate": "20140405",
      "MarketingCategoryName": "UNAPPROVED HOMEOPATHIC",
      "LabelerName": "ABCO Laboratories, Inc.",
      "SubstanceName": "GONADOTROPHIN, CHORIONIC; GARCINIA CAMBOGIA FRUIT; BOS TAURUS HYPOTHALAMUS; BOS TAURUS BRAIN; PORK LIVER; METHYLCOBALAMIN; SUS SCROFA PANCREAS; BEEF KIDNEY; TRIPE; CALCIUM CARBONATE; GELSEMIUM SEMPERVIRENS WHOLE; GRAPHITE; STRYCHNOS NUX-VOMICA SEED; PHYTOLACCA AMERICANA ROOT; 7-KETO-DEHYDROEPIANDROSTERONE; SEMECARPUS ANACARDIUM JUICE; GLUCAGON; INSULIN HUMAN; LACTIC ACID, L-; PROTEUS INCONSTANS; THYROID, UNSPECIFIED; BOS TAURUS PITUITARY GLAND; CALCIUM FLUORIDE; FUCUS VESICULOSUS; AMMONIUM CARBONATE",
      "StrengthNumber": "12; 12; 6; 8; 8; 8; 8; 8; 8; 12; 12; 12; 12; 12; 30; 6; 30; 30; 30; 30; 12; 12; 6; 3; 6",
      "StrengthUnit": "[hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL",
      "Status": "Deprecated",
      "LastUpdate": "2019-09-21",
      "ProductNdcExcludeFlag": "E",
      "ListingRecordCertifiedThrough": "20171231",
      "IndicationAndUsage": "Provides homeopathic support for temporary relief of symptioms related to obesity, weight gain, appetite support, detoxification, regulation of fat metabolism, headache, . fatigue and irritability, while following a proper diet and exercise program."
    },
    {
      "NDCCode": "54118-7967-2",
      "PackageDescription": "60 mL in 1 BOTTLE, DROPPER (54118-7967-2)",
      "NDC11Code": "54118-7967-02",
      "ProductNDC": "54118-7967",
      "ProductTypeName": "HUMAN OTC DRUG",
      "ProprietaryName": "Lymph 1 Acute",
      "NonProprietaryName": "Adrenal, Apis Mellifica",
      "DosageFormName": "SOLUTION/ DROPS",
      "RouteName": "ORAL",
      "StartMarketingDate": "20110228",
      "MarketingCategoryName": "UNAPPROVED HOMEOPATHIC",
      "LabelerName": "ABCO Laboratories, Inc.",
      "SubstanceName": "BOS TAURUS ADRENAL GLAND; APIS MELLIFERA; ARANEUS DIADEMATUS; ADENOSINE TRIPHOSPHATE; ATROPA BELLADONNA; OYSTER SHELL CALCIUM CARBONATE, CRUDE; CONIUM MACULATUM FLOWERING TOP; ECHINACEA ANGUSTIFOLIA; FUMARIA OFFICINALIS FLOWERING TOP; GALIUM APARINE; GRAPHITE; BOS TAURUS HYPOTHALAMUS; POTASSIUM IODIDE; LACHESIS MUTA VENOM; MERCUROUS IODIDE; VIROLA SEBIFERA RESIN; PHOSPHORUS; PHYTOLACCA AMERICANA ROOT; MARITIME PINE; BOS TAURUS PITUITARY GLAND; TOXICODENDRON PUBESCENS LEAF; SCROPHULARIA NODOSA; SULFUR; THYROID, BOVINE; UNCARIA TOMENTOSA LEAF; VESPA CRABRO",
      "StrengthNumber": "3; 3; 9; 4; 6; 9; 6; 1; 6; 9; 6; 3; 3; 12; 9; 9; 12; 2; 6; 3; 12; 9; 12; 6; 3; 12",
      "StrengthUnit": "[hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL",
      "Status": "Deprecated",
      "LastUpdate": "2019-09-21",
      "ProductNdcExcludeFlag": "E",
      "ListingRecordCertifiedThrough": "20171231",
      "IndicationAndUsage": "30 drops 2X daily in warm water or as recommended by a health care practitioner. Shake well before use."
    },
    {
      "NDCCode": "54118-7971-2",
      "PackageDescription": "60 mL in 1 BOTTLE, DROPPER (54118-7971-2)",
      "NDC11Code": "54118-7971-02",
      "ProductNDC": "54118-7971",
      "ProductTypeName": "HUMAN OTC DRUG",
      "ProprietaryName": "Ultimate Fields",
      "NonProprietaryName": "Ultimate Fields",
      "DosageFormName": "SOLUTION/ DROPS",
      "RouteName": "ORAL",
      "StartMarketingDate": "20150715",
      "MarketingCategoryName": "UNAPPROVED HOMEOPATHIC",
      "LabelerName": "ABCO Laboratories, Inc.",
      "SubstanceName": "AGRIMONIA EUPATORIA; POPULUS ALBA WHOLE; FAGUS SYLVATICA FLOWERING TOP; CERATOSTIGMA WILLMOTTIANUM FLOWER; PRUNUS CERASIFERA FLOWER; AESCULUS HIPPOCASTANUM WHOLE; CICHORIUM INTYBUS FLOWER; MALUS SYLVESTRIS FLOWER; ULMUS ALATA WHOLE; GENTIANA ACAULIS; ULEX EUROPAEUS FLOWER; CALLUNA VULGARIS FLOWERING TOP; ILEX AQUIFOLIUM FLOWERING TOP; LONICERA CAPRIFOLIUM FLOWERING TOP; CARPINUS BETULUS FLOWERING TOP; IMPATIENS CAPENSIS WHOLE; LARIX DECIDUA WHOLE; MIMULUS GUTTATUS FLOWERING TOP; BRASSICA NIGRA WHOLE; QUERCUS ROBUR FLOWER; OLEA EUROPAEA FRUIT VOLATILE OIL; PINUS SYLVESTRIS FLOWERING TOP; AESCULUS CARNEA FLOWER; HELIANTHEMUM NUMMULARIUM FLOWER; SCLERANTHUS ANNUUS FLOWERING TOP; ORNITHOGALUM UMBELLATUM; CASTANEA SATIVA FLOWER; VERBENA OFFICINALIS FLOWERING TOP; VITIS VINIFERA FLOWERING TOP; JUGLANS REGIA FLOWERING TOP; HOTTONIA PALUSTRIS FLOWER; AESCULUS HIPPOCASTANUM FLOWER; AVENA FATUA WHOLE; ROSA CANINA FLOWER; SALIX ALBA FLOWERING TOP; ADENOSINE TRIPHOSPHATE; BOS TAURUS PINEAL GLAND; BOS TAURUS THYMUS",
      "StrengthNumber": "30; 30; 30; 30; 30; 30; 30; 30; 30; 30; 30; 30; 30; 30; 30; 30; 30; 30; 30; 30; 30; 30; 30; 30; 30; 30; 30; 30; 30; 30; 30; 30; 30; 30; 30; 5; 6; 6",
      "StrengthUnit": "[hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_X]/60mL; [hp_C]/60mL; [hp_C]/60mL",
      "Status": "Deprecated",
      "LastUpdate": "2019-09-21",
      "ProductNdcExcludeFlag": "E",
      "ListingRecordCertifiedThrough": "20171231",
      "IndicationAndUsage": "For Professional Use Only."
    },
    {
      "NDCCode": "54118-7972-2",
      "PackageDescription": "60 mL in 1 BOTTLE, DROPPER (54118-7972-2)",
      "NDC11Code": "54118-7972-02",
      "ProductNDC": "54118-7972",
      "ProductTypeName": "HUMAN OTC DRUG",
      "ProprietaryName": "Ultimate Rescue",
      "NonProprietaryName": "Cherry Plum, Clematis, Impatiens, Rock Rose, Star Of Bethlehem, Atp, Pineal, Thymus",
      "DosageFormName": "SOLUTION/ DROPS",
      "RouteName": "ORAL",
      "StartMarketingDate": "20110228",
      "MarketingCategoryName": "UNAPPROVED HOMEOPATHIC",
      "LabelerName": "ABCO Laboratories, Inc.",
      "SubstanceName": "CHERRY PLUM; CLEMATIS CHINENSIS ROOT; IMPATIENS BALSAMINA LEAF; CISTUS INCANUS WHOLE; ORNITHOGALUM UMBELLATUM; ADENOSINE TRIPHOSPHATE; BOS TAURUS PINEAL GLAND; BOS TAURUS THYMUS",
      "StrengthNumber": "30; 30; 30; 30; 30; 5; 6; 6",
      "StrengthUnit": "[hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_X]/60mL; [hp_C]/60mL; [hp_C]/60mL",
      "Status": "Deprecated",
      "LastUpdate": "2019-09-21",
      "ProductNdcExcludeFlag": "E",
      "ListingRecordCertifiedThrough": "20171231",
      "IndicationAndUsage": "Directions. 30 drops 2X daily or as recommended by a health care practitioner."
    },
    {
      "NDCCode": "54118-7976-2",
      "PackageDescription": "60 mL in 1 BOTTLE, DROPPER (54118-7976-2)",
      "NDC11Code": "54118-7976-02",
      "ProductNDC": "54118-7976",
      "ProductTypeName": "HUMAN OTC DRUG",
      "ProprietaryName": "Aller-tox 1",
      "NonProprietaryName": "Acetaldehyde, Adrenal, Argentum Nitricum",
      "DosageFormName": "SOLUTION/ DROPS",
      "RouteName": "ORAL",
      "StartMarketingDate": "20121121",
      "MarketingCategoryName": "UNAPPROVED HOMEOPATHIC",
      "LabelerName": "ABCO Laboratories, Inc.",
      "SubstanceName": "ACETALDEHYDE; BOS TAURUS ADRENAL GLAND; SILVER NITRATE; ARSENIC TRIOXIDE; ADENOSINE TRIPHOSPHATE; CORTISONE; BERBERIS VULGARIS ROOT BARK; CORTICOTROPIN; GALLIC ACID MONOHYDRATE; HISTAMINE; HYALURONIDASE; INTERFERON BETA-1A; MAMMAL LIVER; LYCOPODIUM CLAVATUM SPORE; BOS TAURUS MESENCHYME; SEROTONIN; HYDRANGEA ARBORESCENS ROOT; STRYCHNOS NUX-VOMICA SEED",
      "StrengthNumber": "6; 3; 6; 6; 5; 6; 30; 12; 6; 6; 6; 6; 5; 12; 6; 6; 6; 12",
      "StrengthUnit": "[hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL",
      "Status": "Deprecated",
      "LastUpdate": "2019-09-21",
      "ProductNdcExcludeFlag": "E",
      "ListingRecordCertifiedThrough": "20171231",
      "IndicationAndUsage": "30 drops 2X daily in warm water . or as recommended by a health care practitioner."
    },
    {
      "NDCCode": "54118-7977-2",
      "PackageDescription": "60 mL in 1 BOTTLE, DROPPER (54118-7977-2)",
      "NDC11Code": "54118-7977-02",
      "ProductNDC": "54118-7977",
      "ProductTypeName": "HUMAN OTC DRUG",
      "ProprietaryName": "Aller - Tox 11",
      "NonProprietaryName": "Adrenal, Allium Cepa, Ambrosia Artemisiaefolia",
      "DosageFormName": "SOLUTION/ DROPS",
      "RouteName": "ORAL",
      "StartMarketingDate": "20121128",
      "MarketingCategoryName": "UNAPPROVED HOMEOPATHIC",
      "LabelerName": "ABCO Laboratories, Inc",
      "SubstanceName": "BOS TAURUS ADRENAL GLAND; ONION; AMBROSIA ARTEMISIIFOLIA; ARSENIC TRIOXIDE; ADENOSINE TRIPHOSPHATE; COUMARIN; EUPHRASIA STRICTA; HISTAMINE; BEEF LIVER; BEEF LUNG; MENADIONE; BOS TAURUS MESENCHYME; PHOSPHORUS; PIPERINE; HYALURONIDASE; PULSATILLA PRATENSIS; RUTIN; SCHOENOCAULON OFFICINALE SEED; SULFUR",
      "StrengthNumber": "3; 3; 3; 12; 5; 6; 3; 6; 5; 3; 5; 6; 12; 5; 9; 12; 5; 3; 12",
      "StrengthUnit": "[hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL",
      "Status": "Deprecated",
      "LastUpdate": "2019-09-21",
      "ProductNdcExcludeFlag": "E",
      "ListingRecordCertifiedThrough": "20171231",
      "IndicationAndUsage": "30 drops 2X daily . or as recommended by a health care practitioner. Shake well before use."
    },
    {
      "NDCCode": "54118-7978-2",
      "PackageDescription": "60 mL in 1 BOTTLE, DROPPER (54118-7978-2)",
      "NDC11Code": "54118-7978-02",
      "ProductNDC": "54118-7978",
      "ProductTypeName": "HUMAN OTC DRUG",
      "ProprietaryName": "Amoeba Tox",
      "NonProprietaryName": "Adrenal, Amoeba Nosodes, Artemisia Absinthium",
      "DosageFormName": "SOLUTION/ DROPS",
      "RouteName": "ORAL",
      "StartMarketingDate": "20121128",
      "MarketingCategoryName": "UNAPPROVED HOMEOPATHIC",
      "LabelerName": "ABCO Laboratories, Inc",
      "SubstanceName": "BOS TAURUS ADRENAL GLAND; ENTAMOEBA HISTOLYTICA; WORMWOOD; ADENOSINE TRIPHOSPHATE; BAPTISIA TINCTORIA; CAJUPUT OIL; CAPSICUM; SENNA LEAF; CHELONE GLABRA; CINCHONA OFFICINALIS BARK; ALPINE STRAWBERRY; GENTIANA LUTEA ROOT; GOLDENSEAL; CEANOTHUS AMERICANUS LEAF; MAMMAL LIVER; LYCOPODIUM CLAVATUM SPORE; BOS TAURUS MESENCHYME; STRYCHNOS NUX-VOMICA SEED; QUASSIA AMARA WOOD; BOS TAURUS SPLEEN",
      "StrengthNumber": "6; 30; 6; 5; 3; 1; 3; 3; 3; 12; 3; 6; 3; 6; 5; 12; 6; 12; 3; 5",
      "StrengthUnit": "[hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_C]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_Q]/60mL; [hp_X]/60mL",
      "Status": "Deprecated",
      "LastUpdate": "2019-09-21",
      "ProductNdcExcludeFlag": "E",
      "ListingRecordCertifiedThrough": "20171231",
      "IndicationAndUsage": "30 drops 2X daily in warm water . or as recommended by a health care practitioner. Shake well before use."
    },
    {
      "NDCCode": "54118-7981-2",
      "PackageDescription": "60 mL in 1 BOTTLE, DROPPER (54118-7981-2)",
      "NDC11Code": "54118-7981-02",
      "ProductNDC": "54118-7981",
      "ProductTypeName": "HUMAN OTC DRUG",
      "ProprietaryName": "Chem - Tox",
      "NonProprietaryName": "Adrenal, Arctium Lappa, Atp, Belladonna, Chemical Isodes",
      "DosageFormName": "SOLUTION/ DROPS",
      "RouteName": "ORAL",
      "StartMarketingDate": "20121130",
      "MarketingCategoryName": "UNAPPROVED HOMEOPATHIC",
      "LabelerName": "ABCO Laboratories, Inc.",
      "SubstanceName": "BOS TAURUS ADRENAL GLAND; ARCTIUM LAPPA WHOLE; ADENOSINE TRIPHOSPHATE; ATROPA BELLADONNA; ARSENIC TRIOXIDE; LICORICE; BEEF KIDNEY; BEEF LIVER; LYCOPODIUM CLAVATUM SPORE; BOS TAURUS LYMPH; BOS TAURUS MESENCHYME; NITRIC ACID; STRYCHNOS NUX-VOMICA SEED; PHOSPHORIC ACID; PHOSPHORUS; PHYTOLACCA AMERICANA ROOT; FRANGULA PURSHIANA BARK; THYROID, BOVINE; TRIFOLIUM PRATENSE FLOWER; ELYMUS REPENS ROOT",
      "StrengthNumber": "5; 3; 5; 12; 12; 3; 3; 3; 12; 3; 6; 6; 12; 6; 12; 3; 3; 5; 3; 3",
      "StrengthUnit": "[hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL",
      "Status": "Deprecated",
      "LastUpdate": "2019-09-21",
      "ProductNdcExcludeFlag": "E",
      "ListingRecordCertifiedThrough": "20171231",
      "IndicationAndUsage": "30 drops 2X daily in warm water . or as recommended by a health care practitioner. Shake Well before use."
    },
    {
      "NDCCode": "54118-7990-2",
      "PackageDescription": "60 mL in 1 BOTTLE, DROPPER (54118-7990-2)",
      "NDC11Code": "54118-7990-02",
      "ProductNDC": "54118-7990",
      "ProductTypeName": "HUMAN OTC DRUG",
      "ProprietaryName": "Gyne - Tox",
      "NonProprietaryName": "Adrenal, Angelica Atropurpurea, Boricum Acidum, Atp",
      "DosageFormName": "SOLUTION/ DROPS",
      "RouteName": "ORAL",
      "StartMarketingDate": "20121219",
      "MarketingCategoryName": "UNAPPROVED HOMEOPATHIC",
      "LabelerName": "ABCO Laboratories, Inc.",
      "SubstanceName": "BOS TAURUS ADRENAL GLAND; ANGELICA ATROPURPUREA ROOT; BORIC ACID; ADENOSINE TRIPHOSPHATE; BOS TAURUS MESENCHYME; CANDIDA ALBICANS; BLACK COHOSH; WOOD CREOSOTE; BOS TAURUS LYMPH; GONORRHEAL URETHRAL SECRETION HUMAN; MERCURIUS SOLUBILIS; ESTRONE; BOS TAURUS OVARY; BOS TAURUS PLACENTA; SCABIES LESION LYSATE (HUMAN); ANEMONE NEMOROSA; SEPIA OFFICINALIS JUICE; DELPHINIUM STAPHISAGRIA SEED; TREPONEMIC SKIN CANKER HUMAN; THUJA OCCIDENTALIS LEAFY TWIG; THYROID, UNSPECIFIED; BOS TAURUS UTERUS",
      "StrengthNumber": "6; 3; 12; 5; 6; 6; 3; 12; 6; 30; 12; 30; 5; 5; 30; 12; 12; 12; 30; 12; 6; 5",
      "StrengthUnit": "[hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL",
      "Status": "Deprecated",
      "LastUpdate": "2019-09-21",
      "ProductNdcExcludeFlag": "E",
      "ListingRecordCertifiedThrough": "20171231",
      "IndicationAndUsage": "30 drops 2X daily . or as recommended by a health care practitioner. Shake well before use."
    },
    {
      "NDCCode": "54118-7993-2",
      "PackageDescription": "60 mL in 1 BOTTLE, DROPPER (54118-7993-2)",
      "NDC11Code": "54118-7993-02",
      "ProductNDC": "54118-7993",
      "ProductTypeName": "HUMAN OTC DRUG",
      "ProprietaryName": "Hz - Tox",
      "NonProprietaryName": "Arsenicum Album, Asclepias Tuberus, Atp",
      "DosageFormName": "SOLUTION/ DROPS",
      "RouteName": "ORAL",
      "StartMarketingDate": "20121221",
      "MarketingCategoryName": "UNAPPROVED HOMEOPATHIC",
      "LabelerName": "ABCO Laboratories, Inc",
      "SubstanceName": "ARSENIC; ASCLEPIAS TUBEROSA FLOWERING TOP; ADENOSINE TRIPHOSPHATE; BAPTISIA TINCTORIA; HUMAN HERPESVIRUS 5; LOMATIUM DISSECTUM ROOT; BOS TAURUS LYMPH; BOS TAURUS MESENCHYME; DAPHNE MEZEREUM BARK; STRYCHNOS NUX-VOMICA SEED; RANUNCULUS BULBOSUS; BOS TAURUS SPLEEN; THUJA OCCIDENTALIS LEAF; BOS TAURUS THYMUS; THYROID, BOVINE; CAT'S CLAW; CALCIUM SULFATE ANHYDROUS; TOXICODENDRON PUBESCENS LEAF",
      "StrengthNumber": "3; 3; 5; 3; 30; 3; 3; 6; 3; 12; 3; 3; 12; 5; 5; 1; 6; 6",
      "StrengthUnit": "[hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; 1/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL",
      "Status": "Deprecated",
      "LastUpdate": "2019-09-21",
      "ProductNdcExcludeFlag": "E",
      "ListingRecordCertifiedThrough": "20171231",
      "IndicationAndUsage": "30 drops 2X daily in warm water or as recommended by a health care practitioner,. Shake well before use."
    },
    {
      "NDCCode": "0615-7979-39",
      "PackageDescription": "30 TABLET, FILM COATED in 1 BLISTER PACK (0615-7979-39) ",
      "NDC11Code": "00615-7979-39",
      "ProductNDC": "0615-7979",
      "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
      "ProprietaryName": "Levetiracetam",
      "NonProprietaryName": "Levetiracetam",
      "DosageFormName": "TABLET, FILM COATED",
      "RouteName": "ORAL",
      "StartMarketingDate": "20090115",
      "EndMarketingDate": "20241031",
      "MarketingCategoryName": "ANDA",
      "ApplicationNumber": "ANDA090025",
      "LabelerName": "NCS HealthCare of KY, LLC dba Vangard Labs",
      "SubstanceName": "LEVETIRACETAM",
      "StrengthNumber": "1000",
      "StrengthUnit": "mg/1",
      "Pharm_Classes": "Decreased Central Nervous System Disorganized Electrical Activity [PE]",
      "Status": "Deprecated",
      "LastUpdate": "2024-11-01",
      "PackageNdcExcludeFlag": "N",
      "ProductNdcExcludeFlag": "N",
      "StartMarketingDatePackage": "20160504",
      "EndMarketingDatePackage": "20241031",
      "SamplePackage": "N",
      "IndicationAndUsage": "Levetiracetam tablets USP are indicated for adjunctive therapy in the treatment of: 1 Partial onset seizures in patients one month of age and older with epilepsy (1.1), 2 Myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy (1.2), 3 Primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy (1.3).",
      "Description": "Levetiracetam USP is an antiepileptic drug available as 250 mg (blue), 500 mg (yellow), 750 mg (orange), and 1000 mg (white) tablets for oral administration. The chemical name of levetiracetam, a single enantiomer, is (-)-(S)-α-ethyl-2-oxo-1-pyrrolidine acetamide, its molecular formula is C8H14N2O2 and its molecular weight is 170.21. Levetiracetam is chemically unrelated to existing antiepileptic drugs (AEDs). It has the following structural formula. Levetiracetam USP is a white to off-white crystalline powder with a faint odor and a bitter taste. It is very soluble in water (104.0 g/100 mL). It is freely soluble in chloroform (65.3 g/100 mL) and in methanol (53.6 g/100 mL), soluble in ethanol (16.5 g/100 mL), sparingly soluble in acetonitrile (5.7 g/100 mL) and practically insoluble in n-hexane. (Solubility limits are expressed as g/100 mL solvent). Levetiracetam tablets USP contain the labeled amount of levetiracetam. For 250 mg, 500 mg and 750 mg strengths. Inactive ingredients: colloidal silicon dioxide, corn starch, crospovidone, hypromellose, magnesium stearate, microcrystalline cellulose, povidone, polyethylene glycol, polyvinyl alcohol, talc, titanium dioxide, and additional agents listed below. 250 mg tablets: FD&C Blue No. 2/indigo carmine Aluminum Lake. 500 mg tablets: Yellow Iron Oxide. 750 mg tablets: FD&C Blue No. 2/indigo carmine Aluminum Lake, FD&C Yellow No. 6/sunset yellow FCF Aluminum Lake, iron oxide red. For 1000 mg strength. Inactive ingredients: colloidal silicon dioxide, corn starch, croscarmellose sodium, magnesium stearate, microcrystalline cellulose, povidone, polyethylene glycol, polyvinyl alcohol, talc and titanium dioxide."
    },
    {
      "NDCCode": "50090-7979-0",
      "PackageDescription": "30 TABLET in 1 BOTTLE (50090-7979-0) ",
      "NDC11Code": "50090-7979-00",
      "ProductNDC": "50090-7979",
      "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
      "ProprietaryName": "Olmesartan Medoxomil",
      "NonProprietaryName": "Olmesartan Medoxomil",
      "DosageFormName": "TABLET",
      "RouteName": "ORAL",
      "StartMarketingDate": "20220304",
      "MarketingCategoryName": "ANDA",
      "ApplicationNumber": "ANDA206720",
      "LabelerName": "A-S Medication Solutions",
      "SubstanceName": "OLMESARTAN MEDOXOMIL",
      "StrengthNumber": "40",
      "StrengthUnit": "mg/1",
      "Pharm_Classes": "Angiotensin 2 Receptor Antagonists [MoA], Angiotensin 2 Receptor Blocker [EPC]",
      "Status": "Active",
      "LastUpdate": "2026-06-02",
      "PackageNdcExcludeFlag": "N",
      "ProductNdcExcludeFlag": "N",
      "ListingRecordCertifiedThrough": "20271231",
      "StartMarketingDatePackage": "20260527",
      "SamplePackage": "N",
      "IndicationAndUsage": "Olmesartan medoxomil is indicated for the treatment of hypertension in adults and children six years of age and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. It may be used alone or in combination with other antihypertensive agents.",
      "Description": "Olmesartan medoxomil, a prodrug, is hydrolyzed to olmesartan during absorption from the gastrointestinal tract. Olmesartan is a selective AT1 subtype angiotensin II receptor antagonist. Olmesartan medoxomil is described chemically as 2,3-dihydroxy-2-butenyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]imidazole-5-carboxylate, cyclic 2,3-carbonate. Its empirical formula is C29H30N6O6 and its structural formula is:. Olmesartan medoxomil is a white or off-white crystalline powder with a molecular weight of 558.59. It is practically insoluble in water and sparingly soluble in methanol. Olmesartan medoxomil tablets, USP, are available for oral use as film-coated tablets containing 5 mg, 20 mg, or 40 mg of olmesartan medoxomil (USP) and the following inactive ingredients: hydroxypropyl cellulose, lactose monohydrate, low-substituted hydroxypropyl cellulose, magnesium stearate, microcrystalline cellulose, colloidal silicon dioxide, polyvinyl alcohol-part hydrolyzed, titanium dioxide, macrogol/polyethylene glycol 3350, talc, (5 mg only) FD&C Red #40 Aluminum Lake, (5 mg only) FD&C Yellow #6 Aluminum Lake, (5 mg only) FD&C Blue #1 Aluminum Lake. FDA approved dissolution test specifications differ from USP."
    },
    {
      "NDCCode": "50090-7979-1",
      "PackageDescription": "90 TABLET in 1 BOTTLE (50090-7979-1) ",
      "NDC11Code": "50090-7979-01",
      "ProductNDC": "50090-7979",
      "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
      "ProprietaryName": "Olmesartan Medoxomil",
      "NonProprietaryName": "Olmesartan Medoxomil",
      "DosageFormName": "TABLET",
      "RouteName": "ORAL",
      "StartMarketingDate": "20220304",
      "MarketingCategoryName": "ANDA",
      "ApplicationNumber": "ANDA206720",
      "LabelerName": "A-S Medication Solutions",
      "SubstanceName": "OLMESARTAN MEDOXOMIL",
      "StrengthNumber": "40",
      "StrengthUnit": "mg/1",
      "Pharm_Classes": "Angiotensin 2 Receptor Antagonists [MoA], Angiotensin 2 Receptor Blocker [EPC]",
      "Status": "Active",
      "LastUpdate": "2026-06-02",
      "PackageNdcExcludeFlag": "N",
      "ProductNdcExcludeFlag": "N",
      "ListingRecordCertifiedThrough": "20271231",
      "StartMarketingDatePackage": "20260527",
      "SamplePackage": "N",
      "IndicationAndUsage": "Olmesartan medoxomil is indicated for the treatment of hypertension in adults and children six years of age and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. It may be used alone or in combination with other antihypertensive agents.",
      "Description": "Olmesartan medoxomil, a prodrug, is hydrolyzed to olmesartan during absorption from the gastrointestinal tract. Olmesartan is a selective AT1 subtype angiotensin II receptor antagonist. Olmesartan medoxomil is described chemically as 2,3-dihydroxy-2-butenyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]imidazole-5-carboxylate, cyclic 2,3-carbonate. Its empirical formula is C29H30N6O6 and its structural formula is:. Olmesartan medoxomil is a white or off-white crystalline powder with a molecular weight of 558.59. It is practically insoluble in water and sparingly soluble in methanol. Olmesartan medoxomil tablets, USP, are available for oral use as film-coated tablets containing 5 mg, 20 mg, or 40 mg of olmesartan medoxomil (USP) and the following inactive ingredients: hydroxypropyl cellulose, lactose monohydrate, low-substituted hydroxypropyl cellulose, magnesium stearate, microcrystalline cellulose, colloidal silicon dioxide, polyvinyl alcohol-part hydrolyzed, titanium dioxide, macrogol/polyethylene glycol 3350, talc, (5 mg only) FD&C Red #40 Aluminum Lake, (5 mg only) FD&C Yellow #6 Aluminum Lake, (5 mg only) FD&C Blue #1 Aluminum Lake. FDA approved dissolution test specifications differ from USP."
    },
    {
      "NDCCode": "55154-7979-0",
      "PackageDescription": "10 BLISTER PACK in 1 BAG (55154-7979-0)  / 1 CAPSULE in 1 BLISTER PACK",
      "NDC11Code": "55154-7979-00",
      "ProductNDC": "55154-7979",
      "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
      "ProprietaryName": "Extended Phenytoin Sodium",
      "NonProprietaryName": "Phenytoin Sodium",
      "DosageFormName": "CAPSULE",
      "RouteName": "ORAL",
      "StartMarketingDate": "20091216",
      "EndMarketingDate": "20250131",
      "MarketingCategoryName": "ANDA",
      "ApplicationNumber": "ANDA040765",
      "LabelerName": "Cardinal Health 107, LLC",
      "SubstanceName": "PHENYTOIN SODIUM",
      "StrengthNumber": "100",
      "StrengthUnit": "mg/1",
      "Pharm_Classes": "Anti-epileptic Agent [EPC], Cytochrome P450 1A2 Inducers [MoA], Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 2C19 Inducers [MoA], Cytochrome P450 2C8 Inducers [MoA], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 2D6 Inducers [MoA], Cytochrome P450 3A Inducers [MoA], Decreased Central Nervous System Disorganized Electrical Activity [PE]",
      "Status": "Deprecated",
      "LastUpdate": "2025-02-04",
      "PackageNdcExcludeFlag": "N",
      "ProductNdcExcludeFlag": "N",
      "StartMarketingDatePackage": "20091216",
      "EndMarketingDatePackage": "20250131",
      "SamplePackage": "N",
      "IndicationAndUsage": "Extended phenytoin sodium capsules are indicated for the treatment of tonic-clonic (grand mal) and psychomotor (temporal lobe) seizures and prevention and treatment of seizures occurring during or following neurosurgery.",
      "Description": "Phenytoin sodium, USP is related to the barbiturates in chemical structure, but has a five-membered ring. The chemical name is 5,5-diphenyl-2,4 imidazolidinedione, having the following structural formula. Each extended phenytoin sodium capsule, USP for oral administration contains 100 mg phenytoin sodium, USP. Each capsule also contains the following inactive ingredients: D&C Red #28, D&C Red #33, FD&C Blue #1, gelatin, hydroxypropyl cellulose, mannitol, magnesium stearate, talc and titanium dioxide. Product in vivo performance is characterized by a slow and extended rate of absorption with peak blood concentrations expected in 4 to 12 hours as contrasted to Prompt Phenytoin Sodium Capsules, USP with a rapid rate of absorption with peak blood concentration expected in 1½ to 3 hours. Meets USP Dissolution Test 5."
    },
    {
      "NDCCode": "63629-7979-1",
      "PackageDescription": "30 TABLET in 1 BOTTLE (63629-7979-1) ",
      "NDC11Code": "63629-7979-01",
      "ProductNDC": "63629-7979",
      "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
      "ProprietaryName": "Flecainide Acetate",
      "NonProprietaryName": "Flecainide Acetate",
      "DosageFormName": "TABLET",
      "RouteName": "ORAL",
      "StartMarketingDate": "20150708",
      "MarketingCategoryName": "ANDA",
      "ApplicationNumber": "ANDA202821",
      "LabelerName": "Bryant Ranch Prepack",
      "SubstanceName": "FLECAINIDE ACETATE",
      "StrengthNumber": "50",
      "StrengthUnit": "mg/1",
      "Pharm_Classes": "Antiarrhythmic [EPC]",
      "Status": "Active",
      "LastUpdate": "2024-05-03",
      "PackageNdcExcludeFlag": "N",
      "ProductNdcExcludeFlag": "N",
      "ListingRecordCertifiedThrough": "20261231",
      "StartMarketingDatePackage": "20190509",
      "SamplePackage": "N",
      "IndicationAndUsage": "In patients without structural heart disease, flecainide acetate tablets, USP are indicated for the prevention of   —   paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms   —   paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptomsFlecainide acetate tablets, USP are also indicated for the prevention of   —   documented ventricular arrhythmias, such as sustained ventricular tachycardia (sustained VT), that in the judgment of the physician are life-threatening.Use of flecainide acetate tablets, USP for the treatment of sustained VT, like other antiarrhythmics, should be initiated in the hospital. The use of flecainide acetate tablets, USP are not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic.Because of the proarrhythmic effects of flecainide acetate tablets, USP, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks.Flecainide acetate tablets, USP should not be used in patients with recent myocardial infarction. (See BOXED WARNINGS.)Use of flecainide acetate tablets, USP in chronic atrial fibrillation has not been adequately studied and is not recommended. (See BOXED WARNINGS.)As is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of flecainide acetate tablets, USP favorably affects survival or the incidence of sudden death.",
      "Description": "Flecainide acetate is an antiarrhythmic drug available in tablets of 50 mg, 100 mg, or 150 mg for oral administration.Flecainide acetate is benzamide, N-(2-piperidinyl-methyl)-2,5-bis (2,2,2-trifluoroethoxy)-monoacetate. The structural formula is given below. Flecainide acetate USP is a white to slightly off-white, crystalline powder with a pKa of 9.3. It has an aqueous solubility of 48.4 mg/mL at 37°C.Flecainide acetate tablets, USP also contain: croscarmellose sodium, hydrogenated vegetable oil type 1, magnesium stearate, microcrystalline cellulose, and pregelatinized starch."
    },
    {
      "NDCCode": "63629-7979-3",
      "PackageDescription": "90 TABLET in 1 BOTTLE (63629-7979-3) ",
      "NDC11Code": "63629-7979-03",
      "ProductNDC": "63629-7979",
      "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
      "ProprietaryName": "Flecainide Acetate",
      "NonProprietaryName": "Flecainide Acetate",
      "DosageFormName": "TABLET",
      "RouteName": "ORAL",
      "StartMarketingDate": "20150708",
      "MarketingCategoryName": "ANDA",
      "ApplicationNumber": "ANDA202821",
      "LabelerName": "Bryant Ranch Prepack",
      "SubstanceName": "FLECAINIDE ACETATE",
      "StrengthNumber": "50",
      "StrengthUnit": "mg/1",
      "Pharm_Classes": "Antiarrhythmic [EPC]",
      "Status": "Active",
      "LastUpdate": "2024-05-03",
      "PackageNdcExcludeFlag": "N",
      "ProductNdcExcludeFlag": "N",
      "ListingRecordCertifiedThrough": "20261231",
      "StartMarketingDatePackage": "20210107",
      "SamplePackage": "N",
      "IndicationAndUsage": "In patients without structural heart disease, flecainide acetate tablets, USP are indicated for the prevention of   —   paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms   —   paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptomsFlecainide acetate tablets, USP are also indicated for the prevention of   —   documented ventricular arrhythmias, such as sustained ventricular tachycardia (sustained VT), that in the judgment of the physician are life-threatening.Use of flecainide acetate tablets, USP for the treatment of sustained VT, like other antiarrhythmics, should be initiated in the hospital. The use of flecainide acetate tablets, USP are not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic.Because of the proarrhythmic effects of flecainide acetate tablets, USP, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks.Flecainide acetate tablets, USP should not be used in patients with recent myocardial infarction. (See BOXED WARNINGS.)Use of flecainide acetate tablets, USP in chronic atrial fibrillation has not been adequately studied and is not recommended. (See BOXED WARNINGS.)As is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of flecainide acetate tablets, USP favorably affects survival or the incidence of sudden death.",
      "Description": "Flecainide acetate is an antiarrhythmic drug available in tablets of 50 mg, 100 mg, or 150 mg for oral administration.Flecainide acetate is benzamide, N-(2-piperidinyl-methyl)-2,5-bis (2,2,2-trifluoroethoxy)-monoacetate. The structural formula is given below. Flecainide acetate USP is a white to slightly off-white, crystalline powder with a pKa of 9.3. It has an aqueous solubility of 48.4 mg/mL at 37°C.Flecainide acetate tablets, USP also contain: croscarmellose sodium, hydrogenated vegetable oil type 1, magnesium stearate, microcrystalline cellulose, and pregelatinized starch."
    },
    {
      "NDCCode": "63629-7979-4",
      "PackageDescription": "10 TABLET in 1 BOTTLE (63629-7979-4) ",
      "NDC11Code": "63629-7979-04",
      "ProductNDC": "63629-7979",
      "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
      "ProprietaryName": "Flecainide Acetate",
      "NonProprietaryName": "Flecainide Acetate",
      "DosageFormName": "TABLET",
      "RouteName": "ORAL",
      "StartMarketingDate": "20150708",
      "MarketingCategoryName": "ANDA",
      "ApplicationNumber": "ANDA202821",
      "LabelerName": "Bryant Ranch Prepack",
      "SubstanceName": "FLECAINIDE ACETATE",
      "StrengthNumber": "50",
      "StrengthUnit": "mg/1",
      "Pharm_Classes": "Antiarrhythmic [EPC]",
      "Status": "Active",
      "LastUpdate": "2024-05-03",
      "PackageNdcExcludeFlag": "N",
      "ProductNdcExcludeFlag": "N",
      "ListingRecordCertifiedThrough": "20261231",
      "StartMarketingDatePackage": "20240403",
      "SamplePackage": "N",
      "IndicationAndUsage": "In patients without structural heart disease, flecainide acetate tablets, USP are indicated for the prevention of   —   paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms   —   paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptomsFlecainide acetate tablets, USP are also indicated for the prevention of   —   documented ventricular arrhythmias, such as sustained ventricular tachycardia (sustained VT), that in the judgment of the physician are life-threatening.Use of flecainide acetate tablets, USP for the treatment of sustained VT, like other antiarrhythmics, should be initiated in the hospital. The use of flecainide acetate tablets, USP are not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic.Because of the proarrhythmic effects of flecainide acetate tablets, USP, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks.Flecainide acetate tablets, USP should not be used in patients with recent myocardial infarction. (See BOXED WARNINGS.)Use of flecainide acetate tablets, USP in chronic atrial fibrillation has not been adequately studied and is not recommended. (See BOXED WARNINGS.)As is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of flecainide acetate tablets, USP favorably affects survival or the incidence of sudden death.",
      "Description": "Flecainide acetate is an antiarrhythmic drug available in tablets of 50 mg, 100 mg, or 150 mg for oral administration.Flecainide acetate is benzamide, N-(2-piperidinyl-methyl)-2,5-bis (2,2,2-trifluoroethoxy)-monoacetate. The structural formula is given below. Flecainide acetate USP is a white to slightly off-white, crystalline powder with a pKa of 9.3. It has an aqueous solubility of 48.4 mg/mL at 37°C.Flecainide acetate tablets, USP also contain: croscarmellose sodium, hydrogenated vegetable oil type 1, magnesium stearate, microcrystalline cellulose, and pregelatinized starch."
    },
    {
      "NDCCode": "63629-7979-5",
      "PackageDescription": "180 TABLET in 1 BOTTLE (63629-7979-5) ",
      "NDC11Code": "63629-7979-05",
      "ProductNDC": "63629-7979",
      "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
      "ProprietaryName": "Flecainide Acetate",
      "NonProprietaryName": "Flecainide Acetate",
      "DosageFormName": "TABLET",
      "RouteName": "ORAL",
      "StartMarketingDate": "20150708",
      "MarketingCategoryName": "ANDA",
      "ApplicationNumber": "ANDA202821",
      "LabelerName": "Bryant Ranch Prepack",
      "SubstanceName": "FLECAINIDE ACETATE",
      "StrengthNumber": "50",
      "StrengthUnit": "mg/1",
      "Pharm_Classes": "Antiarrhythmic [EPC]",
      "Status": "Active",
      "LastUpdate": "2024-05-03",
      "PackageNdcExcludeFlag": "N",
      "ProductNdcExcludeFlag": "N",
      "ListingRecordCertifiedThrough": "20261231",
      "StartMarketingDatePackage": "20220928",
      "SamplePackage": "N",
      "IndicationAndUsage": "In patients without structural heart disease, flecainide acetate tablets, USP are indicated for the prevention of   —   paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms   —   paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptomsFlecainide acetate tablets, USP are also indicated for the prevention of   —   documented ventricular arrhythmias, such as sustained ventricular tachycardia (sustained VT), that in the judgment of the physician are life-threatening.Use of flecainide acetate tablets, USP for the treatment of sustained VT, like other antiarrhythmics, should be initiated in the hospital. The use of flecainide acetate tablets, USP are not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic.Because of the proarrhythmic effects of flecainide acetate tablets, USP, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks.Flecainide acetate tablets, USP should not be used in patients with recent myocardial infarction. (See BOXED WARNINGS.)Use of flecainide acetate tablets, USP in chronic atrial fibrillation has not been adequately studied and is not recommended. (See BOXED WARNINGS.)As is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of flecainide acetate tablets, USP favorably affects survival or the incidence of sudden death.",
      "Description": "Flecainide acetate is an antiarrhythmic drug available in tablets of 50 mg, 100 mg, or 150 mg for oral administration.Flecainide acetate is benzamide, N-(2-piperidinyl-methyl)-2,5-bis (2,2,2-trifluoroethoxy)-monoacetate. The structural formula is given below. Flecainide acetate USP is a white to slightly off-white, crystalline powder with a pKa of 9.3. It has an aqueous solubility of 48.4 mg/mL at 37°C.Flecainide acetate tablets, USP also contain: croscarmellose sodium, hydrogenated vegetable oil type 1, magnesium stearate, microcrystalline cellulose, and pregelatinized starch."
    }
  ]
}
                    

{"NDC":[{"NDCCode":"54118-7979-2","ProprietaryName":"Bacteria Tox","NonProprietaryName":"Adrenal, Atp, Bac Nosode, Belladonna"},{"NDCCode":"63629-7979-2","ProprietaryName":"Flecainide Acetate","NonProprietaryName":"Flecainide Acetate"},{"NDCCode":"54118-7011-2","ProprietaryName":"Rena Code","NonProprietaryName":"Rena Code"},{"NDCCode":"54118-7017-2","ProprietaryName":"Ultimate Phenolics","NonProprietaryName":"Ultimate Phenolics"},{"NDCCode":"54118-7103-2","ProprietaryName":"Myco-tox","NonProprietaryName":"Myco-tox"},{"NDCCode":"54118-7109-2","ProprietaryName":"Pre And Post Milieu","NonProprietaryName":"Pre And Post Milieu"},{"NDCCode":"54118-7114-2","ProprietaryName":"Throat Milieu","NonProprietaryName":"Throat Milieu"},{"NDCCode":"54118-7134-2","ProprietaryName":"Biocell Salts","NonProprietaryName":"Biocell Slats"},{"NDCCode":"54118-7136-2","ProprietaryName":"Pineal Code","NonProprietaryName":"Pineal Code"},{"NDCCode":"54118-7141-2","ProprietaryName":"Glycopan Tox","NonProprietaryName":"Argentium Nitricum, Kali Carbonicum, Glycirrhiza Glabra"},{"NDCCode":"54118-7188-2","ProprietaryName":"Hcg Plus","NonProprietaryName":"Human Chorionic Gonadotropin (hcg), Garcinia Cambogia, Hypothalamus"},{"NDCCode":"54118-7196-2","ProprietaryName":"Oral Hcg Activator","NonProprietaryName":"Hypothalamus, Hepar Suis, Methyl B12, Renal Suis, Gambogia, Graphites"},{"NDCCode":"54118-7232-2","ProprietaryName":"Hcg Plus","NonProprietaryName":"Human Chorionic Gonadotropin (hcg), Garcinia Cambogia, Hypothalamus"},{"NDCCode":"54118-7967-2","ProprietaryName":"Lymph 1 Acute","NonProprietaryName":"Adrenal, Apis Mellifica"},{"NDCCode":"54118-7971-2","ProprietaryName":"Ultimate Fields","NonProprietaryName":"Ultimate Fields"},{"NDCCode":"54118-7972-2","ProprietaryName":"Ultimate Rescue","NonProprietaryName":"Cherry Plum, Clematis, Impatiens, Rock Rose, Star Of Bethlehem, Atp, Pineal, Thymus"},{"NDCCode":"54118-7976-2","ProprietaryName":"Aller-tox 1","NonProprietaryName":"Acetaldehyde, Adrenal, Argentum Nitricum"},{"NDCCode":"54118-7977-2","ProprietaryName":"Aller - Tox 11","NonProprietaryName":"Adrenal, Allium Cepa, Ambrosia Artemisiaefolia"},{"NDCCode":"54118-7978-2","ProprietaryName":"Amoeba Tox","NonProprietaryName":"Adrenal, Amoeba Nosodes, Artemisia Absinthium"},{"NDCCode":"54118-7981-2","ProprietaryName":"Chem - Tox","NonProprietaryName":"Adrenal, Arctium Lappa, Atp, Belladonna, Chemical Isodes"},{"NDCCode":"54118-7990-2","ProprietaryName":"Gyne - Tox","NonProprietaryName":"Adrenal, Angelica Atropurpurea, Boricum Acidum, Atp"},{"NDCCode":"54118-7993-2","ProprietaryName":"Hz - Tox","NonProprietaryName":"Arsenicum Album, Asclepias Tuberus, Atp"},{"NDCCode":"0615-7979-39","ProprietaryName":"Levetiracetam","NonProprietaryName":"Levetiracetam"},{"NDCCode":"50090-7979-0","ProprietaryName":"Olmesartan Medoxomil","NonProprietaryName":"Olmesartan Medoxomil"},{"NDCCode":"50090-7979-1","ProprietaryName":"Olmesartan Medoxomil","NonProprietaryName":"Olmesartan Medoxomil"},{"NDCCode":"55154-7979-0","ProprietaryName":"Extended Phenytoin Sodium","NonProprietaryName":"Phenytoin Sodium"},{"NDCCode":"63629-7979-1","ProprietaryName":"Flecainide Acetate","NonProprietaryName":"Flecainide Acetate"},{"NDCCode":"63629-7979-3","ProprietaryName":"Flecainide Acetate","NonProprietaryName":"Flecainide Acetate"},{"NDCCode":"63629-7979-4","ProprietaryName":"Flecainide Acetate","NonProprietaryName":"Flecainide Acetate"},{"NDCCode":"63629-7979-5","ProprietaryName":"Flecainide Acetate","NonProprietaryName":"Flecainide Acetate"}]}
                    

<?xml version="1.0" encoding="utf-8"?>
<NDCList>
  <NDC>
    <NDCCode>54118-7979-2</NDCCode>
    <PackageDescription>60 mL in 1 BOTTLE, DROPPER (54118-7979-2)</PackageDescription>
    <NDC11Code>54118-7979-02</NDC11Code>
    <ProductNDC>54118-7979</ProductNDC>
    <ProductTypeName>HUMAN OTC DRUG</ProductTypeName>
    <ProprietaryName>Bacteria Tox</ProprietaryName>
    <NonProprietaryName>Adrenal, Atp, Bac Nosode, Belladonna</NonProprietaryName>
    <DosageFormName>SOLUTION/ DROPS</DosageFormName>
    <RouteName>ORAL</RouteName>
    <StartMarketingDate>20121130</StartMarketingDate>
    <MarketingCategoryName>UNAPPROVED HOMEOPATHIC</MarketingCategoryName>
    <LabelerName>ABCO Laboratories, Inc.</LabelerName>
    <SubstanceName>BOS TAURUS ADRENAL GLAND; ADENOSINE TRIPHOSPHATE; MYCOBACTERIUM TUBERCULOSIS; ATROPA BELLADONNA; MYRRH; CROTALUS HORRIDUS HORRIDUS VENOM; GOLDENSEAL; HYPERICUM PERFORATUM; BEEF LIVER; LOMATIUM DISSECTUM ROOT; BORRELIA BURGDORFERI; BOS TAURUS MESENCHYME; NASTURTIUM OFFICINALE; PHOSPHORUS; BOS TAURUS SPLEEN; TABEBUIA IMPETIGINOSA BARK; HUMAN THYMUS</SubstanceName>
    <StrengthNumber>3; 5; 12; 6; 3; 12; 3; 12; 3; 3; 12; 6; 3; 12; 5; 3; 5</StrengthNumber>
    <StrengthUnit>[hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL</StrengthUnit>
    <Status>Deprecated</Status>
    <LastUpdate>2019-09-21</LastUpdate>
    <ProductNdcExcludeFlag>E</ProductNdcExcludeFlag>
    <ListingRecordCertifiedThrough>20171231</ListingRecordCertifiedThrough>
    <IndicationAndUsage>30 drops 2X daily in warm water . or as recommended by a health care practitioner. Shake Well before use.</IndicationAndUsage>
  </NDC>
  <NDC>
    <NDCCode>63629-7979-2</NDCCode>
    <PackageDescription>60 TABLET in 1 BOTTLE (63629-7979-2) </PackageDescription>
    <NDC11Code>63629-7979-02</NDC11Code>
    <ProductNDC>63629-7979</ProductNDC>
    <ProductTypeName>HUMAN PRESCRIPTION DRUG</ProductTypeName>
    <ProprietaryName>Flecainide Acetate</ProprietaryName>
    <NonProprietaryName>Flecainide Acetate</NonProprietaryName>
    <DosageFormName>TABLET</DosageFormName>
    <RouteName>ORAL</RouteName>
    <StartMarketingDate>20150708</StartMarketingDate>
    <MarketingCategoryName>ANDA</MarketingCategoryName>
    <ApplicationNumber>ANDA202821</ApplicationNumber>
    <LabelerName>Bryant Ranch Prepack</LabelerName>
    <SubstanceName>FLECAINIDE ACETATE</SubstanceName>
    <StrengthNumber>50</StrengthNumber>
    <StrengthUnit>mg/1</StrengthUnit>
    <Pharm_Classes>Antiarrhythmic [EPC]</Pharm_Classes>
    <Status>Active</Status>
    <LastUpdate>2024-05-03</LastUpdate>
    <PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
    <ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
    <ListingRecordCertifiedThrough>20261231</ListingRecordCertifiedThrough>
    <StartMarketingDatePackage>20190328</StartMarketingDatePackage>
    <SamplePackage>N</SamplePackage>
    <IndicationAndUsage>In patients without structural heart disease, flecainide acetate tablets, USP are indicated for the prevention of   —   paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms   —   paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptomsFlecainide acetate tablets, USP are also indicated for the prevention of   —   documented ventricular arrhythmias, such as sustained ventricular tachycardia (sustained VT), that in the judgment of the physician are life-threatening.Use of flecainide acetate tablets, USP for the treatment of sustained VT, like other antiarrhythmics, should be initiated in the hospital. The use of flecainide acetate tablets, USP are not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic.Because of the proarrhythmic effects of flecainide acetate tablets, USP, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks.Flecainide acetate tablets, USP should not be used in patients with recent myocardial infarction. (See BOXED WARNINGS.)Use of flecainide acetate tablets, USP in chronic atrial fibrillation has not been adequately studied and is not recommended. (See BOXED WARNINGS.)As is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of flecainide acetate tablets, USP favorably affects survival or the incidence of sudden death.</IndicationAndUsage>
    <Description>Flecainide acetate is an antiarrhythmic drug available in tablets of 50 mg, 100 mg, or 150 mg for oral administration.Flecainide acetate is benzamide, N-(2-piperidinyl-methyl)-2,5-bis (2,2,2-trifluoroethoxy)-monoacetate. The structural formula is given below. Flecainide acetate USP is a white to slightly off-white, crystalline powder with a pKa of 9.3. It has an aqueous solubility of 48.4 mg/mL at 37°C.Flecainide acetate tablets, USP also contain: croscarmellose sodium, hydrogenated vegetable oil type 1, magnesium stearate, microcrystalline cellulose, and pregelatinized starch.</Description>
  </NDC>
  <NDC>
    <NDCCode>54118-7011-2</NDCCode>
    <PackageDescription>60 mL in 1 BOTTLE, DROPPER (54118-7011-2)</PackageDescription>
    <NDC11Code>54118-7011-02</NDC11Code>
    <ProductNDC>54118-7011</ProductNDC>
    <ProductTypeName>HUMAN OTC DRUG</ProductTypeName>
    <ProprietaryName>Rena Code</ProprietaryName>
    <NonProprietaryName>Rena Code</NonProprietaryName>
    <DosageFormName>SOLUTION/ DROPS</DosageFormName>
    <RouteName>ORAL</RouteName>
    <StartMarketingDate>20150721</StartMarketingDate>
    <MarketingCategoryName>UNAPPROVED HOMEOPATHIC</MarketingCategoryName>
    <LabelerName>ABCO Labratories, Inc.</LabelerName>
    <SubstanceName>ADENOSINE TRIPHOSPHATE; BERBERIS VULGARIS WHOLE; BOS TAURUS URINARY BLADDER; BRYONIA ALBA WHOLE; EUPATORIUM PURPUREUM ROOT; HYDRANGEA ARBORESCENS WHOLE; BEEF KIDNEY; MERCURIC CHLORIDE; SODIUM SULFATE; PARSLEY; RUBIA TINCTORUM WHOLE; SOLIDAGO VIRGAUREA WHOLE; ARCTOSTAPHYLOS UVA-URSI WHOLE; CHERRY PLUM; POPULUS TREMULA FLOWERING TOP</SubstanceName>
    <StrengthNumber>5; 3; 6; 12; 12; 12; 6; 12; 6; 3; 6; 3; 3; 30; 30</StrengthNumber>
    <StrengthUnit>[hp_X]/60mL; [hp_X]/60mL; [hp_C]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_C]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_C]/60mL; [hp_C]/60mL</StrengthUnit>
    <Status>Deprecated</Status>
    <LastUpdate>2019-09-21</LastUpdate>
    <ProductNdcExcludeFlag>E</ProductNdcExcludeFlag>
    <ListingRecordCertifiedThrough>20171231</ListingRecordCertifiedThrough>
    <IndicationAndUsage>Porvides Homeopathic Sarcode Support of Kidneys.</IndicationAndUsage>
  </NDC>
  <NDC>
    <NDCCode>54118-7017-2</NDCCode>
    <PackageDescription>60 mL in 1 PACKAGE (54118-7017-2)</PackageDescription>
    <NDC11Code>54118-7017-02</NDC11Code>
    <ProductNDC>54118-7017</ProductNDC>
    <ProductTypeName>HUMAN OTC DRUG</ProductTypeName>
    <ProprietaryName>Ultimate Phenolics</ProprietaryName>
    <NonProprietaryName>Ultimate Phenolics</NonProprietaryName>
    <DosageFormName>SOLUTION/ DROPS</DosageFormName>
    <RouteName>ORAL</RouteName>
    <StartMarketingDate>20150716</StartMarketingDate>
    <MarketingCategoryName>UNAPPROVED HOMEOPATHIC</MarketingCategoryName>
    <LabelerName>ABCO Labratories, Inc.</LabelerName>
    <SubstanceName>ACETYLCHOLINE CHLORIDE; ACETALDEHYDE; PARSLEY; ASCORBIC ACID; BUTYLATED HYDROXYTOLUENE; CAFFEIC ACID; CANDIDA ALBICANS; CHLOROGENIC ACID; CINNAMIC ACID; CONIFERYL ALCOHOL; COUMARIN; DOPAMINE; ESTROGENS, CONJUGATED; .GAMMA.-AMINOBUTYRIC ACID; GALLIC ACID; HISTAMINE; INDOLE; DOPA, DL-; MALVIN; YEAST MANNAN; MELATONIN; MENADIONE; NORADRENALINE, (+/-)-; OCTOPAMINE; PHENYLALANINE; PHENYL ISOTHIOCYANATE; PHLORIZIN; PIPERINE; PROGESTERONE; PYRROLE; QUERCETIN; RUTIN; SALSOLINOL; SEROTONIN; TAURINE; TESTOSTERONE; TRYPTOPHAN; ADENOSINE TRIPHOSPHATE; BOS TAURUS MESENCEPHALON</SubstanceName>
    <StrengthNumber>6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6; 6</StrengthNumber>
    <StrengthUnit>[hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL</StrengthUnit>
    <Status>Deprecated</Status>
    <LastUpdate>2019-09-21</LastUpdate>
    <ProductNdcExcludeFlag>E</ProductNdcExcludeFlag>
    <ListingRecordCertifiedThrough>20171231</ListingRecordCertifiedThrough>
    <IndicationAndUsage>Phenolics.</IndicationAndUsage>
  </NDC>
  <NDC>
    <NDCCode>54118-7103-2</NDCCode>
    <PackageDescription>60 mL in 1 BOTTLE, DROPPER (54118-7103-2)</PackageDescription>
    <NDC11Code>54118-7103-02</NDC11Code>
    <ProductNDC>54118-7103</ProductNDC>
    <ProductTypeName>HUMAN OTC DRUG</ProductTypeName>
    <ProprietaryName>Myco-tox</ProprietaryName>
    <NonProprietaryName>Myco-tox</NonProprietaryName>
    <DosageFormName>SOLUTION/ DROPS</DosageFormName>
    <RouteName>ORAL</RouteName>
    <StartMarketingDate>20150813</StartMarketingDate>
    <MarketingCategoryName>UNAPPROVED HOMEOPATHIC</MarketingCategoryName>
    <LabelerName>ABCO Labratories, Inc.</LabelerName>
    <SubstanceName>BOS TAURUS ADRENAL GLAND; ARSENIC; ADENOSINE TRIPHOSPHATE; SODIUM BORATE; ECHINACEA ANGUSTIFOLIA; GLIOTOXIN; HYDRASTIS CANADENSIS WHOLE; BEEF LIVER; LOMATIUM DISSECTUM WHOLE; BOS TAURUS LYMPH; BOS TAURUS MESENCHYME; PHYTOLACCA AMERICANA WHOLE; BOS TAURUS SPLEEN; STACHYBOTRYS CHARTARUM; TABEBUIA IMPETIGINOSA WHOLE; BOS TAURUS THYMUS; ELYMUS REPENS WHOLE</SubstanceName>
    <StrengthNumber>5; 6; 5; 12; 12; 12; 3; 3; 3; 3; 6; 12; 3; 12; 3; 3; 3</StrengthNumber>
    <StrengthUnit>[hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL</StrengthUnit>
    <Status>Deprecated</Status>
    <LastUpdate>2019-09-21</LastUpdate>
    <ProductNdcExcludeFlag>E</ProductNdcExcludeFlag>
    <ListingRecordCertifiedThrough>20171231</ListingRecordCertifiedThrough>
    <IndicationAndUsage>Detoxifier Homaccord Tincture. For Professional Use Only. Gluten Free.</IndicationAndUsage>
  </NDC>
  <NDC>
    <NDCCode>54118-7109-2</NDCCode>
    <PackageDescription>60 mL in 1 BOTTLE, DROPPER (54118-7109-2)</PackageDescription>
    <NDC11Code>54118-7109-02</NDC11Code>
    <ProductNDC>54118-7109</ProductNDC>
    <ProductTypeName>HUMAN OTC DRUG</ProductTypeName>
    <ProprietaryName>Pre And Post Milieu</ProprietaryName>
    <NonProprietaryName>Pre And Post Milieu</NonProprietaryName>
    <DosageFormName>SOLUTION/ DROPS</DosageFormName>
    <RouteName>ORAL</RouteName>
    <StartMarketingDate>20150825</StartMarketingDate>
    <MarketingCategoryName>UNAPPROVED HOMEOPATHIC</MarketingCategoryName>
    <LabelerName>ABCO Labratories, Inc.</LabelerName>
    <SubstanceName>ARNICA MONTANA; BELLADONNA LEAF; CORTISONE; HYPERICUM PERFORATUM; SYMPHYTUM OFFICINALE WHOLE; VALERIANA OFFICINALIS WHOLE</SubstanceName>
    <StrengthNumber>200; 6; 6; 6; 12; 1</StrengthNumber>
    <StrengthUnit>[hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL</StrengthUnit>
    <Status>Deprecated</Status>
    <LastUpdate>2019-09-21</LastUpdate>
    <ProductNdcExcludeFlag>E</ProductNdcExcludeFlag>
    <ListingRecordCertifiedThrough>20171231</ListingRecordCertifiedThrough>
    <IndicationAndUsage>Drainage Tonifier. For Professional Use only. Gluten Free.</IndicationAndUsage>
  </NDC>
  <NDC>
    <NDCCode>54118-7114-2</NDCCode>
    <PackageDescription>60 mL in 1 BOTTLE, DROPPER (54118-7114-2)</PackageDescription>
    <NDC11Code>54118-7114-02</NDC11Code>
    <ProductNDC>54118-7114</ProductNDC>
    <ProductTypeName>HUMAN OTC DRUG</ProductTypeName>
    <ProprietaryName>Throat Milieu</ProprietaryName>
    <NonProprietaryName>Throat Milieu</NonProprietaryName>
    <DosageFormName>SOLUTION/ DROPS</DosageFormName>
    <RouteName>ORAL</RouteName>
    <StartMarketingDate>20150824</StartMarketingDate>
    <MarketingCategoryName>UNAPPROVED HOMEOPATHIC</MarketingCategoryName>
    <LabelerName>ABCO labratories, Inc.</LabelerName>
    <SubstanceName>APIS MELLIFERA; BAPTISIA TINCTORIA; BELLADONNA LEAF; COMMIPHORA MYRRHA WHOLE; ECHINACEA ANGUSTIFOLIA; FERRIC PHOSPHATE; CALCIUM SULFIDE; HYDRASTIS CANADENSIS WHOLE; LACHESIS MUTA WHOLE; MERCURIUS SOLUBILIS; PHYTOLACCA AMERICANA WHOLE; SALVIA OFFICINALIS WHOLE; CLOVE; THYMUS VULGARIS WHOLE</SubstanceName>
    <StrengthNumber>12; 3; 12; 1; 1; 6; 12; 1; 12; 12; 3; 1; 1; 1</StrengthNumber>
    <StrengthUnit>[hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL</StrengthUnit>
    <Status>Deprecated</Status>
    <LastUpdate>2019-09-21</LastUpdate>
    <ProductNdcExcludeFlag>E</ProductNdcExcludeFlag>
    <ListingRecordCertifiedThrough>20171231</ListingRecordCertifiedThrough>
    <IndicationAndUsage>Drainage Tonifier.</IndicationAndUsage>
  </NDC>
  <NDC>
    <NDCCode>54118-7134-2</NDCCode>
    <PackageDescription>60 mL in 1 BOTTLE, DROPPER (54118-7134-2)</PackageDescription>
    <NDC11Code>54118-7134-02</NDC11Code>
    <ProductNDC>54118-7134</ProductNDC>
    <ProductTypeName>HUMAN OTC DRUG</ProductTypeName>
    <ProprietaryName>Biocell Salts</ProprietaryName>
    <NonProprietaryName>Biocell Slats</NonProprietaryName>
    <DosageFormName>SOLUTION/ DROPS</DosageFormName>
    <RouteName>ORAL</RouteName>
    <StartMarketingDate>20150714</StartMarketingDate>
    <MarketingCategoryName>UNAPPROVED HOMEOPATHIC</MarketingCategoryName>
    <LabelerName>ABCO Laboratories, Inc.</LabelerName>
    <SubstanceName>CALCIUM FLUORIDE; CALCIUM SULFATE; POTASSIUM CHLORIDE; CALCIUM PHOSPHATE; FERRUM PHOSPHORICUM; POTASSIUM SULFATE; SODIUM CHLORIDE; SODIUM SULFATE; MAGNESIUM PHOSPHATE ANHYDROUS; SODIUM PHOSPHATE; SILICON DIOXIDE; ADENOSINE TRIPHOSPHATE; BOS TAURUS PARATHYROID GLAND; BOS TAURUS HYPOTHALAMUS</SubstanceName>
    <StrengthNumber>6; 3; 3; 3; 3; 3; 6; 3; 3; 3; 6; 5; 6; 6</StrengthNumber>
    <StrengthUnit>[hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_C]/60mL; [hp_C]/60mL</StrengthUnit>
    <Status>Deprecated</Status>
    <LastUpdate>2019-09-21</LastUpdate>
    <ProductNdcExcludeFlag>E</ProductNdcExcludeFlag>
    <ListingRecordCertifiedThrough>20171231</ListingRecordCertifiedThrough>
    <IndicationAndUsage>Dietary Suppliment.</IndicationAndUsage>
  </NDC>
  <NDC>
    <NDCCode>54118-7136-2</NDCCode>
    <PackageDescription>60 mL in 1 BOTTLE, DROPPER (54118-7136-2)</PackageDescription>
    <NDC11Code>54118-7136-02</NDC11Code>
    <ProductNDC>54118-7136</ProductNDC>
    <ProductTypeName>HUMAN OTC DRUG</ProductTypeName>
    <ProprietaryName>Pineal Code</ProprietaryName>
    <NonProprietaryName>Pineal Code</NonProprietaryName>
    <DosageFormName>SOLUTION/ DROPS</DosageFormName>
    <RouteName>ORAL</RouteName>
    <StartMarketingDate>20150717</StartMarketingDate>
    <MarketingCategoryName>UNAPPROVED HOMEOPATHIC</MarketingCategoryName>
    <LabelerName>ABCO Labratories, Inc.</LabelerName>
    <SubstanceName>BOS TAURUS PINEAL GLAND; GOLD; BERBERIS VULGARIS FRUIT; CALCIUM FLUORIDE</SubstanceName>
    <StrengthNumber>6; 5; 3; 12</StrengthNumber>
    <StrengthUnit>[hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_X]/60mL</StrengthUnit>
    <Status>Deprecated</Status>
    <LastUpdate>2019-09-21</LastUpdate>
    <ProductNdcExcludeFlag>E</ProductNdcExcludeFlag>
    <ListingRecordCertifiedThrough>20171231</ListingRecordCertifiedThrough>
    <IndicationAndUsage>Sarcode Organotherapy.</IndicationAndUsage>
  </NDC>
  <NDC>
    <NDCCode>54118-7141-2</NDCCode>
    <PackageDescription>60 mL in 1 BOTTLE, DROPPER (54118-7141-2)</PackageDescription>
    <NDC11Code>54118-7141-02</NDC11Code>
    <ProductNDC>54118-7141</ProductNDC>
    <ProductTypeName>HUMAN OTC DRUG</ProductTypeName>
    <ProprietaryName>Glycopan Tox</ProprietaryName>
    <NonProprietaryName>Argentium Nitricum, Kali Carbonicum, Glycirrhiza Glabra</NonProprietaryName>
    <DosageFormName>SOLUTION/ DROPS</DosageFormName>
    <RouteName>ORAL</RouteName>
    <StartMarketingDate>20130201</StartMarketingDate>
    <MarketingCategoryName>UNAPPROVED HOMEOPATHIC</MarketingCategoryName>
    <LabelerName>ABCO Laboratories, Inc.</LabelerName>
    <SubstanceName>SILVER NITRATE; POTASSIUM CARBONATE; GLYCYRRHIZA GLABRA; MAMMAL LIVER; BOS TAURUS ADRENAL GLAND; SKIM MILK; SUS SCROFA PANCREAS; LACTIC ACID, DL-; LYCOPODIUM CLAVATUM SPORE; PHOSPHORIC ACID; SUCROSE; URANYL NITRATE HEXAHYDRATE; THYROID, UNSPECIFIED; BOS TAURUS PITUITARY GLAND; CHOLESTEROL; KIDNEY BEAN; GYMNEMA SYLVESTRE LEAF; RHUS AROMATICA ROOT BARK; FENUGREEK SEED; CHROMIUM; SYZYGIUM CUMINI SEED; ZINC; SELENIUM; BOS TAURUS MESENCHYME; ADENOSINE TRIPHOSPHATE</SubstanceName>
    <StrengthNumber>9; 9; 1; 6; 6; 6; 6; 3; 30; 4; 6; 30; 6; 6; 7; 1; 1; 3; 3; 3; 1; 9; 9; 6; 5</StrengthNumber>
    <StrengthUnit>[hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_X]/60mL; [hp_C]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL</StrengthUnit>
    <Status>Deprecated</Status>
    <LastUpdate>2019-09-21</LastUpdate>
    <ProductNdcExcludeFlag>E</ProductNdcExcludeFlag>
    <ListingRecordCertifiedThrough>20171231</ListingRecordCertifiedThrough>
    <IndicationAndUsage>30 drops 2X daily . or as recommended by a health care practitioner. Shake well before use.</IndicationAndUsage>
  </NDC>
  <NDC>
    <NDCCode>54118-7188-2</NDCCode>
    <PackageDescription>60 mL in 1 BOTTLE, DROPPER (54118-7188-2)</PackageDescription>
    <NDC11Code>54118-7188-02</NDC11Code>
    <ProductNDC>54118-7188</ProductNDC>
    <ProductTypeName>HUMAN OTC DRUG</ProductTypeName>
    <ProprietaryName>Hcg Plus</ProprietaryName>
    <NonProprietaryName>Human Chorionic Gonadotropin (hcg), Garcinia Cambogia, Hypothalamus</NonProprietaryName>
    <DosageFormName>SOLUTION/ DROPS</DosageFormName>
    <RouteName>ORAL</RouteName>
    <StartMarketingDate>20140516</StartMarketingDate>
    <MarketingCategoryName>UNAPPROVED HOMEOPATHIC</MarketingCategoryName>
    <LabelerName>ABCO Laboratories, Inc.</LabelerName>
    <SubstanceName>AMERICAN GINSENG; FUCUS VESICULOSUS; CALCIUM ARSENATE; GLUTAMIC ACID; LEUCINE; ARGININE; ACETYLCARNITINE; ORNITHINE; GONADOTROPHIN, CHORIONIC</SubstanceName>
    <StrengthNumber>6; 6; 6; 6; 6; 3; 3; 12; 12</StrengthNumber>
    <StrengthUnit>[hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL</StrengthUnit>
    <Status>Deprecated</Status>
    <LastUpdate>2019-09-21</LastUpdate>
    <ProductNdcExcludeFlag>E</ProductNdcExcludeFlag>
    <ListingRecordCertifiedThrough>20171231</ListingRecordCertifiedThrough>
    <IndicationAndUsage>hCG Plus provides homeopathic support for weight management. This product is to be used in conjunction with the specific hCG Nutritional VLCD protocol. . The entire program has shown marvelous results by providing the key nutrients, minerals and essential amino acids that assist with decreasing appetite, restoring hypothalamus function, improving metabolism mechanisms, and detoxifying organs and tissues of the body. .</IndicationAndUsage>
  </NDC>
  <NDC>
    <NDCCode>54118-7196-2</NDCCode>
    <PackageDescription>59 mL in 1 BOTTLE, DROPPER (54118-7196-2)</PackageDescription>
    <NDC11Code>54118-7196-02</NDC11Code>
    <ProductNDC>54118-7196</ProductNDC>
    <ProductTypeName>HUMAN OTC DRUG</ProductTypeName>
    <ProprietaryName>Oral Hcg Activator</ProprietaryName>
    <NonProprietaryName>Hypothalamus, Hepar Suis, Methyl B12, Renal Suis, Gambogia, Graphites</NonProprietaryName>
    <DosageFormName>SOLUTION/ DROPS</DosageFormName>
    <RouteName>ORAL</RouteName>
    <StartMarketingDate>20140305</StartMarketingDate>
    <MarketingCategoryName>UNAPPROVED HOMEOPATHIC</MarketingCategoryName>
    <LabelerName>ABCO Laboratories, Inc.</LabelerName>
    <SubstanceName>BOS TAURUS HYPOTHALAMUS; PORK LIVER; METHYLCOBALAMIN; PORK KIDNEY; GAMBOGE; GRAPHITE; STRYCHNOS NUX-VOMICA SEED; PHYTOLACCA AMERICANA ROOT; 7-KETO-DEHYDROEPIANDROSTERONE; ADENOSINE TRIPHOSPHATE; GLUCAGON; INSULIN PORK; LACTIC ACID, L-; ARGININE; LEVOCARNITINE; TRYPTOPHAN; PHENYLALANINE; THYROID, UNSPECIFIED; BOS TAURUS PITUITARY GLAND; GENTIANA LUTEA ROOT; SEMECARPUS ANACARDIUM JUICE</SubstanceName>
    <StrengthNumber>6; 8; 8; 8; 12; 12; 12; 3; 30; 30; 30; 30; 3; 12; 12; 12; 12; 3; 6; 5; 15</StrengthNumber>
    <StrengthUnit>[hp_X]/59mL; [hp_X]/59mL; [hp_X]/59mL; [hp_X]/59mL; [hp_X]/59mL; [hp_X]/59mL; [hp_X]/59mL; [hp_X]/59mL; [hp_X]/59mL; [hp_X]/59mL; [hp_X]/59mL; [hp_X]/59mL; [hp_X]/59mL; [hp_C]/59mL; [hp_C]/59mL; [hp_C]/59mL; [hp_C]/59mL; [hp_X]/59mL; [hp_X]/59mL; [hp_C]/59mL; [hp_C]/59mL</StrengthUnit>
    <Status>Deprecated</Status>
    <LastUpdate>2019-09-21</LastUpdate>
    <ProductNdcExcludeFlag>E</ProductNdcExcludeFlag>
    <ListingRecordCertifiedThrough>20171231</ListingRecordCertifiedThrough>
    <IndicationAndUsage>Place 10 drops under the tongue three to six times a day . or as directed by your healthcare professional. Consult a physician for use in children under 12 years of age.</IndicationAndUsage>
  </NDC>
  <NDC>
    <NDCCode>54118-7232-2</NDCCode>
    <PackageDescription>60 mL in 1 BOTTLE, DROPPER (54118-7232-2)</PackageDescription>
    <NDC11Code>54118-7232-02</NDC11Code>
    <ProductNDC>54118-7232</ProductNDC>
    <ProductTypeName>HUMAN OTC DRUG</ProductTypeName>
    <ProprietaryName>Hcg Plus</ProprietaryName>
    <NonProprietaryName>Human Chorionic Gonadotropin (hcg), Garcinia Cambogia, Hypothalamus</NonProprietaryName>
    <DosageFormName>SOLUTION/ DROPS</DosageFormName>
    <RouteName>ORAL</RouteName>
    <StartMarketingDate>20140405</StartMarketingDate>
    <MarketingCategoryName>UNAPPROVED HOMEOPATHIC</MarketingCategoryName>
    <LabelerName>ABCO Laboratories, Inc.</LabelerName>
    <SubstanceName>GONADOTROPHIN, CHORIONIC; GARCINIA CAMBOGIA FRUIT; BOS TAURUS HYPOTHALAMUS; BOS TAURUS BRAIN; PORK LIVER; METHYLCOBALAMIN; SUS SCROFA PANCREAS; BEEF KIDNEY; TRIPE; CALCIUM CARBONATE; GELSEMIUM SEMPERVIRENS WHOLE; GRAPHITE; STRYCHNOS NUX-VOMICA SEED; PHYTOLACCA AMERICANA ROOT; 7-KETO-DEHYDROEPIANDROSTERONE; SEMECARPUS ANACARDIUM JUICE; GLUCAGON; INSULIN HUMAN; LACTIC ACID, L-; PROTEUS INCONSTANS; THYROID, UNSPECIFIED; BOS TAURUS PITUITARY GLAND; CALCIUM FLUORIDE; FUCUS VESICULOSUS; AMMONIUM CARBONATE</SubstanceName>
    <StrengthNumber>12; 12; 6; 8; 8; 8; 8; 8; 8; 12; 12; 12; 12; 12; 30; 6; 30; 30; 30; 30; 12; 12; 6; 3; 6</StrengthNumber>
    <StrengthUnit>[hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL</StrengthUnit>
    <Status>Deprecated</Status>
    <LastUpdate>2019-09-21</LastUpdate>
    <ProductNdcExcludeFlag>E</ProductNdcExcludeFlag>
    <ListingRecordCertifiedThrough>20171231</ListingRecordCertifiedThrough>
    <IndicationAndUsage>Provides homeopathic support for temporary relief of symptioms related to obesity, weight gain, appetite support, detoxification, regulation of fat metabolism, headache, . fatigue and irritability, while following a proper diet and exercise program.</IndicationAndUsage>
  </NDC>
  <NDC>
    <NDCCode>54118-7967-2</NDCCode>
    <PackageDescription>60 mL in 1 BOTTLE, DROPPER (54118-7967-2)</PackageDescription>
    <NDC11Code>54118-7967-02</NDC11Code>
    <ProductNDC>54118-7967</ProductNDC>
    <ProductTypeName>HUMAN OTC DRUG</ProductTypeName>
    <ProprietaryName>Lymph 1 Acute</ProprietaryName>
    <NonProprietaryName>Adrenal, Apis Mellifica</NonProprietaryName>
    <DosageFormName>SOLUTION/ DROPS</DosageFormName>
    <RouteName>ORAL</RouteName>
    <StartMarketingDate>20110228</StartMarketingDate>
    <MarketingCategoryName>UNAPPROVED HOMEOPATHIC</MarketingCategoryName>
    <LabelerName>ABCO Laboratories, Inc.</LabelerName>
    <SubstanceName>BOS TAURUS ADRENAL GLAND; APIS MELLIFERA; ARANEUS DIADEMATUS; ADENOSINE TRIPHOSPHATE; ATROPA BELLADONNA; OYSTER SHELL CALCIUM CARBONATE, CRUDE; CONIUM MACULATUM FLOWERING TOP; ECHINACEA ANGUSTIFOLIA; FUMARIA OFFICINALIS FLOWERING TOP; GALIUM APARINE; GRAPHITE; BOS TAURUS HYPOTHALAMUS; POTASSIUM IODIDE; LACHESIS MUTA VENOM; MERCUROUS IODIDE; VIROLA SEBIFERA RESIN; PHOSPHORUS; PHYTOLACCA AMERICANA ROOT; MARITIME PINE; BOS TAURUS PITUITARY GLAND; TOXICODENDRON PUBESCENS LEAF; SCROPHULARIA NODOSA; SULFUR; THYROID, BOVINE; UNCARIA TOMENTOSA LEAF; VESPA CRABRO</SubstanceName>
    <StrengthNumber>3; 3; 9; 4; 6; 9; 6; 1; 6; 9; 6; 3; 3; 12; 9; 9; 12; 2; 6; 3; 12; 9; 12; 6; 3; 12</StrengthNumber>
    <StrengthUnit>[hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL</StrengthUnit>
    <Status>Deprecated</Status>
    <LastUpdate>2019-09-21</LastUpdate>
    <ProductNdcExcludeFlag>E</ProductNdcExcludeFlag>
    <ListingRecordCertifiedThrough>20171231</ListingRecordCertifiedThrough>
    <IndicationAndUsage>30 drops 2X daily in warm water or as recommended by a health care practitioner. Shake well before use.</IndicationAndUsage>
  </NDC>
  <NDC>
    <NDCCode>54118-7971-2</NDCCode>
    <PackageDescription>60 mL in 1 BOTTLE, DROPPER (54118-7971-2)</PackageDescription>
    <NDC11Code>54118-7971-02</NDC11Code>
    <ProductNDC>54118-7971</ProductNDC>
    <ProductTypeName>HUMAN OTC DRUG</ProductTypeName>
    <ProprietaryName>Ultimate Fields</ProprietaryName>
    <NonProprietaryName>Ultimate Fields</NonProprietaryName>
    <DosageFormName>SOLUTION/ DROPS</DosageFormName>
    <RouteName>ORAL</RouteName>
    <StartMarketingDate>20150715</StartMarketingDate>
    <MarketingCategoryName>UNAPPROVED HOMEOPATHIC</MarketingCategoryName>
    <LabelerName>ABCO Laboratories, Inc.</LabelerName>
    <SubstanceName>AGRIMONIA EUPATORIA; POPULUS ALBA WHOLE; FAGUS SYLVATICA FLOWERING TOP; CERATOSTIGMA WILLMOTTIANUM FLOWER; PRUNUS CERASIFERA FLOWER; AESCULUS HIPPOCASTANUM WHOLE; CICHORIUM INTYBUS FLOWER; MALUS SYLVESTRIS FLOWER; ULMUS ALATA WHOLE; GENTIANA ACAULIS; ULEX EUROPAEUS FLOWER; CALLUNA VULGARIS FLOWERING TOP; ILEX AQUIFOLIUM FLOWERING TOP; LONICERA CAPRIFOLIUM FLOWERING TOP; CARPINUS BETULUS FLOWERING TOP; IMPATIENS CAPENSIS WHOLE; LARIX DECIDUA WHOLE; MIMULUS GUTTATUS FLOWERING TOP; BRASSICA NIGRA WHOLE; QUERCUS ROBUR FLOWER; OLEA EUROPAEA FRUIT VOLATILE OIL; PINUS SYLVESTRIS FLOWERING TOP; AESCULUS CARNEA FLOWER; HELIANTHEMUM NUMMULARIUM FLOWER; SCLERANTHUS ANNUUS FLOWERING TOP; ORNITHOGALUM UMBELLATUM; CASTANEA SATIVA FLOWER; VERBENA OFFICINALIS FLOWERING TOP; VITIS VINIFERA FLOWERING TOP; JUGLANS REGIA FLOWERING TOP; HOTTONIA PALUSTRIS FLOWER; AESCULUS HIPPOCASTANUM FLOWER; AVENA FATUA WHOLE; ROSA CANINA FLOWER; SALIX ALBA FLOWERING TOP; ADENOSINE TRIPHOSPHATE; BOS TAURUS PINEAL GLAND; BOS TAURUS THYMUS</SubstanceName>
    <StrengthNumber>30; 30; 30; 30; 30; 30; 30; 30; 30; 30; 30; 30; 30; 30; 30; 30; 30; 30; 30; 30; 30; 30; 30; 30; 30; 30; 30; 30; 30; 30; 30; 30; 30; 30; 30; 5; 6; 6</StrengthNumber>
    <StrengthUnit>[hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_X]/60mL; [hp_C]/60mL; [hp_C]/60mL</StrengthUnit>
    <Status>Deprecated</Status>
    <LastUpdate>2019-09-21</LastUpdate>
    <ProductNdcExcludeFlag>E</ProductNdcExcludeFlag>
    <ListingRecordCertifiedThrough>20171231</ListingRecordCertifiedThrough>
    <IndicationAndUsage>For Professional Use Only.</IndicationAndUsage>
  </NDC>
  <NDC>
    <NDCCode>54118-7972-2</NDCCode>
    <PackageDescription>60 mL in 1 BOTTLE, DROPPER (54118-7972-2)</PackageDescription>
    <NDC11Code>54118-7972-02</NDC11Code>
    <ProductNDC>54118-7972</ProductNDC>
    <ProductTypeName>HUMAN OTC DRUG</ProductTypeName>
    <ProprietaryName>Ultimate Rescue</ProprietaryName>
    <NonProprietaryName>Cherry Plum, Clematis, Impatiens, Rock Rose, Star Of Bethlehem, Atp, Pineal, Thymus</NonProprietaryName>
    <DosageFormName>SOLUTION/ DROPS</DosageFormName>
    <RouteName>ORAL</RouteName>
    <StartMarketingDate>20110228</StartMarketingDate>
    <MarketingCategoryName>UNAPPROVED HOMEOPATHIC</MarketingCategoryName>
    <LabelerName>ABCO Laboratories, Inc.</LabelerName>
    <SubstanceName>CHERRY PLUM; CLEMATIS CHINENSIS ROOT; IMPATIENS BALSAMINA LEAF; CISTUS INCANUS WHOLE; ORNITHOGALUM UMBELLATUM; ADENOSINE TRIPHOSPHATE; BOS TAURUS PINEAL GLAND; BOS TAURUS THYMUS</SubstanceName>
    <StrengthNumber>30; 30; 30; 30; 30; 5; 6; 6</StrengthNumber>
    <StrengthUnit>[hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_C]/60mL; [hp_X]/60mL; [hp_C]/60mL; [hp_C]/60mL</StrengthUnit>
    <Status>Deprecated</Status>
    <LastUpdate>2019-09-21</LastUpdate>
    <ProductNdcExcludeFlag>E</ProductNdcExcludeFlag>
    <ListingRecordCertifiedThrough>20171231</ListingRecordCertifiedThrough>
    <IndicationAndUsage>Directions. 30 drops 2X daily or as recommended by a health care practitioner.</IndicationAndUsage>
  </NDC>
  <NDC>
    <NDCCode>54118-7976-2</NDCCode>
    <PackageDescription>60 mL in 1 BOTTLE, DROPPER (54118-7976-2)</PackageDescription>
    <NDC11Code>54118-7976-02</NDC11Code>
    <ProductNDC>54118-7976</ProductNDC>
    <ProductTypeName>HUMAN OTC DRUG</ProductTypeName>
    <ProprietaryName>Aller-tox 1</ProprietaryName>
    <NonProprietaryName>Acetaldehyde, Adrenal, Argentum Nitricum</NonProprietaryName>
    <DosageFormName>SOLUTION/ DROPS</DosageFormName>
    <RouteName>ORAL</RouteName>
    <StartMarketingDate>20121121</StartMarketingDate>
    <MarketingCategoryName>UNAPPROVED HOMEOPATHIC</MarketingCategoryName>
    <LabelerName>ABCO Laboratories, Inc.</LabelerName>
    <SubstanceName>ACETALDEHYDE; BOS TAURUS ADRENAL GLAND; SILVER NITRATE; ARSENIC TRIOXIDE; ADENOSINE TRIPHOSPHATE; CORTISONE; BERBERIS VULGARIS ROOT BARK; CORTICOTROPIN; GALLIC ACID MONOHYDRATE; HISTAMINE; HYALURONIDASE; INTERFERON BETA-1A; MAMMAL LIVER; LYCOPODIUM CLAVATUM SPORE; BOS TAURUS MESENCHYME; SEROTONIN; HYDRANGEA ARBORESCENS ROOT; STRYCHNOS NUX-VOMICA SEED</SubstanceName>
    <StrengthNumber>6; 3; 6; 6; 5; 6; 30; 12; 6; 6; 6; 6; 5; 12; 6; 6; 6; 12</StrengthNumber>
    <StrengthUnit>[hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL</StrengthUnit>
    <Status>Deprecated</Status>
    <LastUpdate>2019-09-21</LastUpdate>
    <ProductNdcExcludeFlag>E</ProductNdcExcludeFlag>
    <ListingRecordCertifiedThrough>20171231</ListingRecordCertifiedThrough>
    <IndicationAndUsage>30 drops 2X daily in warm water . or as recommended by a health care practitioner.</IndicationAndUsage>
  </NDC>
  <NDC>
    <NDCCode>54118-7977-2</NDCCode>
    <PackageDescription>60 mL in 1 BOTTLE, DROPPER (54118-7977-2)</PackageDescription>
    <NDC11Code>54118-7977-02</NDC11Code>
    <ProductNDC>54118-7977</ProductNDC>
    <ProductTypeName>HUMAN OTC DRUG</ProductTypeName>
    <ProprietaryName>Aller - Tox 11</ProprietaryName>
    <NonProprietaryName>Adrenal, Allium Cepa, Ambrosia Artemisiaefolia</NonProprietaryName>
    <DosageFormName>SOLUTION/ DROPS</DosageFormName>
    <RouteName>ORAL</RouteName>
    <StartMarketingDate>20121128</StartMarketingDate>
    <MarketingCategoryName>UNAPPROVED HOMEOPATHIC</MarketingCategoryName>
    <LabelerName>ABCO Laboratories, Inc</LabelerName>
    <SubstanceName>BOS TAURUS ADRENAL GLAND; ONION; AMBROSIA ARTEMISIIFOLIA; ARSENIC TRIOXIDE; ADENOSINE TRIPHOSPHATE; COUMARIN; EUPHRASIA STRICTA; HISTAMINE; BEEF LIVER; BEEF LUNG; MENADIONE; BOS TAURUS MESENCHYME; PHOSPHORUS; PIPERINE; HYALURONIDASE; PULSATILLA PRATENSIS; RUTIN; SCHOENOCAULON OFFICINALE SEED; SULFUR</SubstanceName>
    <StrengthNumber>3; 3; 3; 12; 5; 6; 3; 6; 5; 3; 5; 6; 12; 5; 9; 12; 5; 3; 12</StrengthNumber>
    <StrengthUnit>[hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL</StrengthUnit>
    <Status>Deprecated</Status>
    <LastUpdate>2019-09-21</LastUpdate>
    <ProductNdcExcludeFlag>E</ProductNdcExcludeFlag>
    <ListingRecordCertifiedThrough>20171231</ListingRecordCertifiedThrough>
    <IndicationAndUsage>30 drops 2X daily . or as recommended by a health care practitioner. Shake well before use.</IndicationAndUsage>
  </NDC>
  <NDC>
    <NDCCode>54118-7978-2</NDCCode>
    <PackageDescription>60 mL in 1 BOTTLE, DROPPER (54118-7978-2)</PackageDescription>
    <NDC11Code>54118-7978-02</NDC11Code>
    <ProductNDC>54118-7978</ProductNDC>
    <ProductTypeName>HUMAN OTC DRUG</ProductTypeName>
    <ProprietaryName>Amoeba Tox</ProprietaryName>
    <NonProprietaryName>Adrenal, Amoeba Nosodes, Artemisia Absinthium</NonProprietaryName>
    <DosageFormName>SOLUTION/ DROPS</DosageFormName>
    <RouteName>ORAL</RouteName>
    <StartMarketingDate>20121128</StartMarketingDate>
    <MarketingCategoryName>UNAPPROVED HOMEOPATHIC</MarketingCategoryName>
    <LabelerName>ABCO Laboratories, Inc</LabelerName>
    <SubstanceName>BOS TAURUS ADRENAL GLAND; ENTAMOEBA HISTOLYTICA; WORMWOOD; ADENOSINE TRIPHOSPHATE; BAPTISIA TINCTORIA; CAJUPUT OIL; CAPSICUM; SENNA LEAF; CHELONE GLABRA; CINCHONA OFFICINALIS BARK; ALPINE STRAWBERRY; GENTIANA LUTEA ROOT; GOLDENSEAL; CEANOTHUS AMERICANUS LEAF; MAMMAL LIVER; LYCOPODIUM CLAVATUM SPORE; BOS TAURUS MESENCHYME; STRYCHNOS NUX-VOMICA SEED; QUASSIA AMARA WOOD; BOS TAURUS SPLEEN</SubstanceName>
    <StrengthNumber>6; 30; 6; 5; 3; 1; 3; 3; 3; 12; 3; 6; 3; 6; 5; 12; 6; 12; 3; 5</StrengthNumber>
    <StrengthUnit>[hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_C]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_Q]/60mL; [hp_X]/60mL</StrengthUnit>
    <Status>Deprecated</Status>
    <LastUpdate>2019-09-21</LastUpdate>
    <ProductNdcExcludeFlag>E</ProductNdcExcludeFlag>
    <ListingRecordCertifiedThrough>20171231</ListingRecordCertifiedThrough>
    <IndicationAndUsage>30 drops 2X daily in warm water . or as recommended by a health care practitioner. Shake well before use.</IndicationAndUsage>
  </NDC>
  <NDC>
    <NDCCode>54118-7981-2</NDCCode>
    <PackageDescription>60 mL in 1 BOTTLE, DROPPER (54118-7981-2)</PackageDescription>
    <NDC11Code>54118-7981-02</NDC11Code>
    <ProductNDC>54118-7981</ProductNDC>
    <ProductTypeName>HUMAN OTC DRUG</ProductTypeName>
    <ProprietaryName>Chem - Tox</ProprietaryName>
    <NonProprietaryName>Adrenal, Arctium Lappa, Atp, Belladonna, Chemical Isodes</NonProprietaryName>
    <DosageFormName>SOLUTION/ DROPS</DosageFormName>
    <RouteName>ORAL</RouteName>
    <StartMarketingDate>20121130</StartMarketingDate>
    <MarketingCategoryName>UNAPPROVED HOMEOPATHIC</MarketingCategoryName>
    <LabelerName>ABCO Laboratories, Inc.</LabelerName>
    <SubstanceName>BOS TAURUS ADRENAL GLAND; ARCTIUM LAPPA WHOLE; ADENOSINE TRIPHOSPHATE; ATROPA BELLADONNA; ARSENIC TRIOXIDE; LICORICE; BEEF KIDNEY; BEEF LIVER; LYCOPODIUM CLAVATUM SPORE; BOS TAURUS LYMPH; BOS TAURUS MESENCHYME; NITRIC ACID; STRYCHNOS NUX-VOMICA SEED; PHOSPHORIC ACID; PHOSPHORUS; PHYTOLACCA AMERICANA ROOT; FRANGULA PURSHIANA BARK; THYROID, BOVINE; TRIFOLIUM PRATENSE FLOWER; ELYMUS REPENS ROOT</SubstanceName>
    <StrengthNumber>5; 3; 5; 12; 12; 3; 3; 3; 12; 3; 6; 6; 12; 6; 12; 3; 3; 5; 3; 3</StrengthNumber>
    <StrengthUnit>[hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL</StrengthUnit>
    <Status>Deprecated</Status>
    <LastUpdate>2019-09-21</LastUpdate>
    <ProductNdcExcludeFlag>E</ProductNdcExcludeFlag>
    <ListingRecordCertifiedThrough>20171231</ListingRecordCertifiedThrough>
    <IndicationAndUsage>30 drops 2X daily in warm water . or as recommended by a health care practitioner. Shake Well before use.</IndicationAndUsage>
  </NDC>
  <NDC>
    <NDCCode>54118-7990-2</NDCCode>
    <PackageDescription>60 mL in 1 BOTTLE, DROPPER (54118-7990-2)</PackageDescription>
    <NDC11Code>54118-7990-02</NDC11Code>
    <ProductNDC>54118-7990</ProductNDC>
    <ProductTypeName>HUMAN OTC DRUG</ProductTypeName>
    <ProprietaryName>Gyne - Tox</ProprietaryName>
    <NonProprietaryName>Adrenal, Angelica Atropurpurea, Boricum Acidum, Atp</NonProprietaryName>
    <DosageFormName>SOLUTION/ DROPS</DosageFormName>
    <RouteName>ORAL</RouteName>
    <StartMarketingDate>20121219</StartMarketingDate>
    <MarketingCategoryName>UNAPPROVED HOMEOPATHIC</MarketingCategoryName>
    <LabelerName>ABCO Laboratories, Inc.</LabelerName>
    <SubstanceName>BOS TAURUS ADRENAL GLAND; ANGELICA ATROPURPUREA ROOT; BORIC ACID; ADENOSINE TRIPHOSPHATE; BOS TAURUS MESENCHYME; CANDIDA ALBICANS; BLACK COHOSH; WOOD CREOSOTE; BOS TAURUS LYMPH; GONORRHEAL URETHRAL SECRETION HUMAN; MERCURIUS SOLUBILIS; ESTRONE; BOS TAURUS OVARY; BOS TAURUS PLACENTA; SCABIES LESION LYSATE (HUMAN); ANEMONE NEMOROSA; SEPIA OFFICINALIS JUICE; DELPHINIUM STAPHISAGRIA SEED; TREPONEMIC SKIN CANKER HUMAN; THUJA OCCIDENTALIS LEAFY TWIG; THYROID, UNSPECIFIED; BOS TAURUS UTERUS</SubstanceName>
    <StrengthNumber>6; 3; 12; 5; 6; 6; 3; 12; 6; 30; 12; 30; 5; 5; 30; 12; 12; 12; 30; 12; 6; 5</StrengthNumber>
    <StrengthUnit>[hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL</StrengthUnit>
    <Status>Deprecated</Status>
    <LastUpdate>2019-09-21</LastUpdate>
    <ProductNdcExcludeFlag>E</ProductNdcExcludeFlag>
    <ListingRecordCertifiedThrough>20171231</ListingRecordCertifiedThrough>
    <IndicationAndUsage>30 drops 2X daily . or as recommended by a health care practitioner. Shake well before use.</IndicationAndUsage>
  </NDC>
  <NDC>
    <NDCCode>54118-7993-2</NDCCode>
    <PackageDescription>60 mL in 1 BOTTLE, DROPPER (54118-7993-2)</PackageDescription>
    <NDC11Code>54118-7993-02</NDC11Code>
    <ProductNDC>54118-7993</ProductNDC>
    <ProductTypeName>HUMAN OTC DRUG</ProductTypeName>
    <ProprietaryName>Hz - Tox</ProprietaryName>
    <NonProprietaryName>Arsenicum Album, Asclepias Tuberus, Atp</NonProprietaryName>
    <DosageFormName>SOLUTION/ DROPS</DosageFormName>
    <RouteName>ORAL</RouteName>
    <StartMarketingDate>20121221</StartMarketingDate>
    <MarketingCategoryName>UNAPPROVED HOMEOPATHIC</MarketingCategoryName>
    <LabelerName>ABCO Laboratories, Inc</LabelerName>
    <SubstanceName>ARSENIC; ASCLEPIAS TUBEROSA FLOWERING TOP; ADENOSINE TRIPHOSPHATE; BAPTISIA TINCTORIA; HUMAN HERPESVIRUS 5; LOMATIUM DISSECTUM ROOT; BOS TAURUS LYMPH; BOS TAURUS MESENCHYME; DAPHNE MEZEREUM BARK; STRYCHNOS NUX-VOMICA SEED; RANUNCULUS BULBOSUS; BOS TAURUS SPLEEN; THUJA OCCIDENTALIS LEAF; BOS TAURUS THYMUS; THYROID, BOVINE; CAT'S CLAW; CALCIUM SULFATE ANHYDROUS; TOXICODENDRON PUBESCENS LEAF</SubstanceName>
    <StrengthNumber>3; 3; 5; 3; 30; 3; 3; 6; 3; 12; 3; 3; 12; 5; 5; 1; 6; 6</StrengthNumber>
    <StrengthUnit>[hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; 1/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL; [hp_X]/60mL</StrengthUnit>
    <Status>Deprecated</Status>
    <LastUpdate>2019-09-21</LastUpdate>
    <ProductNdcExcludeFlag>E</ProductNdcExcludeFlag>
    <ListingRecordCertifiedThrough>20171231</ListingRecordCertifiedThrough>
    <IndicationAndUsage>30 drops 2X daily in warm water or as recommended by a health care practitioner,. Shake well before use.</IndicationAndUsage>
  </NDC>
  <NDC>
    <NDCCode>0615-7979-39</NDCCode>
    <PackageDescription>30 TABLET, FILM COATED in 1 BLISTER PACK (0615-7979-39) </PackageDescription>
    <NDC11Code>00615-7979-39</NDC11Code>
    <ProductNDC>0615-7979</ProductNDC>
    <ProductTypeName>HUMAN PRESCRIPTION DRUG</ProductTypeName>
    <ProprietaryName>Levetiracetam</ProprietaryName>
    <NonProprietaryName>Levetiracetam</NonProprietaryName>
    <DosageFormName>TABLET, FILM COATED</DosageFormName>
    <RouteName>ORAL</RouteName>
    <StartMarketingDate>20090115</StartMarketingDate>
    <EndMarketingDate>20241031</EndMarketingDate>
    <MarketingCategoryName>ANDA</MarketingCategoryName>
    <ApplicationNumber>ANDA090025</ApplicationNumber>
    <LabelerName>NCS HealthCare of KY, LLC dba Vangard Labs</LabelerName>
    <SubstanceName>LEVETIRACETAM</SubstanceName>
    <StrengthNumber>1000</StrengthNumber>
    <StrengthUnit>mg/1</StrengthUnit>
    <Pharm_Classes>Decreased Central Nervous System Disorganized Electrical Activity [PE]</Pharm_Classes>
    <Status>Deprecated</Status>
    <LastUpdate>2024-11-01</LastUpdate>
    <PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
    <ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
    <StartMarketingDatePackage>20160504</StartMarketingDatePackage>
    <EndMarketingDatePackage>20241031</EndMarketingDatePackage>
    <SamplePackage>N</SamplePackage>
    <IndicationAndUsage>Levetiracetam tablets USP are indicated for adjunctive therapy in the treatment of: 1 Partial onset seizures in patients one month of age and older with epilepsy (1.1), 2 Myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy (1.2), 3 Primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy (1.3).</IndicationAndUsage>
    <Description>Levetiracetam USP is an antiepileptic drug available as 250 mg (blue), 500 mg (yellow), 750 mg (orange), and 1000 mg (white) tablets for oral administration. The chemical name of levetiracetam, a single enantiomer, is (-)-(S)-α-ethyl-2-oxo-1-pyrrolidine acetamide, its molecular formula is C8H14N2O2 and its molecular weight is 170.21. Levetiracetam is chemically unrelated to existing antiepileptic drugs (AEDs). It has the following structural formula. Levetiracetam USP is a white to off-white crystalline powder with a faint odor and a bitter taste. It is very soluble in water (104.0 g/100 mL). It is freely soluble in chloroform (65.3 g/100 mL) and in methanol (53.6 g/100 mL), soluble in ethanol (16.5 g/100 mL), sparingly soluble in acetonitrile (5.7 g/100 mL) and practically insoluble in n-hexane. (Solubility limits are expressed as g/100 mL solvent). Levetiracetam tablets USP contain the labeled amount of levetiracetam. For 250 mg, 500 mg and 750 mg strengths. Inactive ingredients: colloidal silicon dioxide, corn starch, crospovidone, hypromellose, magnesium stearate, microcrystalline cellulose, povidone, polyethylene glycol, polyvinyl alcohol, talc, titanium dioxide, and additional agents listed below. 250 mg tablets: FD&amp;C Blue No. 2/indigo carmine Aluminum Lake. 500 mg tablets: Yellow Iron Oxide. 750 mg tablets: FD&amp;C Blue No. 2/indigo carmine Aluminum Lake, FD&amp;C Yellow No. 6/sunset yellow FCF Aluminum Lake, iron oxide red. For 1000 mg strength. Inactive ingredients: colloidal silicon dioxide, corn starch, croscarmellose sodium, magnesium stearate, microcrystalline cellulose, povidone, polyethylene glycol, polyvinyl alcohol, talc and titanium dioxide.</Description>
  </NDC>
  <NDC>
    <NDCCode>50090-7979-0</NDCCode>
    <PackageDescription>30 TABLET in 1 BOTTLE (50090-7979-0) </PackageDescription>
    <NDC11Code>50090-7979-00</NDC11Code>
    <ProductNDC>50090-7979</ProductNDC>
    <ProductTypeName>HUMAN PRESCRIPTION DRUG</ProductTypeName>
    <ProprietaryName>Olmesartan Medoxomil</ProprietaryName>
    <NonProprietaryName>Olmesartan Medoxomil</NonProprietaryName>
    <DosageFormName>TABLET</DosageFormName>
    <RouteName>ORAL</RouteName>
    <StartMarketingDate>20220304</StartMarketingDate>
    <MarketingCategoryName>ANDA</MarketingCategoryName>
    <ApplicationNumber>ANDA206720</ApplicationNumber>
    <LabelerName>A-S Medication Solutions</LabelerName>
    <SubstanceName>OLMESARTAN MEDOXOMIL</SubstanceName>
    <StrengthNumber>40</StrengthNumber>
    <StrengthUnit>mg/1</StrengthUnit>
    <Pharm_Classes>Angiotensin 2 Receptor Antagonists [MoA], Angiotensin 2 Receptor Blocker [EPC]</Pharm_Classes>
    <Status>Active</Status>
    <LastUpdate>2026-06-02</LastUpdate>
    <PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
    <ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
    <ListingRecordCertifiedThrough>20271231</ListingRecordCertifiedThrough>
    <StartMarketingDatePackage>20260527</StartMarketingDatePackage>
    <SamplePackage>N</SamplePackage>
    <IndicationAndUsage>Olmesartan medoxomil is indicated for the treatment of hypertension in adults and children six years of age and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. It may be used alone or in combination with other antihypertensive agents.</IndicationAndUsage>
    <Description>Olmesartan medoxomil, a prodrug, is hydrolyzed to olmesartan during absorption from the gastrointestinal tract. Olmesartan is a selective AT1 subtype angiotensin II receptor antagonist. Olmesartan medoxomil is described chemically as 2,3-dihydroxy-2-butenyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]imidazole-5-carboxylate, cyclic 2,3-carbonate. Its empirical formula is C29H30N6O6 and its structural formula is:. Olmesartan medoxomil is a white or off-white crystalline powder with a molecular weight of 558.59. It is practically insoluble in water and sparingly soluble in methanol. Olmesartan medoxomil tablets, USP, are available for oral use as film-coated tablets containing 5 mg, 20 mg, or 40 mg of olmesartan medoxomil (USP) and the following inactive ingredients: hydroxypropyl cellulose, lactose monohydrate, low-substituted hydroxypropyl cellulose, magnesium stearate, microcrystalline cellulose, colloidal silicon dioxide, polyvinyl alcohol-part hydrolyzed, titanium dioxide, macrogol/polyethylene glycol 3350, talc, (5 mg only) FD&amp;C Red #40 Aluminum Lake, (5 mg only) FD&amp;C Yellow #6 Aluminum Lake, (5 mg only) FD&amp;C Blue #1 Aluminum Lake. FDA approved dissolution test specifications differ from USP.</Description>
  </NDC>
  <NDC>
    <NDCCode>50090-7979-1</NDCCode>
    <PackageDescription>90 TABLET in 1 BOTTLE (50090-7979-1) </PackageDescription>
    <NDC11Code>50090-7979-01</NDC11Code>
    <ProductNDC>50090-7979</ProductNDC>
    <ProductTypeName>HUMAN PRESCRIPTION DRUG</ProductTypeName>
    <ProprietaryName>Olmesartan Medoxomil</ProprietaryName>
    <NonProprietaryName>Olmesartan Medoxomil</NonProprietaryName>
    <DosageFormName>TABLET</DosageFormName>
    <RouteName>ORAL</RouteName>
    <StartMarketingDate>20220304</StartMarketingDate>
    <MarketingCategoryName>ANDA</MarketingCategoryName>
    <ApplicationNumber>ANDA206720</ApplicationNumber>
    <LabelerName>A-S Medication Solutions</LabelerName>
    <SubstanceName>OLMESARTAN MEDOXOMIL</SubstanceName>
    <StrengthNumber>40</StrengthNumber>
    <StrengthUnit>mg/1</StrengthUnit>
    <Pharm_Classes>Angiotensin 2 Receptor Antagonists [MoA], Angiotensin 2 Receptor Blocker [EPC]</Pharm_Classes>
    <Status>Active</Status>
    <LastUpdate>2026-06-02</LastUpdate>
    <PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
    <ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
    <ListingRecordCertifiedThrough>20271231</ListingRecordCertifiedThrough>
    <StartMarketingDatePackage>20260527</StartMarketingDatePackage>
    <SamplePackage>N</SamplePackage>
    <IndicationAndUsage>Olmesartan medoxomil is indicated for the treatment of hypertension in adults and children six years of age and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. It may be used alone or in combination with other antihypertensive agents.</IndicationAndUsage>
    <Description>Olmesartan medoxomil, a prodrug, is hydrolyzed to olmesartan during absorption from the gastrointestinal tract. Olmesartan is a selective AT1 subtype angiotensin II receptor antagonist. Olmesartan medoxomil is described chemically as 2,3-dihydroxy-2-butenyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]imidazole-5-carboxylate, cyclic 2,3-carbonate. Its empirical formula is C29H30N6O6 and its structural formula is:. Olmesartan medoxomil is a white or off-white crystalline powder with a molecular weight of 558.59. It is practically insoluble in water and sparingly soluble in methanol. Olmesartan medoxomil tablets, USP, are available for oral use as film-coated tablets containing 5 mg, 20 mg, or 40 mg of olmesartan medoxomil (USP) and the following inactive ingredients: hydroxypropyl cellulose, lactose monohydrate, low-substituted hydroxypropyl cellulose, magnesium stearate, microcrystalline cellulose, colloidal silicon dioxide, polyvinyl alcohol-part hydrolyzed, titanium dioxide, macrogol/polyethylene glycol 3350, talc, (5 mg only) FD&amp;C Red #40 Aluminum Lake, (5 mg only) FD&amp;C Yellow #6 Aluminum Lake, (5 mg only) FD&amp;C Blue #1 Aluminum Lake. FDA approved dissolution test specifications differ from USP.</Description>
  </NDC>
  <NDC>
    <NDCCode>55154-7979-0</NDCCode>
    <PackageDescription>10 BLISTER PACK in 1 BAG (55154-7979-0)  / 1 CAPSULE in 1 BLISTER PACK</PackageDescription>
    <NDC11Code>55154-7979-00</NDC11Code>
    <ProductNDC>55154-7979</ProductNDC>
    <ProductTypeName>HUMAN PRESCRIPTION DRUG</ProductTypeName>
    <ProprietaryName>Extended Phenytoin Sodium</ProprietaryName>
    <NonProprietaryName>Phenytoin Sodium</NonProprietaryName>
    <DosageFormName>CAPSULE</DosageFormName>
    <RouteName>ORAL</RouteName>
    <StartMarketingDate>20091216</StartMarketingDate>
    <EndMarketingDate>20250131</EndMarketingDate>
    <MarketingCategoryName>ANDA</MarketingCategoryName>
    <ApplicationNumber>ANDA040765</ApplicationNumber>
    <LabelerName>Cardinal Health 107, LLC</LabelerName>
    <SubstanceName>PHENYTOIN SODIUM</SubstanceName>
    <StrengthNumber>100</StrengthNumber>
    <StrengthUnit>mg/1</StrengthUnit>
    <Pharm_Classes>Anti-epileptic Agent [EPC], Cytochrome P450 1A2 Inducers [MoA], Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 2C19 Inducers [MoA], Cytochrome P450 2C8 Inducers [MoA], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 2D6 Inducers [MoA], Cytochrome P450 3A Inducers [MoA], Decreased Central Nervous System Disorganized Electrical Activity [PE]</Pharm_Classes>
    <Status>Deprecated</Status>
    <LastUpdate>2025-02-04</LastUpdate>
    <PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
    <ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
    <StartMarketingDatePackage>20091216</StartMarketingDatePackage>
    <EndMarketingDatePackage>20250131</EndMarketingDatePackage>
    <SamplePackage>N</SamplePackage>
    <IndicationAndUsage>Extended phenytoin sodium capsules are indicated for the treatment of tonic-clonic (grand mal) and psychomotor (temporal lobe) seizures and prevention and treatment of seizures occurring during or following neurosurgery.</IndicationAndUsage>
    <Description>Phenytoin sodium, USP is related to the barbiturates in chemical structure, but has a five-membered ring. The chemical name is 5,5-diphenyl-2,4 imidazolidinedione, having the following structural formula. Each extended phenytoin sodium capsule, USP for oral administration contains 100 mg phenytoin sodium, USP. Each capsule also contains the following inactive ingredients: D&amp;C Red #28, D&amp;C Red #33, FD&amp;C Blue #1, gelatin, hydroxypropyl cellulose, mannitol, magnesium stearate, talc and titanium dioxide. Product in vivo performance is characterized by a slow and extended rate of absorption with peak blood concentrations expected in 4 to 12 hours as contrasted to Prompt Phenytoin Sodium Capsules, USP with a rapid rate of absorption with peak blood concentration expected in 1½ to 3 hours. Meets USP Dissolution Test 5.</Description>
  </NDC>
  <NDC>
    <NDCCode>63629-7979-1</NDCCode>
    <PackageDescription>30 TABLET in 1 BOTTLE (63629-7979-1) </PackageDescription>
    <NDC11Code>63629-7979-01</NDC11Code>
    <ProductNDC>63629-7979</ProductNDC>
    <ProductTypeName>HUMAN PRESCRIPTION DRUG</ProductTypeName>
    <ProprietaryName>Flecainide Acetate</ProprietaryName>
    <NonProprietaryName>Flecainide Acetate</NonProprietaryName>
    <DosageFormName>TABLET</DosageFormName>
    <RouteName>ORAL</RouteName>
    <StartMarketingDate>20150708</StartMarketingDate>
    <MarketingCategoryName>ANDA</MarketingCategoryName>
    <ApplicationNumber>ANDA202821</ApplicationNumber>
    <LabelerName>Bryant Ranch Prepack</LabelerName>
    <SubstanceName>FLECAINIDE ACETATE</SubstanceName>
    <StrengthNumber>50</StrengthNumber>
    <StrengthUnit>mg/1</StrengthUnit>
    <Pharm_Classes>Antiarrhythmic [EPC]</Pharm_Classes>
    <Status>Active</Status>
    <LastUpdate>2024-05-03</LastUpdate>
    <PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
    <ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
    <ListingRecordCertifiedThrough>20261231</ListingRecordCertifiedThrough>
    <StartMarketingDatePackage>20190509</StartMarketingDatePackage>
    <SamplePackage>N</SamplePackage>
    <IndicationAndUsage>In patients without structural heart disease, flecainide acetate tablets, USP are indicated for the prevention of   —   paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms   —   paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptomsFlecainide acetate tablets, USP are also indicated for the prevention of   —   documented ventricular arrhythmias, such as sustained ventricular tachycardia (sustained VT), that in the judgment of the physician are life-threatening.Use of flecainide acetate tablets, USP for the treatment of sustained VT, like other antiarrhythmics, should be initiated in the hospital. The use of flecainide acetate tablets, USP are not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic.Because of the proarrhythmic effects of flecainide acetate tablets, USP, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks.Flecainide acetate tablets, USP should not be used in patients with recent myocardial infarction. (See BOXED WARNINGS.)Use of flecainide acetate tablets, USP in chronic atrial fibrillation has not been adequately studied and is not recommended. (See BOXED WARNINGS.)As is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of flecainide acetate tablets, USP favorably affects survival or the incidence of sudden death.</IndicationAndUsage>
    <Description>Flecainide acetate is an antiarrhythmic drug available in tablets of 50 mg, 100 mg, or 150 mg for oral administration.Flecainide acetate is benzamide, N-(2-piperidinyl-methyl)-2,5-bis (2,2,2-trifluoroethoxy)-monoacetate. The structural formula is given below. Flecainide acetate USP is a white to slightly off-white, crystalline powder with a pKa of 9.3. It has an aqueous solubility of 48.4 mg/mL at 37°C.Flecainide acetate tablets, USP also contain: croscarmellose sodium, hydrogenated vegetable oil type 1, magnesium stearate, microcrystalline cellulose, and pregelatinized starch.</Description>
  </NDC>
  <NDC>
    <NDCCode>63629-7979-3</NDCCode>
    <PackageDescription>90 TABLET in 1 BOTTLE (63629-7979-3) </PackageDescription>
    <NDC11Code>63629-7979-03</NDC11Code>
    <ProductNDC>63629-7979</ProductNDC>
    <ProductTypeName>HUMAN PRESCRIPTION DRUG</ProductTypeName>
    <ProprietaryName>Flecainide Acetate</ProprietaryName>
    <NonProprietaryName>Flecainide Acetate</NonProprietaryName>
    <DosageFormName>TABLET</DosageFormName>
    <RouteName>ORAL</RouteName>
    <StartMarketingDate>20150708</StartMarketingDate>
    <MarketingCategoryName>ANDA</MarketingCategoryName>
    <ApplicationNumber>ANDA202821</ApplicationNumber>
    <LabelerName>Bryant Ranch Prepack</LabelerName>
    <SubstanceName>FLECAINIDE ACETATE</SubstanceName>
    <StrengthNumber>50</StrengthNumber>
    <StrengthUnit>mg/1</StrengthUnit>
    <Pharm_Classes>Antiarrhythmic [EPC]</Pharm_Classes>
    <Status>Active</Status>
    <LastUpdate>2024-05-03</LastUpdate>
    <PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
    <ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
    <ListingRecordCertifiedThrough>20261231</ListingRecordCertifiedThrough>
    <StartMarketingDatePackage>20210107</StartMarketingDatePackage>
    <SamplePackage>N</SamplePackage>
    <IndicationAndUsage>In patients without structural heart disease, flecainide acetate tablets, USP are indicated for the prevention of   —   paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms   —   paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptomsFlecainide acetate tablets, USP are also indicated for the prevention of   —   documented ventricular arrhythmias, such as sustained ventricular tachycardia (sustained VT), that in the judgment of the physician are life-threatening.Use of flecainide acetate tablets, USP for the treatment of sustained VT, like other antiarrhythmics, should be initiated in the hospital. The use of flecainide acetate tablets, USP are not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic.Because of the proarrhythmic effects of flecainide acetate tablets, USP, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks.Flecainide acetate tablets, USP should not be used in patients with recent myocardial infarction. (See BOXED WARNINGS.)Use of flecainide acetate tablets, USP in chronic atrial fibrillation has not been adequately studied and is not recommended. (See BOXED WARNINGS.)As is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of flecainide acetate tablets, USP favorably affects survival or the incidence of sudden death.</IndicationAndUsage>
    <Description>Flecainide acetate is an antiarrhythmic drug available in tablets of 50 mg, 100 mg, or 150 mg for oral administration.Flecainide acetate is benzamide, N-(2-piperidinyl-methyl)-2,5-bis (2,2,2-trifluoroethoxy)-monoacetate. The structural formula is given below. Flecainide acetate USP is a white to slightly off-white, crystalline powder with a pKa of 9.3. It has an aqueous solubility of 48.4 mg/mL at 37°C.Flecainide acetate tablets, USP also contain: croscarmellose sodium, hydrogenated vegetable oil type 1, magnesium stearate, microcrystalline cellulose, and pregelatinized starch.</Description>
  </NDC>
  <NDC>
    <NDCCode>63629-7979-4</NDCCode>
    <PackageDescription>10 TABLET in 1 BOTTLE (63629-7979-4) </PackageDescription>
    <NDC11Code>63629-7979-04</NDC11Code>
    <ProductNDC>63629-7979</ProductNDC>
    <ProductTypeName>HUMAN PRESCRIPTION DRUG</ProductTypeName>
    <ProprietaryName>Flecainide Acetate</ProprietaryName>
    <NonProprietaryName>Flecainide Acetate</NonProprietaryName>
    <DosageFormName>TABLET</DosageFormName>
    <RouteName>ORAL</RouteName>
    <StartMarketingDate>20150708</StartMarketingDate>
    <MarketingCategoryName>ANDA</MarketingCategoryName>
    <ApplicationNumber>ANDA202821</ApplicationNumber>
    <LabelerName>Bryant Ranch Prepack</LabelerName>
    <SubstanceName>FLECAINIDE ACETATE</SubstanceName>
    <StrengthNumber>50</StrengthNumber>
    <StrengthUnit>mg/1</StrengthUnit>
    <Pharm_Classes>Antiarrhythmic [EPC]</Pharm_Classes>
    <Status>Active</Status>
    <LastUpdate>2024-05-03</LastUpdate>
    <PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
    <ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
    <ListingRecordCertifiedThrough>20261231</ListingRecordCertifiedThrough>
    <StartMarketingDatePackage>20240403</StartMarketingDatePackage>
    <SamplePackage>N</SamplePackage>
    <IndicationAndUsage>In patients without structural heart disease, flecainide acetate tablets, USP are indicated for the prevention of   —   paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms   —   paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptomsFlecainide acetate tablets, USP are also indicated for the prevention of   —   documented ventricular arrhythmias, such as sustained ventricular tachycardia (sustained VT), that in the judgment of the physician are life-threatening.Use of flecainide acetate tablets, USP for the treatment of sustained VT, like other antiarrhythmics, should be initiated in the hospital. The use of flecainide acetate tablets, USP are not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic.Because of the proarrhythmic effects of flecainide acetate tablets, USP, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks.Flecainide acetate tablets, USP should not be used in patients with recent myocardial infarction. (See BOXED WARNINGS.)Use of flecainide acetate tablets, USP in chronic atrial fibrillation has not been adequately studied and is not recommended. (See BOXED WARNINGS.)As is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of flecainide acetate tablets, USP favorably affects survival or the incidence of sudden death.</IndicationAndUsage>
    <Description>Flecainide acetate is an antiarrhythmic drug available in tablets of 50 mg, 100 mg, or 150 mg for oral administration.Flecainide acetate is benzamide, N-(2-piperidinyl-methyl)-2,5-bis (2,2,2-trifluoroethoxy)-monoacetate. The structural formula is given below. Flecainide acetate USP is a white to slightly off-white, crystalline powder with a pKa of 9.3. It has an aqueous solubility of 48.4 mg/mL at 37°C.Flecainide acetate tablets, USP also contain: croscarmellose sodium, hydrogenated vegetable oil type 1, magnesium stearate, microcrystalline cellulose, and pregelatinized starch.</Description>
  </NDC>
  <NDC>
    <NDCCode>63629-7979-5</NDCCode>
    <PackageDescription>180 TABLET in 1 BOTTLE (63629-7979-5) </PackageDescription>
    <NDC11Code>63629-7979-05</NDC11Code>
    <ProductNDC>63629-7979</ProductNDC>
    <ProductTypeName>HUMAN PRESCRIPTION DRUG</ProductTypeName>
    <ProprietaryName>Flecainide Acetate</ProprietaryName>
    <NonProprietaryName>Flecainide Acetate</NonProprietaryName>
    <DosageFormName>TABLET</DosageFormName>
    <RouteName>ORAL</RouteName>
    <StartMarketingDate>20150708</StartMarketingDate>
    <MarketingCategoryName>ANDA</MarketingCategoryName>
    <ApplicationNumber>ANDA202821</ApplicationNumber>
    <LabelerName>Bryant Ranch Prepack</LabelerName>
    <SubstanceName>FLECAINIDE ACETATE</SubstanceName>
    <StrengthNumber>50</StrengthNumber>
    <StrengthUnit>mg/1</StrengthUnit>
    <Pharm_Classes>Antiarrhythmic [EPC]</Pharm_Classes>
    <Status>Active</Status>
    <LastUpdate>2024-05-03</LastUpdate>
    <PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
    <ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
    <ListingRecordCertifiedThrough>20261231</ListingRecordCertifiedThrough>
    <StartMarketingDatePackage>20220928</StartMarketingDatePackage>
    <SamplePackage>N</SamplePackage>
    <IndicationAndUsage>In patients without structural heart disease, flecainide acetate tablets, USP are indicated for the prevention of   —   paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms   —   paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptomsFlecainide acetate tablets, USP are also indicated for the prevention of   —   documented ventricular arrhythmias, such as sustained ventricular tachycardia (sustained VT), that in the judgment of the physician are life-threatening.Use of flecainide acetate tablets, USP for the treatment of sustained VT, like other antiarrhythmics, should be initiated in the hospital. The use of flecainide acetate tablets, USP are not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic.Because of the proarrhythmic effects of flecainide acetate tablets, USP, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks.Flecainide acetate tablets, USP should not be used in patients with recent myocardial infarction. (See BOXED WARNINGS.)Use of flecainide acetate tablets, USP in chronic atrial fibrillation has not been adequately studied and is not recommended. (See BOXED WARNINGS.)As is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of flecainide acetate tablets, USP favorably affects survival or the incidence of sudden death.</IndicationAndUsage>
    <Description>Flecainide acetate is an antiarrhythmic drug available in tablets of 50 mg, 100 mg, or 150 mg for oral administration.Flecainide acetate is benzamide, N-(2-piperidinyl-methyl)-2,5-bis (2,2,2-trifluoroethoxy)-monoacetate. The structural formula is given below. Flecainide acetate USP is a white to slightly off-white, crystalline powder with a pKa of 9.3. It has an aqueous solubility of 48.4 mg/mL at 37°C.Flecainide acetate tablets, USP also contain: croscarmellose sodium, hydrogenated vegetable oil type 1, magnesium stearate, microcrystalline cellulose, and pregelatinized starch.</Description>
  </NDC>
</NDCList>
                    

<NDCList><NDC><NDCCode>54118-7979-2</NDCCode><ProprietaryName>Bacteria Tox</ProprietaryName><NonProprietaryName>Adrenal, Atp, Bac Nosode, Belladonna</NonProprietaryName></NDC><NDC><NDCCode>63629-7979-2</NDCCode><ProprietaryName>Flecainide Acetate</ProprietaryName><NonProprietaryName>Flecainide Acetate</NonProprietaryName></NDC><NDC><NDCCode>54118-7011-2</NDCCode><ProprietaryName>Rena Code</ProprietaryName><NonProprietaryName>Rena Code</NonProprietaryName></NDC><NDC><NDCCode>54118-7017-2</NDCCode><ProprietaryName>Ultimate Phenolics</ProprietaryName><NonProprietaryName>Ultimate Phenolics</NonProprietaryName></NDC><NDC><NDCCode>54118-7103-2</NDCCode><ProprietaryName>Myco-tox</ProprietaryName><NonProprietaryName>Myco-tox</NonProprietaryName></NDC><NDC><NDCCode>54118-7109-2</NDCCode><ProprietaryName>Pre And Post Milieu</ProprietaryName><NonProprietaryName>Pre And Post Milieu</NonProprietaryName></NDC><NDC><NDCCode>54118-7114-2</NDCCode><ProprietaryName>Throat Milieu</ProprietaryName><NonProprietaryName>Throat Milieu</NonProprietaryName></NDC><NDC><NDCCode>54118-7134-2</NDCCode><ProprietaryName>Biocell Salts</ProprietaryName><NonProprietaryName>Biocell Slats</NonProprietaryName></NDC><NDC><NDCCode>54118-7136-2</NDCCode><ProprietaryName>Pineal Code</ProprietaryName><NonProprietaryName>Pineal Code</NonProprietaryName></NDC><NDC><NDCCode>54118-7141-2</NDCCode><ProprietaryName>Glycopan Tox</ProprietaryName><NonProprietaryName>Argentium Nitricum, Kali Carbonicum, Glycirrhiza Glabra</NonProprietaryName></NDC><NDC><NDCCode>54118-7188-2</NDCCode><ProprietaryName>Hcg Plus</ProprietaryName><NonProprietaryName>Human Chorionic Gonadotropin (hcg), Garcinia Cambogia, Hypothalamus</NonProprietaryName></NDC><NDC><NDCCode>54118-7196-2</NDCCode><ProprietaryName>Oral Hcg Activator</ProprietaryName><NonProprietaryName>Hypothalamus, Hepar Suis, Methyl B12, Renal Suis, Gambogia, Graphites</NonProprietaryName></NDC><NDC><NDCCode>54118-7232-2</NDCCode><ProprietaryName>Hcg Plus</ProprietaryName><NonProprietaryName>Human Chorionic Gonadotropin (hcg), Garcinia Cambogia, Hypothalamus</NonProprietaryName></NDC><NDC><NDCCode>54118-7967-2</NDCCode><ProprietaryName>Lymph 1 Acute</ProprietaryName><NonProprietaryName>Adrenal, Apis Mellifica</NonProprietaryName></NDC><NDC><NDCCode>54118-7971-2</NDCCode><ProprietaryName>Ultimate Fields</ProprietaryName><NonProprietaryName>Ultimate Fields</NonProprietaryName></NDC><NDC><NDCCode>54118-7972-2</NDCCode><ProprietaryName>Ultimate Rescue</ProprietaryName><NonProprietaryName>Cherry Plum, Clematis, Impatiens, Rock Rose, Star Of Bethlehem, Atp, Pineal, Thymus</NonProprietaryName></NDC><NDC><NDCCode>54118-7976-2</NDCCode><ProprietaryName>Aller-tox 1</ProprietaryName><NonProprietaryName>Acetaldehyde, Adrenal, Argentum Nitricum</NonProprietaryName></NDC><NDC><NDCCode>54118-7977-2</NDCCode><ProprietaryName>Aller - Tox 11</ProprietaryName><NonProprietaryName>Adrenal, Allium Cepa, Ambrosia Artemisiaefolia</NonProprietaryName></NDC><NDC><NDCCode>54118-7978-2</NDCCode><ProprietaryName>Amoeba Tox</ProprietaryName><NonProprietaryName>Adrenal, Amoeba Nosodes, Artemisia Absinthium</NonProprietaryName></NDC><NDC><NDCCode>54118-7981-2</NDCCode><ProprietaryName>Chem - Tox</ProprietaryName><NonProprietaryName>Adrenal, Arctium Lappa, Atp, Belladonna, Chemical Isodes</NonProprietaryName></NDC><NDC><NDCCode>54118-7990-2</NDCCode><ProprietaryName>Gyne - Tox</ProprietaryName><NonProprietaryName>Adrenal, Angelica Atropurpurea, Boricum Acidum, Atp</NonProprietaryName></NDC><NDC><NDCCode>54118-7993-2</NDCCode><ProprietaryName>Hz - Tox</ProprietaryName><NonProprietaryName>Arsenicum Album, Asclepias Tuberus, Atp</NonProprietaryName></NDC><NDC><NDCCode>0615-7979-39</NDCCode><ProprietaryName>Levetiracetam</ProprietaryName><NonProprietaryName>Levetiracetam</NonProprietaryName></NDC><NDC><NDCCode>50090-7979-0</NDCCode><ProprietaryName>Olmesartan Medoxomil</ProprietaryName><NonProprietaryName>Olmesartan Medoxomil</NonProprietaryName></NDC><NDC><NDCCode>50090-7979-1</NDCCode><ProprietaryName>Olmesartan Medoxomil</ProprietaryName><NonProprietaryName>Olmesartan Medoxomil</NonProprietaryName></NDC><NDC><NDCCode>55154-7979-0</NDCCode><ProprietaryName>Extended Phenytoin Sodium</ProprietaryName><NonProprietaryName>Phenytoin Sodium</NonProprietaryName></NDC><NDC><NDCCode>63629-7979-1</NDCCode><ProprietaryName>Flecainide Acetate</ProprietaryName><NonProprietaryName>Flecainide Acetate</NonProprietaryName></NDC><NDC><NDCCode>63629-7979-3</NDCCode><ProprietaryName>Flecainide Acetate</ProprietaryName><NonProprietaryName>Flecainide Acetate</NonProprietaryName></NDC><NDC><NDCCode>63629-7979-4</NDCCode><ProprietaryName>Flecainide Acetate</ProprietaryName><NonProprietaryName>Flecainide Acetate</NonProprietaryName></NDC><NDC><NDCCode>63629-7979-5</NDCCode><ProprietaryName>Flecainide Acetate</ProprietaryName><NonProprietaryName>Flecainide Acetate</NonProprietaryName></NDC></NDCList>
                    

Using REST to Invoke DataLabs API

Introduction

This document is intended for developers who want to write applications that can interact with the DataLabs REST API. With DataLabs Web Services, you can create a customized services for your own website or application. You can use the REST API to retrieve DataLabs Web Services results programmatically.

Important: The REST API requires the use of an API key, which you can get from the DataLabs MyAccount Console.

Working With DataLabs REST API

You can retrieve results for a particular operation (search, getcode, etc) by sending an HTTP GET request to its URI.
For instance, the URI for a “search” request has the following format:

https://www.datalabs.health/api/{domain}/{operation}?q={query}&rt={result type}&token={token}

If the request succeeds, the server responds with a 200 OK HTTP status code and the response data.

Four parameters are required with each “search” request:

• Use the domain parameter to specify required data domain.
• Use the operation parameter to specify “format_check” operation.
• Use the q (query) parameter to specify your query.
• Use the token (API key) query parameter to identify your application.

Optional parameter:

• Use the rt (result type) parameter to specify required result type (json/xml/min.json/min.xml).

All other query parameters (if any) are optional.

Full list of API parameters:

• Use the domain parameter to specify required data domain.
• Use the operation parameter to specify “format_check” operation.
• Use the q (query) parameter to specify your query.
• Use the token (API key) query parameter to identify your application.
• Use the tin (tin number) parameter to specify your query about tin number.
• Use the tinname (tin name) parameter to specify your query about tin name.
• Use the zipcode (zip code) parameter to specify your query about zip code.
• Use the radius (radius) parameter to specify your query about radius.
• Use the fromdate (fromdate) parameter to specify your query about from date.
• Use the todate (todate) parameter to specify your query about to date.

Operations Currently Available in the DataLabs REST API

Currently DataLabs RESTful Lookup Service supports following operations:

• check_status — this method allows to get current code status.
• getcode — this method allows retrieval of full infrormation regarding one item based on the provided key.
• getcodes — this method allows retrieval of full infrormation regarding number of items based on the provided keys (q=1285636522,1730198755,1427145176,1487730636).
• search — allows retrieval of set of items based on the free-form lookup query.
• search_and_keywords — returns not only free-form lookup results but also keywords relevant to the original query.

Plus there are three NPI-specific operations:

• validate — allows to determine whether provider's information is valid based on data in the CMS database.
• paginate_with_predicates — provides server side data pagination using sorting and ordering criteria.
• search_with_predicates — this method is a "blend" of free text search and traditional prdeicate-based data selection.
• zipradius — allows to get npis by zipcode & radius.
• npideactivated — allows to get deactivated npis between two dates.

REST Search Examples

Query Parameter Reference

The query parameters you can use with the DataLabs REST API are summarized in the following table.
All parameter values need to be URL encoded.

Use Case #1 - I Need to Find Healthcare Provider (Doctor or Orgranization) Having Just Partial Information

So, you have to find healthcare provider having just partial information. For instance all you have is "EYE doctor RANIA in REDMOND". Strictly speaking, it is necessary to perform a search with minimum information and the maximum level of relevance of the result.

Coding example below demonstrates simplest implementation in C# language. By default DataLabs full text search API returns 30 results and, as you may see below, the first result in the list is "REDMOND EYE DOCTORS, PLLC" where dr. Rania Montecillo specified an owner.

Feel free to use and modify this code to find doctors you may know. If you provide more or less meaningfull information you will be pleasantly surprised to see them in the search results.

            
//--------------------------------------------------------------------------------------
// Fulltext search on NPI registry. Perform "search" operation to get most relevant results.
//--------------------------------------------------------------------------------------
using System;
using System.Net.Http;
using System.Threading.Tasks;

public class Program
{
    private const string token = "3932f3b0-cfab-11dc-95ff-0800200c9a663932f3b0-cfab-11dc-95ff-0800200c9a66";

    static async Task Main(string[] args)
    {
        string endPoint = $"https://www.datalabs.health/api/npi/search?q=EYE%20RANIA%20REDMOND&token={token}";
        using HttpClient client = new HttpClient();
        string response = await client.GetStringAsync(endPoint);

        Console.WriteLine(response);

        Console.WriteLine("Done. Press any key to exit ...");
        Console.ReadKey();
    }
}
            
        

            
{
  "NPI": [
    {
      "NPI": "1295783033",
      "EntityType": "Organization",
      "EIN": "N/A",
      "IsOrgSubpart": "N",
      "OrgName": "REDMOND EYE DOCTORS, PLLC",
      "FirstLineMailingAddress": "16375 NE 85TH ST",
      "SecondLineMailingAddress": "SUITE 102",
      "MailingAddressCityName": "REDMOND",
      "MailingAddressStateName": "WA",
      "MailingAddressPostalCode": "98052-3554",
      "MailingAddressCountryCode": "US",
      "MailingAddressTelephoneNumber": "425-885-7363",
      "MailingAddressFaxNumber": "425-861-5585",
      "FirstLinePracticeLocationAddress": "16375 NE 85TH ST",
      "SecondLinePracticeLocationAddress": "SUITE 102",
      "PracticeLocationAddressCityName": "REDMOND",
      "PracticeLocationAddressStateName": "WA",
      "PracticeLocationAddressPostalCode": "98052-3554",
      "PracticeLocationAddressCountryCode": "US",
      "PracticeLocationAddressTelephoneNumber": "425-885-7363",
      "PracticeLocationAddressFaxNumber": "425-861-5585",
      "EnumerationDate": "05/04/2006",
      "LastUpdateDate": "12/11/2007",
      "AuthorizedOfficialLastName": "MONTECILLO",
      "AuthorizedOfficialFirstName": "RANIA",
      "AuthorizedOfficialTitle": "OWNER",
      "AuthorizedOfficialNamePrefix": "DR.",
      "AuthorizedOfficialCredential": "O.D.",
      "AuthorizedOfficialTelephoneNumber": "425-885-7363",
      "TaxonomyCode1": "152W00000X",
      "Taxonomy1": "Optometrist",
      "LicenseNumber1": "801TX",
      "LicenseNumberStateCode1": "WA",
      "PrimaryTaxonomySwitch1": "Y",
      "HealthcareProviderTaxonomyGroup1": "193400000X SINGLE SPECIALTY  GROUP",
      "HealthcareProviderTaxonomyGroupDescription1": "Single Specialty Group - A business group of one or more individual practitioners, all of who practice with the same area of specialization."
    },
    {
      "NPI": "1346319878",
      "EntityType": "Organization",
      "EIN": "N/A",
      "OrgName": "REDMOND EYE CLINIC PLLC",
      "FirstLineMailingAddress": "16150 NE 85TH ST STE 206",
      "MailingAddressCityName": "REDMOND",
      "MailingAddressStateName": "WA",
      "MailingAddressPostalCode": "98052-3543",
      "MailingAddressCountryCode": "US",
      "MailingAddressTelephoneNumber": "425-885-3574",
      "MailingAddressFaxNumber": "425-881-0230",
      "FirstLinePracticeLocationAddress": "16150 NE 85TH ST STE 206",
      "PracticeLocationAddressCityName": "REDMOND",
      "PracticeLocationAddressStateName": "WA",
      "PracticeLocationAddressPostalCode": "98052-3543",
      "PracticeLocationAddressCountryCode": "US",
      "PracticeLocationAddressTelephoneNumber": "425-885-3574",
      "PracticeLocationAddressFaxNumber": "425-881-0230",
      "EnumerationDate": "11/07/2006",
      "LastUpdateDate": "07/08/2007",
      "AuthorizedOfficialLastName": "OTTEN",
      "AuthorizedOfficialFirstName": "LARRY",
      "AuthorizedOfficialMiddleName": "C",
      "AuthorizedOfficialTitle": "DR",
      "AuthorizedOfficialNamePrefix": "DR.",
      "AuthorizedOfficialCredential": "O.D.",
      "AuthorizedOfficialTelephoneNumber": "425-885-3574",
      "TaxonomyCode1": "152W00000X",
      "Taxonomy1": "Optometrist",
      "LicenseNumber1": "OD00001172",
      "LicenseNumberStateCode1": "WA",
      "PrimaryTaxonomySwitch1": "Y",
      "HealthcareProviderTaxonomyGroup1": "193200000X MULTI-SPECIALTY GROUP",
      "HealthcareProviderTaxonomyGroupDescription1": "Multi-Specialty Group - A business group of one or more individual practitioners, who practice with different areas of specialization."
    },
    {
      "NPI": "1376755009",
      "EntityType": "Individual",
      "IsSoleProprietor": "N",
      "LastName": "PERIMAN",
      "FirstName": "LAURA",
      "MiddleName": "MARIE",
      "NamePrefix": "DR.",
      "Credential": "MD",
      "FirstLineMailingAddress": "623 W HIGHLAND DR",
      "MailingAddressCityName": "SEATTLE",
      "MailingAddressStateName": "WA",
      "MailingAddressPostalCode": "98119-3446",
      "MailingAddressCountryCode": "US",
      "MailingAddressTelephoneNumber": "206-282-2716",
      "FirstLinePracticeLocationAddress": "16150 NE 85TH ST STE 206",
      "SecondLinePracticeLocationAddress": "REDMOND EYE CLINIC",
      "PracticeLocationAddressCityName": "REDMOND",
      "PracticeLocationAddressStateName": "WA",
      "PracticeLocationAddressPostalCode": "98052-3543",
      "PracticeLocationAddressCountryCode": "US",
      "PracticeLocationAddressTelephoneNumber": "425-885-3574",
      "EnumerationDate": "05/04/2007",
      "LastUpdateDate": "07/08/2007",
      "GenderCode": "F",
      "Gender": "Female",
      "TaxonomyCode1": "207W00000X",
      "Taxonomy1": "Ophthalmology",
      "LicenseNumber1": "MD00039796",
      "LicenseNumberStateCode1": "WA",
      "PrimaryTaxonomySwitch1": "Y"
    },
    {
      "NPI": "1659320539",
      "EntityType": "Individual",
      "IsSoleProprietor": "N",
      "LastName": "MONTECILLO",
      "FirstName": "RANIA",
      "MiddleName": "B",
      "NamePrefix": "DR.",
      "Credential": "OD",
      "FirstLineMailingAddress": "16375 NE 85TH ST",
      "SecondLineMailingAddress": "SUITE 102",
      "MailingAddressCityName": "REDMOND",
      "MailingAddressStateName": "WA",
      "MailingAddressPostalCode": "98052-3554",
      "MailingAddressCountryCode": "US",
      "MailingAddressTelephoneNumber": "425-885-7363",
      "MailingAddressFaxNumber": "425-861-5585",
      "FirstLinePracticeLocationAddress": "16375 NE 85TH ST",
      "SecondLinePracticeLocationAddress": "SUITE 102",
      "PracticeLocationAddressCityName": "REDMOND",
      "PracticeLocationAddressStateName": "WA",
      "PracticeLocationAddressPostalCode": "98052-3554",
      "PracticeLocationAddressCountryCode": "US",
      "PracticeLocationAddressTelephoneNumber": "425-885-7363",
      "PracticeLocationAddressFaxNumber": "425-861-5585",
      "EnumerationDate": "05/09/2006",
      "LastUpdateDate": "12/19/2007",
      "GenderCode": "F",
      "Gender": "Female",
      "TaxonomyCode1": "152W00000X",
      "Taxonomy1": "Optometrist",
      "LicenseNumber1": "3680",
      "LicenseNumberStateCode1": "WA",
      "PrimaryTaxonomySwitch1": "Y"
    },
    {
      "NPI": "1427560267",
      "EntityType": "Individual",
      "IsSoleProprietor": "Y",
      "LastName": "ABOU SHADI",
      "FirstName": "RANIA",
      "NamePrefix": "MRS.",
      "Credential": "RPH",
      "FirstLineMailingAddress": "8862 161ST AVENUE NE",
      "SecondLineMailingAddress": "SUITE 102",
      "MailingAddressCityName": "REDMOND",
      "MailingAddressStateName": "WA",
      "MailingAddressPostalCode": "98052",
      "MailingAddressCountryCode": "US",
      "MailingAddressTelephoneNumber": "425-883-9532",
      "MailingAddressFaxNumber": "425-882-2743",
      "FirstLinePracticeLocationAddress": "8862 161ST AVENUE NE",
      "SecondLinePracticeLocationAddress": "SUITE 102",
      "PracticeLocationAddressCityName": "REDMOND",
      "PracticeLocationAddressStateName": "WA",
      "PracticeLocationAddressPostalCode": "98052",
      "PracticeLocationAddressCountryCode": "US",
      "PracticeLocationAddressTelephoneNumber": "425-883-9532",
      "PracticeLocationAddressFaxNumber": "425-882-2743",
      "EnumerationDate": "11/02/2017",
      "LastUpdateDate": "11/02/2017",
      "GenderCode": "F",
      "Gender": "Female",
      "TaxonomyCode1": "3336C0003X",
      "Taxonomy1": "Community/Retail Pharmacy",
      "PrimaryTaxonomySwitch1": "Y"
    },
    {
      "NPI": "1528050523",
      "EntityType": "Organization",
      "EIN": "N/A",
      "IsOrgSubpart": "N",
      "OrgName": "DESCHUTES EYE CLINIC PC",
      "OtherOrgName": "THE EYE SURGERY INSTITUTE",
      "OtherOrgNameTypeCode": "3",
      "FirstLineMailingAddress": "813 SW HIGHLAND AVE",
      "MailingAddressCityName": "REDMOND",
      "MailingAddressStateName": "OR",
      "MailingAddressPostalCode": "97756-3123",
      "MailingAddressCountryCode": "US",
      "MailingAddressTelephoneNumber": "541-548-7170",
      "MailingAddressFaxNumber": "541-548-3842",
      "FirstLinePracticeLocationAddress": "813 SW HIGHLAND AVE",
      "PracticeLocationAddressCityName": "REDMOND",
      "PracticeLocationAddressStateName": "OR",
      "PracticeLocationAddressPostalCode": "97756-3123",
      "PracticeLocationAddressCountryCode": "US",
      "PracticeLocationAddressTelephoneNumber": "541-548-7170",
      "PracticeLocationAddressFaxNumber": "541-548-3842",
      "EnumerationDate": "08/17/2005",
      "LastUpdateDate": "12/01/2010",
      "AuthorizedOfficialLastName": "TRAUSTASON",
      "AuthorizedOfficialFirstName": "OLI",
      "AuthorizedOfficialMiddleName": "I",
      "AuthorizedOfficialTitle": "PRESIDENT",
      "AuthorizedOfficialNamePrefix": "DR.",
      "AuthorizedOfficialCredential": "M.D.",
      "AuthorizedOfficialTelephoneNumber": "541-548-7170",
      "TaxonomyCode1": "207W00000X",
      "Taxonomy1": "Ophthalmology",
      "PrimaryTaxonomySwitch1": "Y",
      "OtherIdentifier1": "053857000",
      "OtherIdentifierType1": "OTHER",
      "OtherIdentifierState1": "OR",
      "OtherIdentifierIssuer1": "REGENCE BCBS",
      "OtherIdentifier2": "CJ8770",
      "OtherIdentifierType2": "OTHER",
      "OtherIdentifierState2": "OR",
      "OtherIdentifierIssuer2": "RAILROAD MEDICARE",
      "OtherIdentifier3": "38080A",
      "OtherIdentifierType3": "OTHER",
      "OtherIdentifierState3": "OR",
      "OtherIdentifierIssuer3": "CLEAR CHOICE",
      "HealthcareProviderTaxonomyGroup1": "193400000X SINGLE SPECIALTY  GROUP",
      "HealthcareProviderTaxonomyGroupDescription1": "Single Specialty Group - A business group of one or more individual practitioners, all of who practice with the same area of specialization."
    },
    {
      "NPI": "1477596252",
      "EntityType": "Organization",
      "EIN": "N/A",
      "IsOrgSubpart": "N",
      "OrgName": "EYE CARE SPECIALISTS NORTHWEST PLLC",
      "OtherOrgName": "THE CHILDRENS EYE DOCTORS, THE FAMILY EYE DOCTORS, WOODLAWN OPTICAL",
      "OtherOrgNameTypeCode": "3",
      "FirstLineMailingAddress": "17130 AVONDALE WAY NE",
      "SecondLineMailingAddress": "SUITE 111",
      "MailingAddressCityName": "REDMOND",
      "MailingAddressStateName": "WA",
      "MailingAddressPostalCode": "98052",
      "MailingAddressCountryCode": "US",
      "MailingAddressTelephoneNumber": "425-885-6600",
      "MailingAddressFaxNumber": "425-885-6580",
      "FirstLinePracticeLocationAddress": "17130 AVONDALE WAY NE",
      "SecondLinePracticeLocationAddress": "SUITE 111",
      "PracticeLocationAddressCityName": "REDMOND",
      "PracticeLocationAddressStateName": "WA",
      "PracticeLocationAddressPostalCode": "98052",
      "PracticeLocationAddressCountryCode": "US",
      "PracticeLocationAddressTelephoneNumber": "425-885-6600",
      "PracticeLocationAddressFaxNumber": "425-885-6580",
      "EnumerationDate": "06/13/2006",
      "LastUpdateDate": "03/03/2008",
      "AuthorizedOfficialLastName": "LENART",
      "AuthorizedOfficialFirstName": "THOMAS",
      "AuthorizedOfficialTitle": "OWNER",
      "AuthorizedOfficialNamePrefix": "DR.",
      "AuthorizedOfficialCredential": "MD PHD",
      "AuthorizedOfficialTelephoneNumber": "425-885-6600",
      "TaxonomyCode1": "152W00000X",
      "Taxonomy1": "Optometrist",
      "PrimaryTaxonomySwitch1": "N",
      "TaxonomyCode2": "156FX1800X",
      "Taxonomy2": "Optician",
      "PrimaryTaxonomySwitch2": "N",
      "TaxonomyCode3": "207W00000X",
      "Taxonomy3": "Ophthalmology",
      "PrimaryTaxonomySwitch3": "Y",
      "OtherIdentifier1": "1568514032",
      "OtherIdentifierType1": "OTHER",
      "OtherIdentifierIssuer1": "NPI",
      "OtherIdentifier2": "1740297829",
      "OtherIdentifierType2": "OTHER",
      "OtherIdentifierIssuer2": "NPI",
      "OtherIdentifier3": "1205989522",
      "OtherIdentifierType3": "OTHER",
      "OtherIdentifierIssuer3": "NPI",
      "HealthcareProviderTaxonomyGroup1": "193200000X MULTI-SPECIALTY GROUP",
      "HealthcareProviderTaxonomyGroupDescription1": "Multi-Specialty Group - A business group of one or more individual practitioners, who practice with different areas of specialization.",
      "HealthcareProviderTaxonomyGroup2": "193200000X MULTI-SPECIALTY GROUP",
      "HealthcareProviderTaxonomyGroupDescription2": "Multi-Specialty Group - A business group of one or more individual practitioners, who practice with different areas of specialization.",
      "HealthcareProviderTaxonomyGroup3": "193200000X MULTI-SPECIALTY GROUP",
      "HealthcareProviderTaxonomyGroupDescription3": "Multi-Specialty Group - A business group of one or more individual practitioners, who practice with different areas of specialization."
    },
    {
      "NPI": "1215029343",
      "EntityType": "Organization",
      "EIN": "N/A",
      "IsOrgSubpart": "N",
      "OrgName": "EYE HEALTH PROFESSIONALS, P.C.",
      "FirstLineMailingAddress": "85 BARNES RD",
      "SecondLineMailingAddress": "SUITE 102",
      "MailingAddressCityName": "WALLINGFORD",
      "MailingAddressStateName": "CT",
      "MailingAddressPostalCode": "06492-1832",
      "MailingAddressCountryCode": "US",
      "MailingAddressTelephoneNumber": "203-284-9448",
      "MailingAddressFaxNumber": "203-269-1361",
      "FirstLinePracticeLocationAddress": "85 BARNES RD",
      "SecondLinePracticeLocationAddress": "SUITE 102",
      "PracticeLocationAddressCityName": "WALLINGFORD",
      "PracticeLocationAddressStateName": "CT",
      "PracticeLocationAddressPostalCode": "06492-1832",
      "PracticeLocationAddressCountryCode": "US",
      "PracticeLocationAddressTelephoneNumber": "203-284-9448",
      "PracticeLocationAddressFaxNumber": "203-269-1361",
      "EnumerationDate": "09/28/2006",
      "LastUpdateDate": "03/07/2008",
      "AuthorizedOfficialLastName": "REDMOND",
      "AuthorizedOfficialFirstName": "JOHN",
      "AuthorizedOfficialMiddleName": "W",
      "AuthorizedOfficialTitle": "PRESIDENT",
      "AuthorizedOfficialNamePrefix": "DR.",
      "AuthorizedOfficialCredential": "M.D.",
      "AuthorizedOfficialTelephoneNumber": "203-284-9448",
      "TaxonomyCode1": "207W00000X",
      "Taxonomy1": "Ophthalmology",
      "PrimaryTaxonomySwitch1": "Y",
      "HealthcareProviderTaxonomyGroup1": "193400000X SINGLE SPECIALTY  GROUP",
      "HealthcareProviderTaxonomyGroupDescription1": "Single Specialty Group - A business group of one or more individual practitioners, all of who practice with the same area of specialization."
    },
    {
      "NPI": "1982789863",
      "EntityType": "Organization",
      "EIN": "N/A",
      "OrgName": "OVERLAKE EYE DESIGNS, P.C.",
      "FirstLineMailingAddress": "15230 NE 24TH ST STE Q",
      "MailingAddressCityName": "REDMOND",
      "MailingAddressStateName": "WA",
      "MailingAddressPostalCode": "98052-5540",
      "MailingAddressCountryCode": "US",
      "MailingAddressTelephoneNumber": "425-562-2015",
      "MailingAddressFaxNumber": "425-562-2010",
      "FirstLinePracticeLocationAddress": "15230 NE 24TH ST STE Q",
      "PracticeLocationAddressCityName": "REDMOND",
      "PracticeLocationAddressStateName": "WA",
      "PracticeLocationAddressPostalCode": "98052-5540",
      "PracticeLocationAddressCountryCode": "US",
      "PracticeLocationAddressTelephoneNumber": "425-562-2015",
      "PracticeLocationAddressFaxNumber": "425-562-2010",
      "EnumerationDate": "10/26/2006",
      "LastUpdateDate": "07/08/2007",
      "AuthorizedOfficialLastName": "WONG",
      "AuthorizedOfficialFirstName": "TONY",
      "AuthorizedOfficialTitle": "OPTOMETRIST",
      "AuthorizedOfficialNamePrefix": "DR.",
      "AuthorizedOfficialCredential": "O.D.",
      "AuthorizedOfficialTelephoneNumber": "425-562-2015",
      "TaxonomyCode1": "152W00000X",
      "Taxonomy1": "Optometrist",
      "LicenseNumber1": "WA 3422 TX",
      "LicenseNumberStateCode1": "WA",
      "PrimaryTaxonomySwitch1": "Y",
      "HealthcareProviderTaxonomyGroup1": "193400000X SINGLE SPECIALTY  GROUP",
      "HealthcareProviderTaxonomyGroupDescription1": "Single Specialty Group - A business group of one or more individual practitioners, all of who practice with the same area of specialization."
    },
    {
      "NPI": "1760539969",
      "EntityType": "Organization",
      "EIN": "N/A",
      "OrgName": "DR TIFFANY J HOLLENBECK PLLC",
      "OtherOrgName": "REDMOND RIDGE EYE CARE",
      "OtherOrgNameTypeCode": "3",
      "FirstLineMailingAddress": "22310 NE MARKETPLACE DR",
      "SecondLineMailingAddress": "SUITE 106",
      "MailingAddressCityName": "REDMOND",
      "MailingAddressStateName": "WA",
      "MailingAddressPostalCode": "98053-2038",
      "MailingAddressCountryCode": "US",
      "MailingAddressTelephoneNumber": "425-898-9222",
      "MailingAddressFaxNumber": "425-898-9225",
      "FirstLinePracticeLocationAddress": "22310 NE MARKETPLACE DR",
      "SecondLinePracticeLocationAddress": "SUITE 106",
      "PracticeLocationAddressCityName": "REDMOND",
      "PracticeLocationAddressStateName": "WA",
      "PracticeLocationAddressPostalCode": "98053-2038",
      "PracticeLocationAddressCountryCode": "US",
      "PracticeLocationAddressTelephoneNumber": "425-898-9222",
      "PracticeLocationAddressFaxNumber": "425-898-9225",
      "EnumerationDate": "01/03/2007",
      "LastUpdateDate": "07/08/2007",
      "AuthorizedOfficialLastName": "HOLLENBECK",
      "AuthorizedOfficialFirstName": "TIFFANY",
      "AuthorizedOfficialMiddleName": "J",
      "AuthorizedOfficialTitle": "CO OWNER",
      "AuthorizedOfficialNamePrefix": "DR.",
      "AuthorizedOfficialCredential": "O.D.",
      "AuthorizedOfficialTelephoneNumber": "425-898-9222",
      "TaxonomyCode1": "152W00000X",
      "Taxonomy1": "Optometrist",
      "LicenseNumber1": "3825",
      "LicenseNumberStateCode1": "WA",
      "PrimaryTaxonomySwitch1": "Y",
      "HealthcareProviderTaxonomyGroup1": "193400000X SINGLE SPECIALTY  GROUP",
      "HealthcareProviderTaxonomyGroupDescription1": "Single Specialty Group - A business group of one or more individual practitioners, all of who practice with the same area of specialization."
    },
    {
      "NPI": "1629124649",
      "EntityType": "Organization",
      "EIN": "N/A",
      "IsOrgSubpart": "N",
      "OrgName": "TRI-COUNTY EYE CARE AND OPTOMETRY PC",
      "FirstLineMailingAddress": "3685 BURGOYNE AVE",
      "MailingAddressCityName": "HUDSON FALLS",
      "MailingAddressStateName": "NY",
      "MailingAddressPostalCode": "12839-2168",
      "MailingAddressCountryCode": "US",
      "MailingAddressTelephoneNumber": "518-747-4100",
      "MailingAddressFaxNumber": "518-747-6151",
      "FirstLinePracticeLocationAddress": "3685 BURGOYNE AVE",
      "PracticeLocationAddressCityName": "HUDSON FALLS",
      "PracticeLocationAddressStateName": "NY",
      "PracticeLocationAddressPostalCode": "12839-2168",
      "PracticeLocationAddressCountryCode": "US",
      "PracticeLocationAddressTelephoneNumber": "518-747-4100",
      "PracticeLocationAddressFaxNumber": "518-747-6151",
      "EnumerationDate": "01/25/2007",
      "LastUpdateDate": "08/29/2011",
      "AuthorizedOfficialLastName": "REDMOND",
      "AuthorizedOfficialFirstName": "MONICA",
      "AuthorizedOfficialTitle": "OPTOMETRIST",
      "AuthorizedOfficialCredential": "OD",
      "AuthorizedOfficialTelephoneNumber": "518-747-4100",
      "TaxonomyCode1": "152WC0802X",
      "Taxonomy1": "Corneal and Contact Management",
      "LicenseNumber1": "TUV006839-1",
      "LicenseNumberStateCode1": "NY",
      "PrimaryTaxonomySwitch1": "N",
      "TaxonomyCode2": "152WP0200X",
      "Taxonomy2": "Pediatrics",
      "LicenseNumber2": "TUV006839-1",
      "LicenseNumberStateCode2": "NY",
      "PrimaryTaxonomySwitch2": "Y",
      "TaxonomyCode3": "152WS0006X",
      "Taxonomy3": "Sports Vision",
      "LicenseNumber3": "TUV006839-1",
      "LicenseNumberStateCode3": "NY",
      "PrimaryTaxonomySwitch3": "N",
      "OtherIdentifier1": "10089360",
      "OtherIdentifierType1": "OTHER",
      "OtherIdentifierState1": "NY",
      "OtherIdentifierIssuer1": "CDPHP",
      "OtherIdentifier2": "C369F1",
      "OtherIdentifierType2": "OTHER",
      "OtherIdentifierState2": "NY",
      "OtherIdentifierIssuer2": "EMPIRE",
      "OtherIdentifier3": "782077",
      "OtherIdentifierType3": "OTHER",
      "OtherIdentifierState3": "NY",
      "OtherIdentifierIssuer3": "MVP",
      "OtherIdentifier4": "000408532001",
      "OtherIdentifierType4": "OTHER",
      "OtherIdentifierState4": "NY",
      "OtherIdentifierIssuer4": "BSNENY",
      "HealthcareProviderTaxonomyGroup1": "193200000X MULTI-SPECIALTY GROUP",
      "HealthcareProviderTaxonomyGroupDescription1": "Multi-Specialty Group - A business group of one or more individual practitioners, who practice with different areas of specialization.",
      "HealthcareProviderTaxonomyGroup2": "193200000X MULTI-SPECIALTY GROUP",
      "HealthcareProviderTaxonomyGroupDescription2": "Multi-Specialty Group - A business group of one or more individual practitioners, who practice with different areas of specialization.",
      "HealthcareProviderTaxonomyGroup3": "193200000X MULTI-SPECIALTY GROUP",
      "HealthcareProviderTaxonomyGroupDescription3": "Multi-Specialty Group - A business group of one or more individual practitioners, who practice with different areas of specialization."
    },
    {
      "NPI": "1063635506",
      "EntityType": "Organization",
      "EIN": "N/A",
      "IsOrgSubpart": "N",
      "OrgName": "DESCHUTES EYE CLINIC PC",
      "OtherOrgName": "EYE SURGERY INSTITUTE",
      "OtherOrgNameTypeCode": "3",
      "FirstLineMailingAddress": "813 SW HIGHLAND AVE",
      "MailingAddressCityName": "REDMOND",
      "MailingAddressStateName": "OR",
      "MailingAddressPostalCode": "97756-3123",
      "MailingAddressCountryCode": "US",
      "MailingAddressTelephoneNumber": "541-548-7170",
      "MailingAddressFaxNumber": "541-548-3842",
      "FirstLinePracticeLocationAddress": "813 SW HIGHLAND AVE",
      "PracticeLocationAddressCityName": "REDMOND",
      "PracticeLocationAddressStateName": "OR",
      "PracticeLocationAddressPostalCode": "97756-3123",
      "PracticeLocationAddressCountryCode": "US",
      "PracticeLocationAddressTelephoneNumber": "541-548-7170",
      "PracticeLocationAddressFaxNumber": "541-548-3842",
      "EnumerationDate": "04/11/2007",
      "LastUpdateDate": "12/01/2010",
      "AuthorizedOfficialLastName": "TRAUSTASON",
      "AuthorizedOfficialFirstName": "OLI",
      "AuthorizedOfficialTitle": "PRESIDENT",
      "AuthorizedOfficialNamePrefix": "DR.",
      "AuthorizedOfficialCredential": "M.D.",
      "AuthorizedOfficialTelephoneNumber": "541-548-7170",
      "TaxonomyCode1": "261QA1903X",
      "Taxonomy1": "Ambulatory Surgical",
      "LicenseNumber1": "071581",
      "LicenseNumberStateCode1": "OR",
      "PrimaryTaxonomySwitch1": "Y",
      "OtherIdentifier1": "165450",
      "OtherIdentifierType1": "MEDICAID",
      "OtherIdentifierState1": "OR",
      "OtherIdentifier2": "138874101",
      "OtherIdentifierType2": "OTHER",
      "OtherIdentifierState2": "OR",
      "OtherIdentifierIssuer2": "BLUE CROSS PARTICIPATING",
      "OtherIdentifier3": "490003253",
      "OtherIdentifierType3": "OTHER",
      "OtherIdentifierState3": "OR",
      "OtherIdentifierIssuer3": "RR MEDICARE",
      "OtherIdentifier4": "180029258",
      "OtherIdentifierType4": "OTHER",
      "OtherIdentifierState4": "OR",
      "OtherIdentifierIssuer4": "UNITED HEALTHCARE RR"
    },
    {
      "NPI": "1437480456",
      "EntityType": "Organization",
      "EIN": "N/A",
      "IsOrgSubpart": "N",
      "OrgName": "VANESSA MICHEL PLLC",
      "OtherOrgName": "REDMOND RIDGE EYE CARE",
      "OtherOrgNameTypeCode": "3",
      "FirstLineMailingAddress": "23535 NE NOVELTY HILL RD",
      "SecondLineMailingAddress": "D302",
      "MailingAddressCityName": "REDMOND",
      "MailingAddressStateName": "WA",
      "MailingAddressPostalCode": "98053-5502",
      "MailingAddressCountryCode": "US",
      "MailingAddressTelephoneNumber": "425-898-9222",
      "MailingAddressFaxNumber": "425-898-9225",
      "FirstLinePracticeLocationAddress": "23535 NE NOVELTY HILL RD",
      "SecondLinePracticeLocationAddress": "D302",
      "PracticeLocationAddressCityName": "REDMOND",
      "PracticeLocationAddressStateName": "WA",
      "PracticeLocationAddressPostalCode": "98053-5502",
      "PracticeLocationAddressCountryCode": "US",
      "PracticeLocationAddressTelephoneNumber": "425-898-9222",
      "PracticeLocationAddressFaxNumber": "425-898-9225",
      "EnumerationDate": "01/15/2010",
      "LastUpdateDate": "01/17/2017",
      "AuthorizedOfficialLastName": "MICHEL",
      "AuthorizedOfficialFirstName": "VANESSA",
      "AuthorizedOfficialMiddleName": "G",
      "AuthorizedOfficialTitle": "OPTOMETRIST/OWNER",
      "AuthorizedOfficialNamePrefix": "DR.",
      "AuthorizedOfficialCredential": "O.D.",
      "AuthorizedOfficialTelephoneNumber": "425-898-9222",
      "TaxonomyCode1": "152W00000X",
      "Taxonomy1": "Optometrist",
      "LicenseNumber1": "3908",
      "LicenseNumberStateCode1": "WA",
      "PrimaryTaxonomySwitch1": "Y",
      "HealthcareProviderTaxonomyGroup1": "193400000X SINGLE SPECIALTY  GROUP",
      "HealthcareProviderTaxonomyGroupDescription1": "Single Specialty Group - A business group of one or more individual practitioners, all of who practice with the same area of specialization."
    },
    {
      "NPI": "1609157460",
      "EntityType": "Organization",
      "EIN": "N/A",
      "IsOrgSubpart": "Y",
      "ParentOrgLBN": "OVERLAKE EYE DESIGNS, P.C.",
      "ParentOrgTIN": "N/A",
      "OrgName": "OVERLAKE EYE DESIGNS, P.C.",
      "OtherOrgName": "EYECARE AT THE COMMONS",
      "OtherOrgNameTypeCode": "3",
      "FirstLineMailingAddress": "15101 NE 40TH ST.",
      "SecondLineMailingAddress": "SUBMIXER / 1023 B / 1 MICROSOFT WAY",
      "MailingAddressCityName": "REDMOND",
      "MailingAddressStateName": "WA",
      "MailingAddressPostalCode": "98052",
      "MailingAddressCountryCode": "US",
      "MailingAddressTelephoneNumber": "425-497-9400",
      "MailingAddressFaxNumber": "425-497-0219",
      "FirstLinePracticeLocationAddress": "15253 N.E. 40TH ST.,",
      "SecondLinePracticeLocationAddress": "BUILDING 98, S. SUBMIXER",
      "PracticeLocationAddressCityName": "REDMOND",
      "PracticeLocationAddressStateName": "WA",
      "PracticeLocationAddressPostalCode": "98052",
      "PracticeLocationAddressCountryCode": "US",
      "PracticeLocationAddressTelephoneNumber": "425-497-9400",
      "PracticeLocationAddressFaxNumber": "425-497-0219",
      "EnumerationDate": "09/07/2011",
      "LastUpdateDate": "09/07/2011",
      "AuthorizedOfficialLastName": "PIAN",
      "AuthorizedOfficialFirstName": "BESSIE",
      "AuthorizedOfficialMiddleName": "M",
      "AuthorizedOfficialTitle": "SECRETARY",
      "AuthorizedOfficialNamePrefix": "DR.",
      "AuthorizedOfficialCredential": "O.D.",
      "AuthorizedOfficialTelephoneNumber": "425-260-6747",
      "TaxonomyCode1": "152W00000X",
      "Taxonomy1": "Optometrist",
      "PrimaryTaxonomySwitch1": "Y",
      "HealthcareProviderTaxonomyGroup1": "193400000X SINGLE SPECIALTY  GROUP",
      "HealthcareProviderTaxonomyGroupDescription1": "Single Specialty Group - A business group of one or more individual practitioners, all of who practice with the same area of specialization."
    },
    {
      "NPI": "1992044903",
      "EntityType": "Organization",
      "EIN": "N/A",
      "IsOrgSubpart": "N",
      "OrgName": "ORION EYE CENTER LLC",
      "FirstLineMailingAddress": "1775 SW UMATILLA AVE",
      "MailingAddressCityName": "REDMOND",
      "MailingAddressStateName": "OR",
      "MailingAddressPostalCode": "97756-7197",
      "MailingAddressCountryCode": "US",
      "MailingAddressTelephoneNumber": "541-548-7170",
      "FirstLinePracticeLocationAddress": "1775 SW UMATILLA AVE",
      "PracticeLocationAddressCityName": "REDMOND",
      "PracticeLocationAddressStateName": "OR",
      "PracticeLocationAddressPostalCode": "97756-7197",
      "PracticeLocationAddressCountryCode": "US",
      "PracticeLocationAddressTelephoneNumber": "541-548-7170",
      "EnumerationDate": "02/11/2013",
      "LastUpdateDate": "02/11/2013",
      "AuthorizedOfficialLastName": "SCHAEFER",
      "AuthorizedOfficialFirstName": "GINGER",
      "AuthorizedOfficialTitle": "ADMINISTRATOR",
      "AuthorizedOfficialTelephoneNumber": "541-548-7170",
      "TaxonomyCode1": "207W00000X",
      "Taxonomy1": "Ophthalmology",
      "PrimaryTaxonomySwitch1": "Y",
      "HealthcareProviderTaxonomyGroup1": "193400000X SINGLE SPECIALTY  GROUP",
      "HealthcareProviderTaxonomyGroupDescription1": "Single Specialty Group - A business group of one or more individual practitioners, all of who practice with the same area of specialization."
    },
    {
      "NPI": "1265986376",
      "EntityType": "Organization",
      "EIN": "N/A",
      "IsOrgSubpart": "N",
      "OrgName": "PROLIANCE SURGEONS, INC., P.S.",
      "OtherOrgName": "PROLIANCE EASTSIDE ENT/THE CHILDREN AND FAMILY EYE DOCTORS",
      "OtherOrgNameTypeCode": "3",
      "FirstLineMailingAddress": "805 MADISON ST",
      "SecondLineMailingAddress": "SUITE 901",
      "MailingAddressCityName": "SEATTLE",
      "MailingAddressStateName": "WA",
      "MailingAddressPostalCode": "98104-1172",
      "MailingAddressCountryCode": "US",
      "MailingAddressTelephoneNumber": "206-264-8100",
      "FirstLinePracticeLocationAddress": "17130 AVONDALE WAY NE",
      "SecondLinePracticeLocationAddress": "SUITE 111",
      "PracticeLocationAddressCityName": "REDMOND",
      "PracticeLocationAddressStateName": "WA",
      "PracticeLocationAddressPostalCode": "98052-4455",
      "PracticeLocationAddressCountryCode": "US",
      "PracticeLocationAddressTelephoneNumber": "425-885-6600",
      "PracticeLocationAddressFaxNumber": "425-885-6580",
      "EnumerationDate": "08/05/2016",
      "LastUpdateDate": "04/21/2017",
      "AuthorizedOfficialLastName": "FITZGERALD",
      "AuthorizedOfficialFirstName": "DAVID",
      "AuthorizedOfficialMiddleName": "G.",
      "AuthorizedOfficialTitle": "CEO",
      "AuthorizedOfficialNamePrefix": "MR.",
      "AuthorizedOfficialTelephoneNumber": "206-838-2599",
      "TaxonomyCode1": "152W00000X",
      "Taxonomy1": "Optometrist",
      "LicenseNumber1": "601484763",
      "LicenseNumberStateCode1": "WA",
      "PrimaryTaxonomySwitch1": "N",
      "TaxonomyCode2": "207W00000X",
      "Taxonomy2": "Ophthalmology",
      "LicenseNumber2": "601484763",
      "LicenseNumberStateCode2": "WA",
      "PrimaryTaxonomySwitch2": "Y",
      "OtherIdentifier1": "222338",
      "OtherIdentifierType1": "OTHER",
      "OtherIdentifierState1": "WA",
      "OtherIdentifierIssuer1": "WA STATE L & I",
      "OtherIdentifier2": "2001403",
      "OtherIdentifierType2": "MEDICAID",
      "OtherIdentifierState2": "WA",
      "OtherIdentifier3": "G8867851",
      "OtherIdentifierType3": "OTHER",
      "OtherIdentifierState3": "WA",
      "OtherIdentifierIssuer3": "MEDICARE PTAN",
      "HealthcareProviderTaxonomyGroup1": "193200000X MULTI-SPECIALTY GROUP",
      "HealthcareProviderTaxonomyGroupDescription1": "Multi-Specialty Group - A business group of one or more individual practitioners, who practice with different areas of specialization.",
      "HealthcareProviderTaxonomyGroup2": "193200000X MULTI-SPECIALTY GROUP",
      "HealthcareProviderTaxonomyGroupDescription2": "Multi-Specialty Group - A business group of one or more individual practitioners, who practice with different areas of specialization."
    },
    {
      "NPI": "1447771951",
      "EntityType": "Organization",
      "EIN": "N/A",
      "IsOrgSubpart": "N",
      "OrgName": "JEFF BINSTOCK, DVM, OD, FAAO, PLLC",
      "OtherOrgName": "REDMOND EYE CLINIC",
      "OtherOrgNameTypeCode": "3",
      "FirstLineMailingAddress": "16150 NE 85TH ST STE 206",
      "MailingAddressCityName": "REDMOND",
      "MailingAddressStateName": "WA",
      "MailingAddressPostalCode": "98052-3543",
      "MailingAddressCountryCode": "US",
      "MailingAddressTelephoneNumber": "425-885-3574",
      "FirstLinePracticeLocationAddress": "16150 NE 85TH ST STE 206",
      "PracticeLocationAddressCityName": "REDMOND",
      "PracticeLocationAddressStateName": "WA",
      "PracticeLocationAddressPostalCode": "98052-3543",
      "PracticeLocationAddressCountryCode": "US",
      "PracticeLocationAddressTelephoneNumber": "(425) 885-3574",
      "EnumerationDate": "07/05/2017",
      "LastUpdateDate": "12/27/2017",
      "AuthorizedOfficialLastName": "BINSTOCK",
      "AuthorizedOfficialFirstName": "JEFF",
      "AuthorizedOfficialTitle": "MEMBER",
      "AuthorizedOfficialNamePrefix": "DR.",
      "AuthorizedOfficialCredential": "DVM, OD, FAAO",
      "AuthorizedOfficialTelephoneNumber": "818-620-7641",
      "TaxonomyCode1": "152WC0802X",
      "Taxonomy1": "Corneal and Contact Management",
      "LicenseNumber1": "60553429",
      "LicenseNumberStateCode1": "WA",
      "PrimaryTaxonomySwitch1": "Y",
      "HealthcareProviderTaxonomyGroup1": "193400000X SINGLE SPECIALTY  GROUP",
      "HealthcareProviderTaxonomyGroupDescription1": "Single Specialty Group - A business group of one or more individual practitioners, all of who practice with the same area of specialization."
    },
    {
      "NPI": "1689189151",
      "EntityType": "Organization",
      "EIN": "N/A",
      "IsOrgSubpart": "N",
      "OrgName": "PERSONALEYES, LLC",
      "OtherOrgName": "WILLOW CREEK EYE CARE",
      "OtherOrgNameTypeCode": "3",
      "FirstLineMailingAddress": "1000 SW INDIAN AVE",
      "MailingAddressCityName": "REDMOND",
      "MailingAddressStateName": "OR",
      "MailingAddressPostalCode": "97756-3039",
      "MailingAddressCountryCode": "US",
      "MailingAddressTelephoneNumber": "541-548-2488",
      "MailingAddressFaxNumber": "541-548-5334",
      "FirstLinePracticeLocationAddress": "14740 NW CORNELL RD",
      "PracticeLocationAddressCityName": "PORTLAND",
      "PracticeLocationAddressStateName": "OR",
      "PracticeLocationAddressPostalCode": "97229-5496",
      "PracticeLocationAddressCountryCode": "US",
      "PracticeLocationAddressTelephoneNumber": "503-645-8002",
      "PracticeLocationAddressFaxNumber": "503-645-9455",
      "EnumerationDate": "12/06/2017",
      "LastUpdateDate": "12/06/2017",
      "AuthorizedOfficialLastName": "SHELDON",
      "AuthorizedOfficialFirstName": "TODD",
      "AuthorizedOfficialTitle": "PRESIDENT",
      "AuthorizedOfficialCredential": "OD, MBA, FAAO",
      "AuthorizedOfficialTelephoneNumber": "541-548-2488",
      "TaxonomyCode1": "261QM2500X",
      "Taxonomy1": "Medical Specialty ",
      "LicenseNumber1": "2823ATI",
      "LicenseNumberStateCode1": "OR",
      "PrimaryTaxonomySwitch1": "Y"
    },
    {
      "NPI": "1225534910",
      "EntityType": "Individual",
      "IsSoleProprietor": "N",
      "LastName": "MAZHAR",
      "FirstName": "SAHAR",
      "MiddleName": "RANIA",
      "FirstLineMailingAddress": "1108 ROSS CLARK CIR",
      "MailingAddressCityName": "DOTHAN",
      "MailingAddressStateName": "AL",
      "MailingAddressPostalCode": "36301-3022",
      "MailingAddressCountryCode": "US",
      "MailingAddressTelephoneNumber": "334-712-3329",
      "FirstLinePracticeLocationAddress": "1108 ROSS CLARK CIR",
      "PracticeLocationAddressCityName": "DOTHAN",
      "PracticeLocationAddressStateName": "AL",
      "PracticeLocationAddressPostalCode": "36301-3022",
      "PracticeLocationAddressCountryCode": "US",
      "PracticeLocationAddressTelephoneNumber": "334-712-3329",
      "EnumerationDate": "04/02/2018",
      "LastUpdateDate": "04/02/2018",
      "GenderCode": "F",
      "Gender": "Female",
      "TaxonomyCode1": "390200000X",
      "Taxonomy1": "Student in an Organized Health Care Education/Training Program",
      "PrimaryTaxonomySwitch1": "Y"
    },
    {
      "NPI": "1922502889",
      "EntityType": "Individual",
      "IsSoleProprietor": "N",
      "LastName": "FADLALLA",
      "FirstName": "RANIA",
      "MiddleName": "ABDALLA DAW ELBEIT",
      "NamePrefix": "DR.",
      "Credential": "MD",
      "FirstLineMailingAddress": "1 BAY AVE",
      "MailingAddressCityName": "MONTCLAIR",
      "MailingAddressStateName": "NJ",
      "MailingAddressPostalCode": "07042-4837",
      "MailingAddressCountryCode": "US",
      "MailingAddressTelephoneNumber": "973-429-6196",
      "FirstLinePracticeLocationAddress": "1 BAY AVE",
      "PracticeLocationAddressCityName": "MONTCLAIR",
      "PracticeLocationAddressStateName": "NJ",
      "PracticeLocationAddressPostalCode": "07042-4837",
      "PracticeLocationAddressCountryCode": "US",
      "PracticeLocationAddressTelephoneNumber": "973-429-6196",
      "EnumerationDate": "03/23/2018",
      "LastUpdateDate": "03/23/2018",
      "GenderCode": "F",
      "Gender": "Female",
      "TaxonomyCode1": "390200000X",
      "Taxonomy1": "Student in an Organized Health Care Education/Training Program",
      "PrimaryTaxonomySwitch1": "Y"
    },
    {
      "NPI": "1629068499",
      "EntityType": "Individual",
      "IsSoleProprietor": "N",
      "LastName": "FAHOURY",
      "FirstName": "RANIA",
      "NamePrefix": "DR.",
      "Credential": "MD",
      "FirstLineMailingAddress": "4411 N HOLLAND SYLVANIA RD",
      "SecondLineMailingAddress": "SUITE 201",
      "MailingAddressCityName": "TOLEDO",
      "MailingAddressStateName": "OH",
      "MailingAddressPostalCode": "43623-3525",
      "MailingAddressCountryCode": "US",
      "MailingAddressTelephoneNumber": "419-843-3627",
      "MailingAddressFaxNumber": "419-843-9697",
      "FirstLinePracticeLocationAddress": "4411 N HOLLAND SYLVANIA RD",
      "SecondLinePracticeLocationAddress": "SUITE 201",
      "PracticeLocationAddressCityName": "TOLEDO",
      "PracticeLocationAddressStateName": "OH",
      "PracticeLocationAddressPostalCode": "43623-3525",
      "PracticeLocationAddressCountryCode": "US",
      "PracticeLocationAddressTelephoneNumber": "419-843-3627",
      "PracticeLocationAddressFaxNumber": "419-843-9697",
      "EnumerationDate": "10/24/2005",
      "LastUpdateDate": "09/02/2011",
      "GenderCode": "F",
      "Gender": "Female",
      "TaxonomyCode1": "207Q00000X",
      "Taxonomy1": "Family Medicine",
      "LicenseNumber1": "35086663",
      "LicenseNumberStateCode1": "OH",
      "PrimaryTaxonomySwitch1": "Y",
      "OtherIdentifier1": "2621621",
      "OtherIdentifierType1": "MEDICAID",
      "OtherIdentifierState1": "OH",
      "OtherIdentifier2": "P00401238",
      "OtherIdentifierType2": "OTHER",
      "OtherIdentifierState2": "OH",
      "OtherIdentifierIssuer2": "RAILROAD MEDICARE"
    },
    {
      "NPI": "1033186986",
      "EntityType": "Individual",
      "IsSoleProprietor": "N",
      "LastName": "NICOLA",
      "FirstName": "RANIA",
      "MiddleName": "SOLIMAN",
      "NamePrefix": "DR.",
      "Credential": "DDS",
      "FirstLineMailingAddress": "110 S WOODLAND ST",
      "MailingAddressCityName": "WINTER GARDEN",
      "MailingAddressStateName": "FL",
      "MailingAddressPostalCode": "34787-3546",
      "MailingAddressCountryCode": "US",
      "MailingAddressTelephoneNumber": "407-905-8827",
      "MailingAddressFaxNumber": "407-645-4587",
      "FirstLinePracticeLocationAddress": "7900 FOREST CITY RD",
      "PracticeLocationAddressCityName": "ORLANDO",
      "PracticeLocationAddressStateName": "FL",
      "PracticeLocationAddressPostalCode": "32810-3002",
      "PracticeLocationAddressCountryCode": "US",
      "PracticeLocationAddressTelephoneNumber": "407-905-8827",
      "PracticeLocationAddressFaxNumber": "407-645-4587",
      "EnumerationDate": "02/28/2006",
      "LastUpdateDate": "07/28/2017",
      "GenderCode": "F",
      "Gender": "Female",
      "TaxonomyCode1": "1223G0001X",
      "Taxonomy1": "General Practice",
      "LicenseNumber1": "DN15582",
      "LicenseNumberStateCode1": "FL",
      "PrimaryTaxonomySwitch1": "N",
      "TaxonomyCode2": "122300000X",
      "Taxonomy2": "Dentist",
      "LicenseNumber2": "DN15582",
      "LicenseNumberStateCode2": "FL",
      "PrimaryTaxonomySwitch2": "Y",
      "OtherIdentifier1": "075156100",
      "OtherIdentifierType1": "MEDICAID",
      "OtherIdentifierState1": "FL"
    },
    {
      "NPI": "1720032899",
      "EntityType": "Individual",
      "IsSoleProprietor": "N",
      "LastName": "ALBATAINEH",
      "FirstName": "RANIA",
      "MiddleName": "QASSIEM",
      "Credential": "M.D.",
      "FirstLineMailingAddress": "11476 OKEECHOBEE BLVD",
      "MailingAddressCityName": "ROYAL PALM BEACH",
      "MailingAddressStateName": "FL",
      "MailingAddressPostalCode": "33411-8715",
      "MailingAddressCountryCode": "US",
      "MailingAddressTelephoneNumber": "561-204-5111",
      "MailingAddressFaxNumber": "561-204-5150",
      "FirstLinePracticeLocationAddress": "11476 OKEECHOBEE BLVD",
      "PracticeLocationAddressCityName": "ROYAL PALM BEACH",
      "PracticeLocationAddressStateName": "FL",
      "PracticeLocationAddressPostalCode": "33411-8715",
      "PracticeLocationAddressCountryCode": "US",
      "PracticeLocationAddressTelephoneNumber": "561-204-5111",
      "PracticeLocationAddressFaxNumber": "561-204-5150",
      "EnumerationDate": "05/21/2006",
      "LastUpdateDate": "09/11/2007",
      "GenderCode": "F",
      "Gender": "Female",
      "TaxonomyCode1": "207R00000X",
      "Taxonomy1": "Internal Medicine",
      "LicenseNumber1": "ME 79876",
      "LicenseNumberStateCode1": "FL",
      "PrimaryTaxonomySwitch1": "Y"
    },
    {
      "NPI": "1326095100",
      "EntityType": "Individual",
      "IsSoleProprietor": "N",
      "LastName": "ROSBOROUGH",
      "FirstName": "RANIA",
      "MiddleName": "BAJWA",
      "Credential": "M.D.",
      "FirstLineMailingAddress": "3100 WYMAN PARK DR",
      "MailingAddressCityName": "BALTIMORE",
      "MailingAddressStateName": "MD",
      "MailingAddressPostalCode": "21211-2803",
      "MailingAddressCountryCode": "US",
      "MailingAddressTelephoneNumber": "410-338-3500",
      "FirstLinePracticeLocationAddress": "3601 SW 160TH AVE",
      "SecondLinePracticeLocationAddress": "SUITE 250",
      "PracticeLocationAddressCityName": "MIRAMAR",
      "PracticeLocationAddressStateName": "FL",
      "PracticeLocationAddressPostalCode": "33027-6308",
      "PracticeLocationAddressCountryCode": "US",
      "PracticeLocationAddressTelephoneNumber": "877-866-7123",
      "EnumerationDate": "05/27/2006",
      "LastUpdateDate": "12/10/2014",
      "GenderCode": "F",
      "Gender": "Female",
      "TaxonomyCode1": "207R00000X",
      "Taxonomy1": "Internal Medicine",
      "LicenseNumber1": "D0063732",
      "LicenseNumberStateCode1": "MD",
      "PrimaryTaxonomySwitch1": "Y",
      "TaxonomyCode2": "207Q00000X",
      "Taxonomy2": "Family Medicine",
      "LicenseNumber2": "0101257197",
      "LicenseNumberStateCode2": "VA",
      "PrimaryTaxonomySwitch2": "N"
    },
    {
      "NPI": "1528015310",
      "EntityType": "Individual",
      "IsSoleProprietor": "N",
      "LastName": "HUSSEINI",
      "FirstName": "RANIA",
      "MiddleName": "I",
      "Credential": "M.D.",
      "FirstLineMailingAddress": "111 CYPRESS ST",
      "MailingAddressCityName": "BROOKLINE",
      "MailingAddressStateName": "MA",
      "MailingAddressPostalCode": "02445-6002",
      "MailingAddressCountryCode": "US",
      "MailingAddressTelephoneNumber": "508-718-4050",
      "FirstLinePracticeLocationAddress": "20 PATRIOT PL",
      "PracticeLocationAddressCityName": "FOXBORO",
      "PracticeLocationAddressStateName": "MA",
      "PracticeLocationAddressPostalCode": "02035-1375",
      "PracticeLocationAddressCountryCode": "US",
      "PracticeLocationAddressTelephoneNumber": "508-718-4050",
      "EnumerationDate": "05/27/2006",
      "LastUpdateDate": "04/17/2012",
      "GenderCode": "F",
      "Gender": "Female",
      "TaxonomyCode1": "207R00000X",
      "Taxonomy1": "Internal Medicine",
      "LicenseNumber1": "209649",
      "LicenseNumberStateCode1": "MA",
      "PrimaryTaxonomySwitch1": "Y"
    },
    {
      "NPI": "1760429591",
      "EntityType": "Individual",
      "IsSoleProprietor": "N",
      "LastName": "RAYES-DANAN",
      "FirstName": "RANIA",
      "NamePrefix": "DR.",
      "Credential": "MD",
      "OtherLastName": "RAYES",
      "OtherFirstName": "RANIA",
      "OtherLastNameTypeCode": "1",
      "FirstLineMailingAddress": "2500 METROHEALTH DR",
      "MailingAddressCityName": "CLEVELAND",
      "MailingAddressStateName": "OH",
      "MailingAddressPostalCode": "44109-1900",
      "MailingAddressCountryCode": "US",
      "MailingAddressTelephoneNumber": "216-778-7800",
      "FirstLinePracticeLocationAddress": "2500 METROHEALTH DR",
      "PracticeLocationAddressCityName": "CLEVELAND",
      "PracticeLocationAddressStateName": "OH",
      "PracticeLocationAddressPostalCode": "44109-1900",
      "PracticeLocationAddressCountryCode": "US",
      "PracticeLocationAddressTelephoneNumber": "216-778-7800",
      "EnumerationDate": "06/01/2006",
      "LastUpdateDate": "01/30/2014",
      "GenderCode": "F",
      "Gender": "Female",
      "TaxonomyCode1": "207ZP0102X",
      "Taxonomy1": "Anatomic Pathology & Clinical Pathology",
      "LicenseNumber1": "35086346",
      "LicenseNumberStateCode1": "OH",
      "PrimaryTaxonomySwitch1": "Y",
      "OtherIdentifier1": "2687703",
      "OtherIdentifierType1": "MEDICAID",
      "OtherIdentifierState1": "OH"
    },
    {
      "NPI": "1699717660",
      "EntityType": "Individual",
      "IsSoleProprietor": "Y",
      "LastName": "AMPEY",
      "FirstName": "RANIA",
      "MiddleName": "L",
      "Credential": "LPC",
      "FirstLineMailingAddress": "5930 LOVERS LN",
      "SecondLineMailingAddress": "PREMIER NEUROPSYCHIATRY, PLC",
      "MailingAddressCityName": "PORTAGE",
      "MailingAddressStateName": "MI",
      "MailingAddressPostalCode": "49002-1673",
      "MailingAddressCountryCode": "US",
      "MailingAddressTelephoneNumber": "269-873-1611",
      "FirstLinePracticeLocationAddress": "5930 LOVERS LN",
      "SecondLinePracticeLocationAddress": "PREMIER NEUROPSYCHIATRY, PLC",
      "PracticeLocationAddressCityName": "PORTAGE",
      "PracticeLocationAddressStateName": "MI",
      "PracticeLocationAddressPostalCode": "49002-1673",
      "PracticeLocationAddressCountryCode": "US",
      "PracticeLocationAddressTelephoneNumber": "269-873-1611",
      "EnumerationDate": "06/12/2006",
      "LastUpdateDate": "12/30/2010",
      "GenderCode": "F",
      "Gender": "Female",
      "TaxonomyCode1": "101YP2500X",
      "Taxonomy1": "Professional",
      "LicenseNumber1": "6401007658",
      "LicenseNumberStateCode1": "MI",
      "PrimaryTaxonomySwitch1": "Y"
    },
    {
      "NPI": "1801839667",
      "EntityType": "Individual",
      "IsSoleProprietor": "N",
      "LastName": "ABOUJAOUDE",
      "FirstName": "RANIA",
      "Credential": "M.D.",
      "FirstLineMailingAddress": "PO BOX 1283",
      "MailingAddressCityName": "MEDFORD",
      "MailingAddressStateName": "NJ",
      "MailingAddressPostalCode": "08055-6283",
      "MailingAddressCountryCode": "US",
      "MailingAddressTelephoneNumber": "609-677-1046",
      "MailingAddressFaxNumber": "609-677-1306",
      "FirstLinePracticeLocationAddress": "200 TRENTON RD",
      "PracticeLocationAddressCityName": "BROWNS MILLS",
      "PracticeLocationAddressStateName": "NJ",
      "PracticeLocationAddressPostalCode": "08015-1705",
      "PracticeLocationAddressCountryCode": "US",
      "PracticeLocationAddressTelephoneNumber": "609-677-1046",
      "PracticeLocationAddressFaxNumber": "609-677-1306",
      "EnumerationDate": "06/13/2006",
      "LastUpdateDate": "09/15/2014",
      "GenderCode": "F",
      "Gender": "Female",
      "TaxonomyCode1": "207RI0200X",
      "Taxonomy1": "Infectious Disease",
      "LicenseNumber1": "39215",
      "LicenseNumberStateCode1": "KY",
      "PrimaryTaxonomySwitch1": "N",
      "TaxonomyCode2": "207RI0200X",
      "Taxonomy2": "Infectious Disease",
      "LicenseNumber2": "25MA07672000",
      "LicenseNumberStateCode2": "NJ",
      "PrimaryTaxonomySwitch2": "Y"
    },
    {
      "NPI": "1184645301",
      "EntityType": "Individual",
      "IsSoleProprietor": "Y",
      "LastName": "BAIK",
      "FirstName": "RANIA",
      "Credential": "D.O.",
      "FirstLineMailingAddress": "602 ROUTE 169",
      "SecondLineMailingAddress": "PO BOX 865",
      "MailingAddressCityName": "WOODSTOCK",
      "MailingAddressStateName": "CT",
      "MailingAddressPostalCode": "06281-2225",
      "MailingAddressCountryCode": "US",
      "MailingAddressTelephoneNumber": "860-821-3406",
      "MailingAddressFaxNumber": "860-821-3407",
      "FirstLinePracticeLocationAddress": "602 ROUTE 169",
      "PracticeLocationAddressCityName": "WOODSTOCK",
      "PracticeLocationAddressStateName": "CT",
      "PracticeLocationAddressPostalCode": "06281-2225",
      "PracticeLocationAddressCountryCode": "US",
      "PracticeLocationAddressTelephoneNumber": "860-821-3406",
      "PracticeLocationAddressFaxNumber": "860-821-3407",
      "EnumerationDate": "07/22/2006",
      "LastUpdateDate": "01/14/2016",
      "GenderCode": "F",
      "Gender": "Female",
      "TaxonomyCode1": "207Q00000X",
      "Taxonomy1": "Family Medicine",
      "LicenseNumber1": "000260",
      "LicenseNumberStateCode1": "CT",
      "PrimaryTaxonomySwitch1": "Y"
    },
    {
      "NPI": "1265443618",
      "EntityType": "Individual",
      "IsSoleProprietor": "N",
      "LastName": "LOUTFI",
      "FirstName": "RANIA",
      "MiddleName": "H",
      "Credential": "MD",
      "FirstLineMailingAddress": "1 COOPER PLZ",
      "SecondLineMailingAddress": "THE COOPER HOSPITALIST TEAM",
      "MailingAddressCityName": "CAMDEN",
      "MailingAddressStateName": "NJ",
      "MailingAddressPostalCode": "08103-1461",
      "MailingAddressCountryCode": "US",
      "MailingAddressTelephoneNumber": "856-342-3150",
      "MailingAddressFaxNumber": "856-968-8418",
      "FirstLinePracticeLocationAddress": "1 COOPER PLZ",
      "SecondLinePracticeLocationAddress": "THE COOPER HOSPITALIST TEAM",
      "PracticeLocationAddressCityName": "CAMDEN",
      "PracticeLocationAddressStateName": "NJ",
      "PracticeLocationAddressPostalCode": "08103-1461",
      "PracticeLocationAddressCountryCode": "US",
      "PracticeLocationAddressTelephoneNumber": "856-342-3150",
      "PracticeLocationAddressFaxNumber": "856-968-8418",
      "EnumerationDate": "08/11/2006",
      "LastUpdateDate": "06/30/2014",
      "GenderCode": "F",
      "Gender": "Female",
      "TaxonomyCode1": "207R00000X",
      "Taxonomy1": "Internal Medicine",
      "LicenseNumber1": "MA080819",
      "LicenseNumberStateCode1": "NJ",
      "PrimaryTaxonomySwitch1": "Y",
      "OtherIdentifier1": "01007800000",
      "OtherIdentifierType1": "OTHER",
      "OtherIdentifierIssuer1": "AMERICHOICE",
      "OtherIdentifier2": "0118460",
      "OtherIdentifierType2": "MEDICAID",
      "OtherIdentifierState2": "NJ",
      "OtherIdentifier3": "P00381177",
      "OtherIdentifierType3": "OTHER",
      "OtherIdentifierIssuer3": "RAIL ROAD MEDICARE",
      "OtherIdentifier4": "2798670000",
      "OtherIdentifierType4": "OTHER",
      "OtherIdentifierIssuer4": "AMERIHEALTH, HMO, KEYSTONE, IBC",
      "OtherIdentifier5": "1376273",
      "OtherIdentifierType5": "OTHER",
      "OtherIdentifierIssuer5": "AETNA US-HEALTHCARE",
      "OtherIdentifier6": "44132",
      "OtherIdentifierType6": "OTHER",
      "OtherIdentifierIssuer6": "UNIVERSITY HEALTH PLAN",
      "OtherIdentifier7": "60027465",
      "OtherIdentifierType7": "OTHER",
      "OtherIdentifierIssuer7": "HORIZON NJ HEALTH",
      "OtherIdentifier8": "3K6229",
      "OtherIdentifierType8": "OTHER",
      "OtherIdentifierIssuer8": "HEALTHNET",
      "OtherIdentifier9": "6761897",
      "OtherIdentifierType9": "OTHER",
      "OtherIdentifierIssuer9": "CIGNA"
    }
  ]
}

Done. Press any key to exit ...
            
        

Use Case #2 - I Need to Find Detailed Healthcare Provider Information Using Known NPI Number

This is very common scenario. You need to get full replica of NPI record. Again, it simple. Just use code provided below. API response may contain single NPI record, or empty list in case NPI does not exist in the CMS National Plan and Provider Enumeration System (NPPES) Registry.

                
    //--------------------------------------------------------------------------------------
    // Perform "getcode" operation to get healthcare provider information using NPI number.
    //--------------------------------------------------------------------------------------
    using System;
    using System.Net.Http;
    using System.Threading.Tasks;

    public class Program
    {
        private const string token = "3932f3b0-cfab-11dc-95ff-0800200c9a663932f3b0-cfab-11dc-95ff-0800200c9a66";

        static async Task Main(string[] args)
        {
            string endPoint = $"https://www.datalabs.health/api/npi/getcode?q=1285636522&token={token}";
            using HttpClient client = new HttpClient();
            string response = await client.GetStringAsync(endPoint);

            Console.WriteLine(response);

            Console.WriteLine("Done. Press any key to exit ...");
            Console.ReadKey();
        }
    }
                
            

                
    {
      "NPI": [
        {
          "NPI": "1285636522",
          "EntityType": "Organization",
          "EIN": "N/A",
          "IsOrgSubpart": "N",
          "OrgName": "MEDSTAR GEORGETOWN MEDICAL CENTER, INC",
          "FirstLineMailingAddress": "PO BOX 418283",
          "MailingAddressCityName": "BOSTON",
          "MailingAddressStateName": "MA",
          "MailingAddressPostalCode": "02241-8283",
          "MailingAddressCountryCode": "US",
          "FirstLinePracticeLocationAddress": "3800 RESERVOIR RD NW",
          "PracticeLocationAddressCityName": "WASHINGTON",
          "PracticeLocationAddressStateName": "DC",
          "PracticeLocationAddressPostalCode": "20007-2113",
          "PracticeLocationAddressCountryCode": "US",
          "PracticeLocationAddressTelephoneNumber": "888-896-1400",
          "EnumerationDate": "06/01/2005",
          "LastUpdateDate": "11/25/2011",
          "AuthorizedOfficialLastName": "SCHNEIDER",
          "AuthorizedOfficialFirstName": "STEPHANIE",
          "AuthorizedOfficialTitle": "VP",
          "AuthorizedOfficialTelephoneNumber": "703-558-1403",
          "TaxonomyCode1": "207R00000X",
          "Taxonomy1": "Internal Medicine",
          "LicenseNumber1": "=========",
          "LicenseNumberStateCode1": "DC",
          "PrimaryTaxonomySwitch1": "Y",
          "OtherIdentifier1": "W677",
          "OtherIdentifierType1": "OTHER",
          "OtherIdentifierState1": "DC",
          "OtherIdentifierIssuer1": "BLUE SHIELD ADULT PCP GRP",
          "OtherIdentifier2": "027174100",
          "OtherIdentifierType2": "MEDICAID",
          "OtherIdentifierState2": "DC",
          "OtherIdentifier3": "097005100",
          "OtherIdentifierType3": "MEDICAID",
          "OtherIdentifierState3": "MD",
          "OtherIdentifier4": "442AGE",
          "OtherIdentifierType4": "OTHER",
          "OtherIdentifierState4": "MD",
          "OtherIdentifierIssuer4": "BLUE SHIELD PEDS PCP GRP#",
          "OtherIdentifier5": "6572",
          "OtherIdentifierType5": "OTHER",
          "OtherIdentifierState5": "DC",
          "OtherIdentifierIssuer5": "BLUE SHIELD GROUP NUMBER",
          "OtherIdentifier6": "W675",
          "OtherIdentifierType6": "OTHER",
          "OtherIdentifierState6": "DC",
          "OtherIdentifierIssuer6": "BLUE SHIELD PEDS PCP GRP#",
          "HealthcareProviderTaxonomyGroup1": "193200000X MULTI-SPECIALTY GROUP",
          "HealthcareProviderTaxonomyGroupDescription1": "Multi-Specialty Group - A business group of one or more individual practitioners, who practice with different areas of specialization."
        }
      ]
    }
    Done. Press any key to exit ...
                
            

Use Case #3 - I Need to Get Multiple Healthcare Providers Using List of NPI Numbers

You may need to perform bulk search for performance optimization. The "getcodes" operation allows you to decrease number of round trips in orders of magnitude. For instance you can get information about hundred NPI in one REST call, instead of sending NPI numbers one-by-one.

                
    //--------------------------------------------------------------------------------------
    // Perform "getcodes" operation to get multiple healthcare providers using list of NPIs. 
    //--------------------------------------------------------------------------------------
    using System;
    using System.Net.Http;
    using System.Threading.Tasks;

    public class Program
    {
        private const string token = "3932f3b0-cfab-11dc-95ff-0800200c9a663932f3b0-cfab-11dc-95ff-0800200c9a66";

        static async Task Main(string[] args)
        {
            string endPoint = $"https://www.datalabs.health/api/npi/getcodes?q=1285636522,1730198755,1427145176&rt=minjson&token={token}";
            using HttpClient client = new HttpClient();
            string response = await client.GetStringAsync(endPoint);

            Console.WriteLine(response);

            Console.WriteLine("Done. Press any key to exit ...");
            Console.ReadKey();
        }
    }
                
            

                
    {
      "NPI": [
        {
          "NPI": "1285636522",
          "OrgName": "MEDSTAR GEORGETOWN MEDICAL CENTER, INC",
          "FirstLinePracticeLocationAddress": "3800 RESERVOIR RD NW",
          "PracticeLocationAddressCityName": "WASHINGTON",
          "PracticeLocationAddressStateName": "DC",
          "PracticeLocationAddressPostalCode": "20007-2113",
          "PracticeLocationAddressCountryCode": "US",
          "PracticeLocationAddressTelephoneNumber": "888-896-1400"
        },
        {
          "NPI": "1730198755",
          "OrgName": "MEDSTAR GEORGETOWN MEDICAL CENTER",
          "FirstLinePracticeLocationAddress": "3800 RESERVOIR RD NW",
          "PracticeLocationAddressCityName": "WASHINGTON",
          "PracticeLocationAddressStateName": "DC",
          "PracticeLocationAddressPostalCode": "20007-2113",
          "PracticeLocationAddressCountryCode": "US",
          "PracticeLocationAddressTelephoneNumber": "888-896-1400"
        },
        {
          "NPI": "1427145176",
          "OrgName": "MEDSTAR - GEORGETOWN MEDICAL CENTER, INC.",
          "OtherOrgName": "GEORGETOWN UNIVERSITY HOSPITAL",
          "OtherOrgNameTypeCode": "3",
          "FirstLinePracticeLocationAddress": "3800 RESERVOIR RD., NW",
          "PracticeLocationAddressCityName": "WASHINGTON",
          "PracticeLocationAddressStateName": "DC",
          "PracticeLocationAddressPostalCode": "20007-2113",
          "PracticeLocationAddressCountryCode": "US",
          "PracticeLocationAddressTelephoneNumber": "202-444-3000",
          "PracticeLocationAddressFaxNumber": "202-444-3095"
        }
      ]
    }
    Done. Press any key to exit ...
                
            

Use Case #4 - I Need to Check NPI Number Status

Again, very common scenario. You just need to check NPI number status. It is simple. Take a look at the code below. Expected result contains requested NPI number, status, and short status description.

                
    //--------------------------------------------------------------------------------------
    // Perform "check_status" operation to get NPI Number status (active, deactivated, etc).
    //--------------------------------------------------------------------------------------
    using System;
    using System.Net.Http;
    using System.Threading.Tasks;

    public class Program
    {
        private const string token = "3932f3b0-cfab-11dc-95ff-0800200c9a663932f3b0-cfab-11dc-95ff-0800200c9a66";

        static async Task Main(string[] args)
        {
            string endPoint = $"https://www.datalabs.health/api/npi/check_status?q=1285636522&token={token}";
            using HttpClient client = new HttpClient();
            string response = await client.GetStringAsync(endPoint);

            Console.WriteLine(response);

            Console.WriteLine("Done. Press any key to exit ...");
            Console.ReadKey();
        }
    }
                
            

                
    {
      "Code": "1285636522",
      "Status": "Active",
      "Message": "\"1285636522\" NPI Number does exist and has \"active\" status"
    }
                
    Done. Press any key to exit ...
                
            

Use Case #5 - I need to retrieve a list of healthcare providers based on specified search parameters.

The system allows users to retrieve a list of healthcare providers by filtering on specified fields (e.g., organization name, state, city, ZIP code, etc.). The example below demonstrates how to retrieve all providers with a specified city, state, and ZIP code.

                
    //--------------------------------------------------------------------------------------
    // Perform "search_with_predicates" operation to get multiple healthcare providers using specified city, state, and ZIP code. 
    //--------------------------------------------------------------------------------------
    using System;
    using System.Net.Http;
    using System.Threading.Tasks;

    public class Program
    {
        private const string token = "3932f3b0-cfab-11dc-95ff-0800200c9a663932f3b0-cfab-11dc-95ff-0800200c9a66";

        static async Task Main(string[] args)
        {
            string endPoint = $"https://www.datalabs.health/api/npi/search_with_predicates?q=&qf=City:true:REDMOND&qf=State:true:OR&qf=Zip:true:97756-9069&rt=json&token={token}";
            using HttpClient client = new HttpClient();
            string response = await client.GetStringAsync(endPoint);

            Console.WriteLine(response);

            Console.WriteLine("Done. Press any key to exit ...");
            Console.ReadKey();
        }
    }
                
            

                
{
  "NPI": [
    {
      "NPI": "1083349906",
      "EntityType": "Individual",
      "IsSoleProprietor": "N",
      "LastName": "STAFFORD",
      "FirstName": "KADY",
      "NamePrefix": "MS.",
      "Credential": "LPC",
      "FirstLineMailingAddress": "13574 SW HIGHWAY 126",
      "MailingAddressCityName": "POWELL BUTTE",
      "MailingAddressStateName": "OR",
      "MailingAddressPostalCode": "97753-1541",
      "MailingAddressCountryCode": "US",
      "MailingAddressTelephoneNumber": "541-480-6360",
      "FirstLinePracticeLocationAddress": "6396 SW MCVEY AVE",
      "PracticeLocationAddressCityName": "REDMOND",
      "PracticeLocationAddressStateName": "OR",
      "PracticeLocationAddressPostalCode": "97756-9069",
      "PracticeLocationAddressCountryCode": "US",
      "PracticeLocationAddressTelephoneNumber": "541-203-0307",
      "EnumerationDate": "07/24/2022",
      "LastUpdateDate": "04/21/2025",
      "GenderCode": "F",
      "Gender": "Female",
      "TaxonomyCode1": "101YP2500X",
      "Taxonomy1": "Professional Counselor",
      "LicenseNumber1": "LPC6225",
      "LicenseNumberStateCode1": "ID",
      "PrimaryTaxonomySwitch1": "N",
      "TaxonomyCode2": "101YP2500X",
      "Taxonomy2": "Professional Counselor",
      "LicenseNumber2": "C9084",
      "LicenseNumberStateCode2": "OR",
      "PrimaryTaxonomySwitch2": "Y",
      "CertificationDate": "04/21/2025",
      "PrimaryTaxonomyCode": "101YP2500X",
      "PrimaryTaxonomy": "Professional Counselor"
    },
    {
      "NPI": "1215724679",
      "EntityType": "Individual",
      "IsSoleProprietor": "N",
      "LastName": "SCHAY",
      "FirstName": "ANGELICA",
      "MiddleName": "NICOLE",
      "FirstLineMailingAddress": "6396 SW MCVEY AVE",
      "MailingAddressCityName": "REDMOND",
      "MailingAddressStateName": "OR",
      "MailingAddressPostalCode": "97756-9069",
      "MailingAddressCountryCode": "US",
      "MailingAddressTelephoneNumber": "541-389-1841",
      "FirstLinePracticeLocationAddress": "6396 SW MCVEY AVE",
      "PracticeLocationAddressCityName": "REDMOND",
      "PracticeLocationAddressStateName": "OR",
      "PracticeLocationAddressPostalCode": "97756-9069",
      "PracticeLocationAddressCountryCode": "US",
      "PracticeLocationAddressTelephoneNumber": "541-389-1841",
      "EnumerationDate": "04/21/2025",
      "LastUpdateDate": "04/21/2025",
      "GenderCode": "F",
      "Gender": "Female",
      "TaxonomyCode1": "101Y00000X",
      "Taxonomy1": "Counselor",
      "PrimaryTaxonomySwitch1": "Y",
      "CertificationDate": "04/21/2025",
      "PrimaryTaxonomyCode": "101Y00000X",
      "PrimaryTaxonomy": "Counselor"
    },
    {
      "NPI": "1013556505",
      "EntityType": "Individual",
      "IsSoleProprietor": "N",
      "LastName": "IVENS",
      "FirstName": "KRYSTA",
      "FirstLineMailingAddress": "743 NW QUINCE AVE",
      "MailingAddressCityName": "REDMOND",
      "MailingAddressStateName": "OR",
      "MailingAddressPostalCode": "97756-1250",
      "MailingAddressCountryCode": "US",
      "MailingAddressTelephoneNumber": "360-526-1448",
      "FirstLinePracticeLocationAddress": "6396 SW MCVEY AVE",
      "PracticeLocationAddressCityName": "REDMOND",
      "PracticeLocationAddressStateName": "OR",
      "PracticeLocationAddressPostalCode": "97756-9069",
      "PracticeLocationAddressCountryCode": "US",
      "PracticeLocationAddressTelephoneNumber": "971-217-6150",
      "EnumerationDate": "12/31/2019",
      "LastUpdateDate": "02/15/2025",
      "GenderCode": "F",
      "Gender": "Female",
      "TaxonomyCode1": "101YM0800X",
      "Taxonomy1": "Mental Health Counselor",
      "PrimaryTaxonomySwitch1": "N",
      "TaxonomyCode2": "101YP2500X",
      "Taxonomy2": "Professional Counselor",
      "LicenseNumber2": "C7963",
      "LicenseNumberStateCode2": "OR",
      "PrimaryTaxonomySwitch2": "Y",
      "CertificationDate": "02/15/2025",
      "PrimaryTaxonomyCode": "101YP2500X",
      "PrimaryTaxonomy": "Professional Counselor"
    },
    {
      "NPI": "1497336275",
      "EntityType": "Individual",
      "IsSoleProprietor": "Y",
      "LastName": "ARANT",
      "FirstName": "ERIN",
      "MiddleName": "HENNESSEY",
      "FirstLineMailingAddress": "4639 SW 37TH ST",
      "MailingAddressCityName": "REDMOND",
      "MailingAddressStateName": "OR",
      "MailingAddressPostalCode": "97756-6776",
      "MailingAddressCountryCode": "US",
      "FirstLinePracticeLocationAddress": "6396 SW MCVEY AVE",
      "PracticeLocationAddressCityName": "REDMOND",
      "PracticeLocationAddressStateName": "OR",
      "PracticeLocationAddressPostalCode": "97756-9069",
      "PracticeLocationAddressCountryCode": "US",
      "PracticeLocationAddressTelephoneNumber": "541-389-1848",
      "EnumerationDate": "04/14/2021",
      "LastUpdateDate": "04/14/2021",
      "GenderCode": "F",
      "Gender": "Female",
      "TaxonomyCode1": "225X00000X",
      "Taxonomy1": "Occupational Therapist",
      "LicenseNumber1": "390047",
      "LicenseNumberStateCode1": "OR",
      "PrimaryTaxonomySwitch1": "Y",
      "CertificationDate": "04/14/2021",
      "PrimaryTaxonomyCode": "225X00000X",
      "PrimaryTaxonomy": "Occupational Therapist"
    },
    {
      "NPI": "1174191407",
      "EntityType": "Individual",
      "IsSoleProprietor": "Y",
      "LastName": "GRIMALT",
      "FirstName": "EUGENIA",
      "MiddleName": "N",
      "Credential": "PT",
      "FirstLineMailingAddress": "6396 SW MCVEY AVE",
      "MailingAddressCityName": "REDMOND",
      "MailingAddressStateName": "OR",
      "MailingAddressPostalCode": "97756-9069",
      "MailingAddressCountryCode": "US",
      "MailingAddressTelephoneNumber": "541-389-1848",
      "FirstLinePracticeLocationAddress": "6396 SW MCVEY AVE",
      "PracticeLocationAddressCityName": "REDMOND",
      "PracticeLocationAddressStateName": "OR",
      "PracticeLocationAddressPostalCode": "97756-9069",
      "PracticeLocationAddressCountryCode": "US",
      "PracticeLocationAddressTelephoneNumber": "541-389-1848",
      "EnumerationDate": "06/14/2021",
      "LastUpdateDate": "06/14/2021",
      "GenderCode": "F",
      "Gender": "Female",
      "TaxonomyCode1": "2251P0200X",
      "Taxonomy1": "Pediatric Physical Therapist",
      "LicenseNumber1": "63979",
      "LicenseNumberStateCode1": "OR",
      "PrimaryTaxonomySwitch1": "Y",
      "HealthcareProviderTaxonomyGroup1": "193400000X SINGLE SPECIALTY  GROUP",
      "HealthcareProviderTaxonomyGroupDescription1": "Single Specialty Group - A business group of one or more individual practitioners, all of who practice with the same area of specialization.",
      "CertificationDate": "06/14/2021",
      "PrimaryTaxonomyCode": "2251P0200X",
      "PrimaryTaxonomy": "Pediatric Physical Therapist"
    },
    {
      "NPI": "1912604117",
      "EntityType": "Individual",
      "IsSoleProprietor": "Y",
      "LastName": "PAINTER",
      "FirstName": "JENNIFER",
      "FirstLineMailingAddress": "20080 DOANNA WAY UNIT 3",
      "MailingAddressCityName": "BEND",
      "MailingAddressStateName": "OR",
      "MailingAddressPostalCode": "97702-2931",
      "MailingAddressCountryCode": "US",
      "MailingAddressTelephoneNumber": "209-743-9813",
      "FirstLinePracticeLocationAddress": "6396 SW MCVEY AVE",
      "PracticeLocationAddressCityName": "REDMOND",
      "PracticeLocationAddressStateName": "OR",
      "PracticeLocationAddressPostalCode": "97756-9069",
      "PracticeLocationAddressCountryCode": "US",
      "PracticeLocationAddressTelephoneNumber": "541-389-1848",
      "EnumerationDate": "02/08/2023",
      "LastUpdateDate": "02/08/2023",
      "GenderCode": "F",
      "Gender": "Female",
      "TaxonomyCode1": "101YM0800X",
      "Taxonomy1": "Mental Health Counselor",
      "PrimaryTaxonomySwitch1": "Y",
      "CertificationDate": "02/08/2023",
      "PrimaryTaxonomyCode": "101YM0800X",
      "PrimaryTaxonomy": "Mental Health Counselor"
    },
    {
      "NPI": "1396434700",
      "EntityType": "Individual",
      "IsSoleProprietor": "N",
      "LastName": "GROVE",
      "FirstName": "JENNIFER",
      "MiddleName": "RHEA",
      "FirstLineMailingAddress": "303 NW BROADWAY ST",
      "MailingAddressCityName": "BEND",
      "MailingAddressStateName": "OR",
      "MailingAddressPostalCode": "97703-2658",
      "MailingAddressCountryCode": "US",
      "MailingAddressTelephoneNumber": "801-573-6047",
      "FirstLinePracticeLocationAddress": "6396 SW MCVEY AVE",
      "PracticeLocationAddressCityName": "REDMOND",
      "PracticeLocationAddressStateName": "OR",
      "PracticeLocationAddressPostalCode": "97756-9069",
      "PracticeLocationAddressCountryCode": "US",
      "PracticeLocationAddressTelephoneNumber": "801-573-6047",
      "EnumerationDate": "05/02/2023",
      "LastUpdateDate": "05/02/2023",
      "GenderCode": "F",
      "Gender": "Female",
      "TaxonomyCode1": "1041C0700X",
      "Taxonomy1": "Clinical Social Worker",
      "PrimaryTaxonomySwitch1": "Y",
      "CertificationDate": "05/02/2023",
      "PrimaryTaxonomyCode": "1041C0700X",
      "PrimaryTaxonomy": "Clinical Social Worker"
    },
    {
      "NPI": "1407698970",
      "EntityType": "Individual",
      "IsSoleProprietor": "N",
      "LastName": "REDDEN",
      "FirstName": "SHANNON",
      "Credential": "CHW",
      "OtherLastName": "MCDOUGALL",
      "OtherFirstName": "SHANNON",
      "OtherLastNameTypeCode": "1",
      "FirstLineMailingAddress": "2312 NE 5TH ST",
      "MailingAddressCityName": "REDMOND",
      "MailingAddressStateName": "OR",
      "MailingAddressPostalCode": "97756-8488",
      "MailingAddressCountryCode": "US",
      "MailingAddressTelephoneNumber": "541-460-2192",
      "FirstLinePracticeLocationAddress": "6396 SW MCVEY AVE",
      "PracticeLocationAddressCityName": "REDMOND",
      "PracticeLocationAddressStateName": "OR",
      "PracticeLocationAddressPostalCode": "97756-9069",
      "PracticeLocationAddressCountryCode": "US",
      "PracticeLocationAddressTelephoneNumber": "541-389-1848",
      "PracticeLocationAddressFaxNumber": "541-550-7956",
      "EnumerationDate": "06/06/2024",
      "LastUpdateDate": "06/06/2024",
      "GenderCode": "F",
      "Gender": "Female",
      "TaxonomyCode1": "172V00000X",
      "Taxonomy1": "Community Health Worker",
      "LicenseNumberStateCode1": "OR",
      "PrimaryTaxonomySwitch1": "Y",
      "CertificationDate": "06/06/2024",
      "PrimaryTaxonomyCode": "172V00000X",
      "PrimaryTaxonomy": "Community Health Worker"
    },
    {
      "NPI": "1942022256",
      "EntityType": "Individual",
      "IsSoleProprietor": "Y",
      "LastName": "JACQUOT",
      "FirstName": "SHAYLA",
      "FirstLineMailingAddress": "PO BOX 1397",
      "MailingAddressCityName": "BEND",
      "MailingAddressStateName": "OR",
      "MailingAddressPostalCode": "97709-1397",
      "MailingAddressCountryCode": "US",
      "MailingAddressTelephoneNumber": "541-389-1848",
      "FirstLinePracticeLocationAddress": "6396 SW MCVEY AVE",
      "PracticeLocationAddressCityName": "REDMOND",
      "PracticeLocationAddressStateName": "OR",
      "PracticeLocationAddressPostalCode": "97756-9069",
      "PracticeLocationAddressCountryCode": "US",
      "PracticeLocationAddressTelephoneNumber": "541-389-1848",
      "EnumerationDate": "10/28/2024",
      "LastUpdateDate": "10/28/2024",
      "GenderCode": "F",
      "Gender": "Female",
      "TaxonomyCode1": "101YM0800X",
      "Taxonomy1": "Mental Health Counselor",
      "PrimaryTaxonomySwitch1": "Y",
      "CertificationDate": "10/26/2024",
      "PrimaryTaxonomyCode": "101YM0800X",
      "PrimaryTaxonomy": "Mental Health Counselor"
    },
    {
      "NPI": "1912723131",
      "EntityType": "Individual",
      "IsSoleProprietor": "N",
      "LastName": "WEIMER",
      "FirstName": "ALAYNA",
      "FirstLineMailingAddress": "2748 NW 19TH ST",
      "MailingAddressCityName": "REDMOND",
      "MailingAddressStateName": "OR",
      "MailingAddressPostalCode": "97756-7766",
      "MailingAddressCountryCode": "US",
      "FirstLinePracticeLocationAddress": "6396 SW MCVEY AVE",
      "PracticeLocationAddressCityName": "REDMOND",
      "PracticeLocationAddressStateName": "OR",
      "PracticeLocationAddressPostalCode": "97756-9069",
      "PracticeLocationAddressCountryCode": "US",
      "PracticeLocationAddressTelephoneNumber": "541-499-8292",
      "EnumerationDate": "12/03/2024",
      "LastUpdateDate": "12/03/2024",
      "GenderCode": "F",
      "Gender": "Female",
      "TaxonomyCode1": "171M00000X",
      "Taxonomy1": "Case Manager/Care Coordinator",
      "PrimaryTaxonomySwitch1": "Y",
      "CertificationDate": "12/03/2024",
      "PrimaryTaxonomyCode": "171M00000X",
      "PrimaryTaxonomy": "Case Manager/Care Coordinator"
    },
    {
      "NPI": "1790594125",
      "EntityType": "Individual",
      "IsSoleProprietor": "Y",
      "LastName": "WIDDER",
      "FirstName": "JENNIFER",
      "MiddleName": "LYNN",
      "FirstLineMailingAddress": "22350 CALGARY DR",
      "MailingAddressCityName": "BEND",
      "MailingAddressStateName": "OR",
      "MailingAddressPostalCode": "97702-9216",
      "MailingAddressCountryCode": "US",
      "MailingAddressTelephoneNumber": "541-749-8895",
      "FirstLinePracticeLocationAddress": "6396 SW MCVEY AVE",
      "PracticeLocationAddressCityName": "REDMOND",
      "PracticeLocationAddressStateName": "OR",
      "PracticeLocationAddressPostalCode": "97756-9069",
      "PracticeLocationAddressCountryCode": "US",
      "PracticeLocationAddressTelephoneNumber": "541-389-1858",
      "EnumerationDate": "12/31/2024",
      "LastUpdateDate": "12/31/2024",
      "GenderCode": "F",
      "Gender": "Female",
      "TaxonomyCode1": "175T00000X",
      "Taxonomy1": "Peer Specialist",
      "LicenseNumber1": "112910",
      "LicenseNumberStateCode1": "OR",
      "PrimaryTaxonomySwitch1": "Y",
      "CertificationDate": "12/31/2024",
      "PrimaryTaxonomyCode": "175T00000X",
      "PrimaryTaxonomy": "Peer Specialist"
    },
    {
      "NPI": "1538965306",
      "EntityType": "Individual",
      "IsSoleProprietor": "N",
      "LastName": "PARSONS",
      "FirstName": "JEANINE",
      "MiddleName": "JEWELL",
      "FirstLineMailingAddress": "2821 SW 28TH ST",
      "MailingAddressCityName": "REDMOND",
      "MailingAddressStateName": "OR",
      "MailingAddressPostalCode": "97756-8681",
      "MailingAddressCountryCode": "US",
      "MailingAddressTelephoneNumber": "760-927-4761",
      "FirstLinePracticeLocationAddress": "6396 SW MCVEY AVE",
      "PracticeLocationAddressCityName": "REDMOND",
      "PracticeLocationAddressStateName": "OR",
      "PracticeLocationAddressPostalCode": "97756-9069",
      "PracticeLocationAddressCountryCode": "US",
      "PracticeLocationAddressTelephoneNumber": "541-389-1848",
      "EnumerationDate": "02/21/2025",
      "LastUpdateDate": "02/21/2025",
      "GenderCode": "F",
      "Gender": "Female",
      "TaxonomyCode1": "175T00000X",
      "Taxonomy1": "Peer Specialist",
      "LicenseNumber1": "113398",
      "LicenseNumberStateCode1": "OR",
      "PrimaryTaxonomySwitch1": "Y",
      "CertificationDate": "02/21/2025",
      "PrimaryTaxonomyCode": "175T00000X",
      "PrimaryTaxonomy": "Peer Specialist"
    }
  ]
}
Done. Press any key to exit ...